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NOTICE TO READERS 
 
Assets Acquired in a Business Combination to Be Used in Research and Development 
Activities: A Focus on Software, Electronic Devices, and Pharmaceutical Industries was 
developed by staff of the American Institute of Certified Public Accountants (AICPA) and a 
task force comprising representatives from the appraisal, financial analyst, preparer, and 
public accounting communities. Its conclusions reflect what the developers believe are best 
practices. However, this Practice Aid has not been approved, disapproved, or otherwise 
acted upon by any senior technical committee of the AICPA or the Financial Accounting 
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INTRODUCTION 
At the acquisition date of a business combination, Financial Accounting Standards 
Board (FASB) Statement of Financial Accounting Standards No. 141, Business 
Combinations, requires that an entity allocate the cost of the acquired company (that is, 
the purchase price) to tangible and intangible assets acquired and liabilities assumed 
based on fair value.1 Paragraph 35 of FASB Statement No. 141 states that an acquiring 
company should assign a portion of the purchase price to the assets acquired and 
liabilities assumed based on their estimated fair values at the date of acquisition. That 
allocation includes any assets resulting from research and development (R&D) activities 
of the acquired company or to be used in R&D activities of the combined enterprise. 
Independent appraisals may be used as an aid in determining the fair values of assets 
and liabilities. 
FASB Interpretation No. 4, Applicability of FASB Statement No. 2 to Business 
Combinations Accounted for by the Purchase Method, clarifies the accounting treatment 
for assets to be used in R&D activities acquired in a purchase business combination. 
FASB Interpretation No. 4 specifies that “the accounting for the cost of an item to be 
used in research and development activities is the same under paragraphs 11 and 12 of 
Statement No. 2, whether the item is purchased singly, or as part of a group of assets, 
or as part of an entire enterprise in a business combination accounted for by the 
purchase method.”2 
FASB Interpretation No. 4 requires that at the acquisition date, the acquiring company 
should charge to income costs allocated to assets acquired to be used in R&D activities, 
unless the assets have an alternative future use. Costs allocated to assets to be used in 
R&D activities that have an alternative future use and assets resulting from R&D 
activities are capitalized. After initial recognition, those assets acquired are accounted 
for in accordance with the provisions of FASB Statement No. 142, Goodwill and Other 
Intangible Assets. 
The allocation of purchase price of an acquired business can significantly affect the 
financial reporting of current and future operating results of the combined enterprise. In 
the past, the amount of goodwill the combined enterprise amortized to income in future 
periods was directly affected by the immediate charge to income of amounts allocated 
to assets acquired to be used in R&D activities that have no alternative future use.3 
                                            
1
 Paragraph 9 of Financial Accounting Standards Board (FASB) Statement No. 141, Business 
Combinations, states that “a business combination occurs when an entity acquires net assets that 
constitute a business or acquires equity interests of one or more entities and obtains control over that 
entity or entities.” (Footnote references omitted) Emerging Issues Task Force (EITF) Issue No. 00-5, 
Determining Whether a Nonmonetary Transaction Is an Exchange of Similar Productive Assets, and EITF 
Issue No. 98-3, Determining Whether a Nonmonetary Transaction Involved Receipt of Productive Assets 
or of a Business, provide guidance on assessing whether a transaction is a business combination. 
2
 While best practices within this Practice Aid are written in the context of a business combination 
transaction, they also apply to an asset to be used in research and development (R&D) activities that is 
acquired singly or as part of a group of assets. The valuation of an asset acquired singly in a monetary 
transaction is relatively straightforward and is not addressed in this Practice Aid. 
3
 The FASB recently issued FASB Statement No. 142, Goodwill and Other Intangible Assets, which 
requires that goodwill not be amortized, but rather tested in subsequent periods for impairment.
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Amounts assigned to assets acquired to be used in R&D activities (including specific in-
process research and development [IPR&D] projects), which are immediately charged 
to income, reduce the amount of excess purchase price that would otherwise be 
recorded as goodwill. 
The financial reporting of assets acquired to be used in R&D activities, especially 
specific IPR&D projects, recently has come under increased scrutiny by management, 
analysts, investors, regulators, valuation specialists, and auditors. Until the early 1990s, 
amounts allocated to specific IPR&D projects acquired purchase business combinations 
were not significant. Later, however, amounts assigned to acquired IPR&D became an 
increasing portion of the total purchase price—in some instances more than 75 percent 
of the total purchase price. 
Financial reporting constituents in the software, electronic devices, and pharmaceutical 
industries have expressed concern about the lack of comparability among entities for 
the: (1) definition of what constitutes assets acquired to be used in R&D activities, 
including specific IPR&D projects; (2) methodologies and assumptions used to value 
specific assets acquired to be used in R&D activities, including specific IPR&D projects; 
and (3) level of disclosures made for amounts allocated to assets acquired to be used in 
R&D activities, including specific IPR&D projects. In addition, some, including staff of 
the United States Securities and Exchange Commission (SEC), are concerned about 
valuations of assets acquired to be used in R&D activities, including specific IPR&D 
projects, that appear to be unreasonable determinations of fair value, and some are 
concerned about the adequacy of procedures employed in audits of financial statements 
that include a charge for the acquisition of assets acquired to be used in R&D activities, 
including specific IPR&D projects. As a result, on September 9, 1998, the Chief 
Accountant of the SEC released a letter to the chair of the AICPA SEC Regulations 
Committee (available on the SEC’s Web site at www.sec.gov) citing a number of issues 
relating to the valuation of assets acquired in a purchase business combination that the 
SEC staff noted in its review of public registrant filings. 
The AICPA responded to these concerns by forming a task force comprising 
representatives from various constituencies to study the issues and to prepare a best 
practices publication that would benefit all parties interested in the financial reporting of 
assets acquired to be used in R&D activities, including specific IPR&D projects, in the 
software, electronic devices, and pharmaceutical industries (though generally accepted 
accounting principles underlying the best practices apply to all industries). 
This Practice Aid identifies what the task force members perceive as best practices 
related to defining and accounting for, disclosing, valuing, and auditing assets acquired 
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CONCEPT OF FAIR VALUE 
1.1 OVERVIEW 
1.1.01 Acquiring assets in a business combination requires ascertaining the cost of 
the acquired company (that is, purchase price) and assigning that cost to the assets 
acquired and liabilities assumed on the basis of their fair values. 
1.1.02 In accordance with paragraph 37 of Financial Accounting Standards Board 
(FASB) Statement of Financial Accounting Standards No. 141, Business Combinations, 
the portion of the purchase price assigned to an asset is affected by the acquiring 
company’s plans for that asset. If the acquiring company expects to abandon an 
acquired asset, that asset would be assigned a portion of the purchase price equal to 
that asset’s salvage value. If the acquiring company expects to sell the acquired asset, 
that asset would be allocated a portion of the purchase price equal to its fair value less 
cost to sell. (See FASB Statement No. 121, Accounting for the Impairment of Long-
Lived Assets and for Long-Lived Assets to Be Disposed Of, and Emerging Issues Task 
Force [EITF] Issues No. 87-11, Allocation of Purchase Price to Assets to Be Sold, and 
No. 95-21, Accounting for Assets to Be Disposed Of Acquired in a Purchase Business 
Combination.) If the acquiring company plans to hold the acquired asset for use in its 
operations or for investment, that asset initially would be assigned a portion of the 
purchase price based on its fair value. Valuation specialists would not take into 
consideration any company-specific benefits or cost savings in estimating fair value of 
assets acquired because “investment value” and “buyer-specific value” do not conform 
to the concept of fair value, as that term is defined by generally accepted accounting 
principles (GAAP). 
1.1.03 As noted in the glossary to FASB Statement No. 141, Business Combinations, 
the fair value of an asset for financial reporting purposes is defined as the amount at which 
the asset could be bought or sold in a current transaction between willing parties, that is, 
other than in a forced or liquidation sale. GAAP uses a hierarchy for evidential matter to be 
used in determining fair value. Quoted market prices in active markets are the best 
evidence of fair value and would be used as the basis for the measurement, if available. If a 
quoted market price is not available, the estimate of fair value should approximate the price 
at which the asset would be expected to be bought or sold in a current transaction between 
a willing buyer and seller and would be based on the best information available in the 
circumstances. The estimate of fair value should consider prices for similar assets and the 
result of valuation methods to the extent available in the circumstances. Examples of 
valuation methods cited in accounting literature include (a) the present value of estimated 
future cash flows using discount rates commensurate with the risks involved, (b) the 
present value of probability-based expected future cash flows using a risk-free discount 
rate, and (c) option-pricing models. The valuation methods selected for measuring assets 
should be consistent with the objective of measuring fair value. Those methods should 
incorporate assumptions that market participants would use in their estimates of values, 
future revenues, future expenses, and interest rates (if applicable).  
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1.1.04 It is presumed that absent evidence to the contrary, the assumptions used by 
the acquiring company and acquired company in negotiating the value of the 
consideration exchanged in the transaction is indicative of assumptions that market 
participants would use in making estimates of fair value.1 If the acquiring company pays 
the owners of the acquired company any significant consideration for synergistic or 
strategic benefits in excess of those expected to be realized by market participants, the 
valuation specialist would identify those excess benefits and remove them from the 
valuation of assets acquired. The ultimate assumptions used in making estimates of fair 
value would reflect the best estimate of how market participants would benefit from use 
of the asset being valued.  
1.1.05 The IPR&D Task Force believes that market participants include all potential 
buyers (other than financial buyers and investors that would not intend to take an active 
role in managing the acquired company) whether or not the potential buyers are 
engaged in discussions with the seller of the business. In considering which potential 
buyers may be market participants, the valuation specialist would consider only those 
potential buyers that appear to have the ability to acquire the assets being valued. 
Ability would be evaluated in the context of financial wherewithal, or ability to obtain it, 
as well as a plausible postcombination operating strategy for the assets being valued. 
Market participants would include competitors in the same line of business as the 
company being acquired. 
1.1.06 CONCEPT OF FAIR VALUE TO BE USED IN VALUATIONS 
PREPARED FOR FINANCIAL REPORTING PURPOSES 
1.1.07 The Task Force believes that the concept of fair value in the accounting 
literature does not have an equal in the appraisal literature. Historically, valuation 
specialists may have used premises/standards of value in assigning cost to assets 
acquired in a business combination that include “liquidation,” “in-exchange,” “in-use,” 
or “investment” value. These premises/standards of value should be neither used nor 
referred to in valuation reports that will be used in assigning cost to assets acquired 
in a business combination pursuant to FASB Statement No. 141; these 
premises/standards of value would not be appropriate because GAAP requires the 
use of fair value. 
• Liquidation value. This premise/standard suggests that the seller is compelled to 
sell. The buyer may be a willing buyer but the seller must sell, unwillingly. Generally 
there are two levels of liquidation value: forced and orderly. Forced is a one-day 
“gavel” or auction sale; orderly may take place over a period of time. Liquidation 
value for most intangible assets would be zero or close to it because there are 
infrequent sales of intangible assets in such a setting. However, liquidation value 
may be an appropriate basis for determining fair value only in those cases where an 
asset has been identified for immediate disposal. 
                                            
1
 Paragraph B174 of FASB Statement No. 141, Business Combinations, provides that an entity may use its 
estimates of cash flows if market participant assumptions are not available without undue cost and effort. 
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• In-exchange value. This premise/standard typically includes the traditional fair 
market value (FMV) definition, which emanates from the income tax literature, albeit 
on a piecemeal basis. It is further described by some appraisers as the value of an 
asset “on the loading dock,” which is a tangible asset concept. FMV is often 
considered stand-alone value or value to a financial buyer. Real estate appraisers 
generally use the term market value as being synonymous with FMV, as their 
literature generally avoids value being associated with the word fair in relation to 
some sort of perceived fairness doctrine (which might be construed as a legal 
concept). Some appraisers argue that liquidation value is simply a subset of in-
exchange value, because liquidation is also an exchange transaction. In-exchange 
value generally is impossible to assess for many intangibles as they are not sold 
piecemeal (for example, workforce, company infrastructure, base (or core) 
technology2), but instead, are bundled with other assets of a particular going 
concern. The willing buyer-willing seller transaction is taking place at an enterprise 
level, and the asset is expected to continue to be used as it is currently by the 
hypothetical willing buyer (commonly referred to as FMV-in-use). In-exchange value 
is premised on the willing buyer-willing seller concept that is contained in the 
concept of fair value, and it would be an appropriate basis for determining fair value 
if an active market existed for the asset being valued. However, assets to be used in 
research and development (R&D) activities, including specific in-process research 
and development (IPR&D) projects, seldom are sold other than in the sale of an 
entire business, and sufficient data to conclude on the value of assets acquired to be 
used in R&D activities based on similar transactions rarely, if ever, would exist. 
• In-use value. This premise/standard also might include FMV, as described 
previously, but the important distinction is that the asset is looked at, not on a 
piecemeal basis, but in concert with the other assets of the enterprise of which it is a 
part. For tangible assets, the premise/standard of value includes installation costs 
and sales tax. For intangible assets, the premise/standard of value may include the 
contribution of the asset to the enterprise of which it is a part. In-use value generally 
considers the present value of the benefits contributed by the asset to the enterprise 
when it works in concert with the other assets of the enterprise. Because the 
hierarchy of evidentiary matter to be used to determine fair value includes 
discounted cash flow analysis, in-use value may seem to be an appropriate basis for 
determining fair value. However, the discounted cash flow analysis for determining 
in-use value should not be used to determine fair value, as defined by GAAP. 
• Investment value. This premise/standard is often described as synergistic or 
strategic value. Investment value also can be part of both in-exchange or in-use 
value, with the distinction that the willing buyer is not a hypothetical marketplace 
buyer but rather is a particular buyer with specific expectations about future events, 
cost of capital, tax circumstances, and other issues. Investment value, with regard to 
intangibles, implies not only an in-use premise/standard of value, but also the value 
as expected to be deployed by a particular buyer, in a strategic or synergistic sense, 
as opposed to the current user (that is, the seller). Investment value is not an 
appropriate basis for determining fair value, as it would encompass benefits 
expected by a particular buyer of the asset that are different from those available to 
market participants in general. 
                                            
2
 Terms defined in the glossary of terms (see appendix A) are set in boldface type the first time they 
appear in this Practice Aid. 
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1.1.08 FAIR VALUE OF AN ACQUIRED ASSET IS BASED ON A 
SEPARATE STAND-ALONE BASIS 
1.1.09 Except for a few specific industries (for example, pharmaceutical), 
intangible assets seldom are exchanged on a separate stand-alone basis (that is, a 
piecemeal basis). Instead, intangible assets typically are exchanged in combination 
with other assets that make up a business. A willing buyer would factor into the 
amount that it would be willing to pay the seller to acquire the seller’s business a 
portion of the incremental cash flows resulting from the acquisition that are 
expected to inure to the benefit of that buyer. The incremental cash flows would 
include those resulting from enterprise or going-concern components and synergies 
between the businesses of the buyer and seller. Thus, the cost of the acquired 
company may include an element of enterprise or going-concern value and 
synergistic value. If the buyer pays the seller any significant consideration for 
going-concern and synergistic benefits in excess of those expected to be realized 
by market participants, the valuation specialist would identify those excess benefits 
and remove them from the valuation of assets acquired. For purposes of assigning 
cost to the assets acquired in accordance with FASB Statement No. 141, the 
amount of the purchase price allocated to an acquired intangible asset would not 
be based on that intangible asset’s contribution to the enterprise or going-concern 
value or synergistic value. The fair value of an acquired intangible asset would be 
based on an asset-by-asset analysis, and would be the hypothetical market price 
for that asset on a piecemeal basis as if that asset were traded on an established 
market. The hypothetical market price would incorporate assumptions that market 
participants would use in their estimates of values.  
1.1.10 Paragraph 39 of FASB Statement No. 141 provides guidance on when an 
intangible asset should be recognized as an asset apart from goodwill. That paragraph 
states, in part, “An intangible asset shall be recognized as an asset apart from goodwill 
if it arises from contractual or other legal rights (regardless of whether those rights are 
transferable or separable from the acquired entity or from other rights and obligations).  
If an intangible asset does not arise from contractual or other legal rights, it shall be 
recognized as an asset apart from goodwill only if it is separable, that is, it is capable of 
being separated or divided from the acquired entity and sold, transferred, licensed, 
rented, or exchanged (regardless of whether there is an intent to do so).” 
1.1.11 The task force believes that assets acquired to be used in R&D activities, 
which meet the criteria for separate recognition apart from goodwill, also should 
possess the characteristics and attributes of an asset (that is, control, economic 
benefit, measurability, and for specific acquired IPR&D projects, substance and 
incompleteness). Often a combination of assets (which may include tangible and 
intangible assets) is necessary to generate identifiable cash flows. Those cash 
flows may be the basis for the valuation of specific intangible assets within that 
combination and, therefore, a basis for the allocation of the purchase price to 
certain assets acquired. An issue arises over whether certain assets acquired in 
the business combination may be aggregated or combined and treated collectively 
as a single asset for financial reporting purposes in allocating the cost of the 
acquired company to the assets acquired. Paragraph A14 of FASB Statement No. 
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141 provides examples of intangible assets that meet the criteria for separate 
recognition apart from goodwill. 
1.1.12 Each “single asset” for financial reporting purposes would be allocated a 
portion of the purchase price based on its fair value. 
1.1.13 Example—Value of an Acquired Asset Is Determined on a  
“Single Asset” Basis 
1.1.14 Company A acquired Company X in a business combination. Company A 
engages a valuation specialist to value the assets acquired in the business combination. 
The valuation specialist, in consultation with the respective management teams of 
Companies A and X, identifies a list of assets to be valued, in accordance with 
paragraph 5.3.26. The valuation specialist started the process by using a broad list of 
potential assets, such as that shown in paragraph 5.3.60. Based on procedures 
performed by the valuation specialist, assets identified include trade name; customer 
base; and technology, including its subcomponents base (or core), developed, and in-
process.3 Each of these assets is valued individually. The valuation specialist performs 
a separate analysis for each asset, estimating the price at which that asset would be 
exchanged between a willing buyer and seller, on an individual basis. Individual asset 
values would not include synergies or benefits attributed to other assets. 
1.1.15 STRATEGIC OR SYNERGISTIC VALUE EXCLUDED FROM VALUE 
ASSIGNED TO ACQUIRED ASSETS 
1.1.16 A willing buyer may factor into the amount that it would pay to acquire the 
seller’s business a portion of the incremental cash flows that are expected to inure to 
the benefit of that buyer. The incremental cash flows may include those resulting from 
strategic or synergistic components. If the buyer pays the seller any significant 
consideration for strategic or synergistic benefits in excess of those expected to be 
realized by market participants, the valuation specialist would identify those excess 
benefits and remove them from the valuation of assets acquired.4 Thus, the cost of the 
acquired company may include an element of synergistic value (that is, investment 
value). However, for purposes of assigning cost to the assets acquired in accordance 
with FASB Statement No. 141, the amount of the purchase price allocated to an 
acquired asset would not include any entity-specific synergistic value. Fair value does 
not include strategic or synergistic value resulting from expectations about future events 
that are specific to a particular buyer because the value associated with those 
components is unique to the buyer and seller and would not reflect market-based 
assumptions. Therefore, entity-specific value associated with strategic or synergistic 
components would be included in goodwill. Fair value would incorporate expectations 
about future events that affect market participants. If the acquiring company concludes 
that the discounted cash flow method best approximates the fair value of an acquired 
                                            
3
 The FASB recently issued FASB Statement No. 141, which provides guidance on determining which 
intangible assets should be recognized apart from goodwill in the allocation of purchase price in a 
business combination.  
4
 See footnote 1 in chapter 1 of this Practice Aid. 
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asset, the discounted cash flows would incorporate assumptions that market 
participants would use in their estimates of fair values, future revenues, future 
expenses, and discount rates (if applicable).  
1.1.17 Example—Exclude Effects of Synergies From Value of Assets Acquired 
1.1.18 Company A acquired Company X in a business combination. At the 
acquisition date of the combination, Company X has specific IPR&D projects that meet 
the characteristics and attributes set forth in this Practice Aid. Company A concludes 
that a discounted cash flow method best approximates the fair value of the specific 
IPR&D projects. In estimating the cash flows expected to be generated from the 
successful development of the specific IPR&D projects, Company A should estimate its 
distribution costs associated with selling the completed products resulting from the 
successful development of the IPR&D. Company A’s historical distribution costs have 
averaged 20 percent of product revenue. After the combination, Company A expects its 
distribution costs to be consistent with its historical experience. Company X’s historical 
distribution costs have averaged 30 percent of product revenue. Market participants’ 
historical distribution costs have averaged 25 percent of product revenue. 
1.1.19 Company A would use 25 percent of product revenue as the cost of 
distribution in its estimate of future cash flows for purposes of valuing the acquired 
specific IPR&D projects because it reflects the assumption that market participants 
would use in their estimates of future cash flows. The excess of the anticipated benefits 
to be derived from Company A’s expected postcombination distribution costs of 20 
percent of product revenues over the market participants’ distribution costs of 25 
percent would be excluded from the value assigned to assets acquired to be used in 
R&D activities.  
1.1.20 SUMMARY OF FAIR VALUE 
1.1.21 The fair value of an acquired asset, including an intangible asset, for financial 
reporting purposes is the amount at which that asset would be bought or sold on a 
piecemeal basis in a current transaction between the seller and a hypothetical 
marketplace buyer (that is, a market participant) in other than a forced or liquidation 
sale. GAAP uses a hierarchy for evidential matter in determining the fair value of an 
asset. In the absence of quoted market prices, the technique used to estimate fair value 
would be the method that produces a fair value that would best approximate quoted 
market prices. Because quoted market prices do not exist for most intangible assets, 
the technique used to value identifiable intangible assets would be the technique that 
produces a value that best approximates a hypothetical market price. The application of 
the multi-period excess earnings method (a form of discounted cash flow analysis), 
as discussed in chapter 5, would reflect assumptions used by market participants. 
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CHAPTER 2 
VALUATION APPROACHES TO ESTIMATING FAIR VALUE OF 
ASSETS ACQUIRED—GENERAL DISCUSSION 
2.1 OVERVIEW 
2.1.01 All valuation methodologies applied to a valuation of an asset may be broadly 
classified into the cost, market, or income approaches. In a valuation study, all three 
would be considered, and the approach or approaches deemed most indicative of fair 
value, as that term is defined by generally accepted accounting principles (GAAP), 
would then be selected as the proper approach(es) to use in the valuation of that asset.  
See paragraph 1.1.06. 
2.1.02 All three approaches have application in the valuation of assets acquired in a 
business combination, depending on the nature of the asset being valued. However, 
most assets acquired to be used in research and development (R&D) activities, 
including specific in-process R&D (IPR&D) projects, are valued by the income approach 
or, in limited circumstances, the cost approach. Except for certain limited circumstances 
in a few specific industries (for example, pharmaceutical), the market approach rarely is 
used due to the absence of observable market values for comparable assets acquired 
to be used in R&D activities. 
2.1.03 COST APPROACH 
2.1.04 The cost approach establishes value based on the cost of reproducing or 
replacing the asset. The principle behind the cost approach is that the fair value of 
an asset should not exceed the cost to obtain a substitute asset of comparable 
features and functionality. In other words, replacement cost is the greatest amount 
that a buyer would pay for a specific asset. By its very nature, the relationship 
between cost incurred and value created is tenuous at best for assets acquired to be 
used in R&D activities, including specific IPR&D projects. For example, certain R&D 
projects may go on for years at great expense without ever producing a 
commercially viable product. In that case, the cost of reproducing the historical 
development steps may overstate the value of the technology. Conversely, great 
discoveries may be made for little cost. In this case, the cost of reproducing the 
historical development steps would be low compared with the value of the resulting 
technology. The principle of substitution, which is discussed in the tenth edition of 
The Appraisal of Real Estate, published by the Appraisal Institute, states that a 
buyer would pay no more than the costs to recreate the asset for itself. This principle 
is applicable when a perfect substitute can be developed in-house, as opposed to 
purchasing the asset from a third party. Unfortunately, many assets are one-of-a-
kind, novel, or proprietary, and do not lend themselves to this make-versus-buy 
decision pattern. As a consequence, the IPR&D Task Force believes that it would be 
rare where the cost approach would be appropriate for use in valuing assets 
acquired to be used in R&D activities, including specific IPR&D projects. However, 
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the cost approach may be the only applicable approach in those cases where 
“substitutability” does exist, and for specific IPR&D projects where the stage of 
development while demonstrating substance is, nonetheless, so early that reliable 
forecasts of future benefit do not exist, or where no market exists for sale or transfer 
of comparable discoveries. Under these facts and circumstances, the cost approach 
may be deemed to result in a reasonably reliable estimate of fair value.  
2.1.05 For purposes of assigning costs to the assets acquired in accordance with 
Financial Accounting Standards Board (FASB) Statement No. 141, Business 
Combinations, the valuation of an acquired asset using the cost approach, when 
appropriate, would be based on replacement cost. Paragraph 37 of FASB Statement 
No. 141 states that property and equipment to be used would be valued at current 
replacement cost for similar capacity unless the expected future use of the asset 
indicates a lower value to the acquiring company.  Footnote 12 to paragraph 37 states 
that replacement cost would be approximated from replacement cost new less 
estimated accumulated depreciation in the absence of a used asset market price. The 
task force believes that best practices would extend the guidance in paragraph 37 and 
footnote 12 to the valuation of acquired intangible assets in those rare instances when 
the cost approach is used to value assets acquired to be used in R&D activities 
(including specific IPR&D projects). 
2.1.06 MARKET APPROACH 
2.1.07 The market approach is used to estimate value through the analysis of recent 
sales of comparable assets. However, sales prices of intangible assets seldom are 
available because intangible assets typically are transferred only as part of the sale of a 
business, not in piecemeal transactions. Furthermore, because intangible assets are 
unique to a particular enterprise, comparison between enterprises is difficult. For these 
reasons, the market approach seldom is used and rarely is appropriate in the valuation of 
intangible assets, unless exchanges of individual assets comparable to the subject asset 
can be observed. However, in certain limited circumstances in a few specific industries 
(for example, pharmaceutical), active markets exist for the purchase by operating 
companies of early-stage discoveries from academic institutions. These prices may 
provide the best indication of value for early-stage discoveries. For early-stage 
technologies in which comparable technology exchanges recently have occurred, prices 
reflected in those exchanges may serve as a reasonably reliable estimate of fair value. 
2.1.08 INCOME APPROACH 
2.1.09 The term income as used in this approach is a general term that suggests 
future benefits that can be quantified in the form of expected future cash flows. It does 
not imply that the income approach should be used only with forecasts of net income in 
the financial reporting sense. Rather, the income approach involves two general steps. 
The first is establishing a forecast of the estimated future net cash flows expected to 
accrue directly or indirectly to an investor resulting from ownership of the asset or a 
group of assets. The second step involves discounting these estimated future net cash 
flows to their present value. 
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2.1.10 The valuation of intangible assets is most commonly quantified under the 
general principles of the income approach in which there is an identifiable stream of cash 
flows. This stream of cash flows can manifest itself in many ways; among them are— 
• Multiperiod excess earnings. In cases where the intangible assets result in unique 
products (for example, pharmaceuticals), or the intangible assets are necessary to 
compete in an industry (for example, semiconductor design), a multiperiod excess 
earnings method may be the best indicator of value. This method requires a forecast 
of cash inflows, cash outflows, and pro-forma charges for economic returns of and 
on tangible assets employed (for example, working capital and property, plant, and 
equipment). It also may be necessary to charge a return on other enabling intangible 
assets, such as trademarks, distribution channels, or relationships with customers, 
as well as base (or core) technologies. Cash outflows include direct and indirect 
expenses for costs to complete, manufacturing, sales, marketing, routine technical 
maintenance, general, and administrative and taxes. The net cash inflows (or 
multiperiod excess earnings) are ascribable to the intangible asset and, when 
discounted to present value, provide an estimate of its fair value. 
• Royalties not paid through ownership of the asset. Because the owner enjoys the 
right to manufacture and sell products that incorporate the intangible assets without 
having to pay a royalty fee to the inventor, the “relief from royalty” is a cash flow 
savings that can be discounted to present value. See paragraph 2.1.12 for best 
practices regarding the use of the relief from royalty method. 
• Manufacturing cost savings. An intangible asset may afford its owner a cost savings 
over the next best alternative available (that is, a reduced or eliminated cash 
outflow). These cost savings also represent a measure of the benefits enjoyed by 
the owner of the intangible asset. The present value of the cost savings would be 
included in the estimate of fair value of the intangible asset provided that the cost 
savings would be available to market participants if they owned the intangible asset. 
• Incremental revenue. The intangible asset may allow the owner to charge premium 
prices for the product, as it incorporates features, functions, or capabilities that the 
alternative cannot offer (that is, a higher cash inflow). The premium price is a direct 
measure of the benefits derived from ownership of the intangible asset and would be 
included in its estimate of fair value provided that the premium price would be 
available to market participants if they owned this intangible asset. 
2.1.11 The income approach may be broken down into two basic sub-component 
methods: (a) single-period capitalization and (b) multiperiod discounted cash flow. The 
single-period-capitalization method is used primarily in the valuation of small 
businesses, professional practices, certain types of real property, and constant growth 
intangible assets that are expected to exist in perpetuity. This method rarely is of use in 
the valuation of assets acquired to be used in R&D activities because the assumptions 
as to perpetual existence and continuous growth would be inappropriate. The 
multiperiod discounted cash flow method is most commonly used and takes on many 
methodological forms (for example, the relief-from-royalty method and the multiperiod 
excess earnings method). 
2.1.12 Relief-from-royalty method. A relief-from-royalty method may be appropriate 
for certain categories of intangible assets. For instance, trademarks and tradenames, 
patents, developed product technology, and base (or core) technology are all categories of 
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intangible assets that frequently are licensed in exchange for a royalty payment. 
Ownership of the asset relieves the owner of the need to pay a royalty to a third 
party for use of the asset. A key challenge in applying this method is to develop a 
royalty rate that is comparable to ownership of the specific asset (for example, a rate 
that equates to worldwide, exclusive rights to use that asset in perpetuity in any 
manner desired). 
2.1.13 The basic tenet of the relief-from-royalty method is that without ownership of 
the subject intangible asset, the user of that intangible asset would have to make a 
stream of payments to the owner of the asset in return for the rights to use that asset. 
By acquiring the intangible asset, the user avoids these payments. 
2.1.14 Generally, the relief-from-royalty method would be appropriate in cases where— 
• The intangible asset makes a contribution to the relevant cash flows that is 
comparable to that made by a comparable licensed asset (for example, licensed 
assets typically do not represent the only or major source of return; they are usually 
sub-components or ancillary items). 
• The intangible asset can reasonably be separated from other assets and it is 
practical and possible to separately license it. 
• The rights of ownership can reasonably be compared to the rights under a license 
(for example, similar geographic market coverage, duration, exclusivity, limitation, 
technology, and type of customer). 
• Verifiable objective information regarding royalty rates can be obtained, including rates 
for agreements that confirm comparable economic rights for similar intellectual 
property. Typically the best source of information would be other licensing agreements 
made by the acquired company or acquiring company for comparable technologies. 
Use of industry average rates or other broad benchmarks would not be acceptable. 
2.1.15 The task force believes that the relief-from-royalty method rarely would be 
appropriate in the valuation of specific IPR&D projects due to a lack of observable 
comparable royalty rates. However, it may be appropriate as a means of measuring the 
value of contributory assets needed to generate the expected cash flows from specific 
IPR&D projects (for example, royalties paid for the use of trademarks, developed 
product technology, base (or core) technology, subject to the points discussed in 
paragraph 2.1.14). See paragraph 5.3.54 for guidance on contributory asset charges.  
2.1.16 Multi-period excess earnings method. The multi-period excess earnings 
method is a specific application of the discounted cash flow method under the income 
approach. The principle behind the multi-period excess earnings method is that the 
value of an intangible asset is equal to the present value of the incremental after-tax 
cash flows attributable only to the subject intangible asset. The incremental after-tax 
cash flows attributable to the subject intangible asset are then discounted to their 
present value. This method is discussed in detail in chapter 5 of this Practice Aid. 
2.1.17 Real option method. Recent finance and valuation literature describe 
emerging methods and techniques for economic analysis and valuation employing the 
use of option pricing models. Option pricing models (for example, binomial, econometric 
[such as Shelton and Kassouf], and riskless-hedge arbitrage [such as Merton, Black 
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Scholes, Noreen Wolfson, and Gastineau Madansky]) historically have been used to 
value financial contracts, such as warrants and options. The use of these models 
recently has been extended to value strategic choices (in effect, options) and assets 
subject to strategic choices. This class of economic analysis and valuation modeling 
has been referred to in the literature as “real options,” signifying its use with corporate 
(real) assets as opposed to financial assets. 
2.1.18 Real option methods, when used to value assets, may be classified as a 
subset of the income approach because those methods are forward-looking. Real 
option methods can be considerably different, in terms of calculations, from other 
methods under the income approach. As opposed to viewing the future as a singular 
best estimate outcome, or even multiple outcomes subject to probability factors used to 
calculate expected value, real option methods look at the optionality inherent at various 
future milestones, considering the success achieved at those various milestones and 
the multiple probabilistic outcomes then to be contemplated. 
2.1.19 Real option methods have begun to achieve acceptance as a superior 
method for evaluating income streams subject to both uncertainty and choice. For 
example, in the discounted cash flow method, when using very high discount rates 
(such as with some early stage research project cash flows), the negative cash outflows 
occur at the beginning of the estimation period (in which the present value interest 
factor is still relatively significant), and the positive cash inflows occur at the end of the 
estimation period (in which the present value interest factor has become exponentially 
lower), thus often resulting in negative present values. Management often will still invest 
in those projects because they have the choice either to stop investing or to continue 
investing based on either failing to reach or reaching or exceeding certain targets at 
certain time-based milestones. They are still willing, however, to invest small amounts in 
a portfolio of projects (which they can discontinue midstream, on an individual project 
basis) in anticipation of the occasional big payoff. A tradition-based observer might 
conclude that management has acted irrationally to invest in a project with negative net 
present value, while emerging theory might suggest that the discounted cash flow 
method is inaccurate or incomplete when used in a circumstance of high risk 
(uncertainty) and multiple-choice points in the future. 
2.1.20 The use of real option methods has yet to become readily accepted as a 
valuation tool, and the level of standardization among practitioners has not yet reached 
a point for inclusion in this Practice Aid. The real option method warrants mention, 
however, as it may be increasingly used in the future as a supplement to the basic 
multiperiod excess earnings method described in this Practice Aid. 
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CHAPTER 3 
DEFINITION OF ASSETS ACQUIRED THAT ARE TO BE USED IN 
RESEARCH AND DEVELOPMENT ACTIVITIES 
3.1 INTRODUCTION 
3.1.01 This chapter sets forth what the IPR&D Task Force believes are best 
practices in defining assets acquired in a business combination that are to be 
used in research and development (R&D) activities, including specific in-process 
R&D (IPR&D) projects, for purposes of applying Financial Accounting Standards 
Board (FASB) Interpretation No. 4, Applicability of FASB Statement No. 2 to 
Business Combinations Accounted for by the Purchase Method, and related 
accounting guidance. The task force notes that business combinations involving 
the software, electronic devices, and pharmaceutical industries recently have 
exhibited the greatest proportional amount (in terms of total value) of assets 
acquired to be used in R&D activities. Accordingly, the task force chose examples 
that focus on those industries. 
3.1.02 This chapter’s “Introduction” and “Key Concepts” sections are supplemented 
by section 3.3, “Explanatory Comments,” which expands on the definition and sets forth 
the task force’s support for the determination of best practices. In addition, section 3.3 
includes questions and the task force’s answers, which are intended to aid in the 
application of the best practices. 
3.1.03 FASB Statement of Financial Accounting Standards No. 2, Accounting for 
Research and Development Costs, sets forth broad guidelines on the activities that 
constitute R&D activities and defines R&D for purposes of applying generally 
accepted accounting principles (GAAP) in the United States. In a business 
combination, assets acquired to be used in R&D activities are separately 
identifiable assets and each one is allocated a portion of the cost of the acquired 
company based on its fair value. Assets to be used in R&D activities subsequently 
are accounted for under FASB Interpretation No. 4, and are either reported as an 
asset if an alternative future use exists for the asset or immediately charged to 
income. Such separately identifiable assets include both tangible and intangible 
assets, including intangible assets representing specific IPR&D projects to be 
pursued by the combined enterprise. Each specific IPR&D project must have been 
the result of activities undertaken by the acquired company, the costs of which 
qualified as R&D costs under FASB Statement No. 2 and related guidance. 
3.1.04 The following diagram illustrates an overall description of assets acquired in a 
business combination. This Practice Aid focuses on the assets that are italicized and in 
bold type. 
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Assets Acquired 
    
Not Used in R&D Activities  To Be Used in R&D Activities 
  
Tangible  Intangibles    Tangible  Intangibles  
(including specific IPR&D  
Goodwill Intangibles     projects) 
  (including assets resulting  
from R&D activities) 
3.2 KEY CONCEPTS 
3.2.01 Best practices suggest that assets acquired to be used in R&D activities 
should exhibit certain essential characteristics and one attribute, as described in the 
following paragraphs.  
3.2.02 Characteristics of Assets to Be Used in R&D Activities 
• Control—An acquiring company’s interest in each asset is controllable by the 
enterprise (that is, the consolidated entity and its equity investees) so that it can 
obtain benefit from the asset and control others’ access to the asset. 
• Economic benefit—An acquiring company anticipates that each asset singly, or in 
combination with other assets of the combined enterprise, will be used in its post-
combination R&D activities. 
3.2.03 Attribute of Assets to Be Used in R&D Activities  
• Measurability—The fair value of each asset is estimable with reasonable reliability. 
3.2.04 With respect to specific IPR&D projects to be recognized initially as assets to 
be used in R&D activities (which are then immediately expensed), there also is 
persuasive evidence that each of the projects has substance and is incomplete. 
• Substance—For a specific IPR&D project of an acquired company to give rise 
initially to an asset, the acquired company performed R&D activities that constitute 
more than insignificant efforts and that (a) meet the definition of R&D under FASB 
Statement No. 2 and (b) result in the creation of value. 
• Incompleteness—Incompleteness means there are remaining risks (for example, 
technological or engineering) or certain remaining regulatory approvals at the date of 
acquisition. Overcoming those risks or obtaining the approvals requires that the 
combined enterprise will incur additional R&D costs. 
3.2.05 In summary, for costs to be allocated to assets acquired to be used in R&D 
activities, the task force believes that each asset should possess the characteristics of 
control and anticipated economic benefit and the attribute of its fair value being 
estimable with reasonable reliability. Further, if the asset to be used in R&D activities is 
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a specific IPR&D project, that project should have substance and be incomplete. Finally, 
for the allocated cost to be charged to income immediately, the asset acquired should 
have no alternative future use, as discussed in the following paragraphs. 
3.2.06 Alternative future use. If an asset acquired to be used in a current R&D 
activity has no alternative future use, FASB Interpretation No. 4 requires that the portion 
of the purchase price allocated to that asset be immediately charged to income by the 
combined enterprise. If there is an alternative future use that is identified by the 
acquiring company at the acquisition date or through the allocation period, the purchase 
price allocated to that asset is capitalized by the combined enterprise (an acquired 
intangible is capitalized if it meets the criteria in paragraph 39 of FASB Statement No. 
141, Business Combinations).  
3.2.07 For an asset acquired for use in an R&D activity to have an alternative future 
use, the task force believes that (a) it is reasonably expected1 that the combined 
enterprise will use the asset acquired in the alternative manner and anticipates 
economic benefit from that alternative use, and (b) the combined enterprise’s use of the 
asset acquired is not contingent on further development of the asset subsequent to the 
acquisition date (that is, the asset can be used in the alternative manner in the condition 
in which it existed at the acquisition date). 
3.2.08 If the use of the acquired asset is only in one or more other R&D projects of 
the combined enterprise that have commenced2 at the acquisition date, the task force 
believes that use represents a present (as opposed to a future) R&D activity and the 
purchase price allocated to that asset should be immediately charged to income. If the 
asset’s use (see paragraph 3.2.07) is in an R&D project to be commenced at a future 
date, the task force believes that such use is an alternative future use and that the 
purchase price allocated to that asset should be capitalized.  
3.2.09 The task force believes that the determination of whether there is an 
alternative future use for an asset is based on specific facts and circumstances. 
However, for an acquired tangible asset to be used in R&D activities (for example, 
computer testing equipment used in an R&D department), the task force believes that 
there is a rebuttable presumption that such asset has an alternative future use (see 
paragraph 3.2.07) because that asset generally has separate economic value 
independent of the successful completion and commercialization of the IPR&D project. 
This presumption would be overcome, for example, if it were reasonably expected that 
the combined enterprise will use that asset only in a specific IPR&D project that had 
commenced before the acquisition date.  
                                            
1
 For purposes of this Practice Aid, reasonably expected is used in the context of its meaning as provided 
in footnote 18 of paragraph 25 of Financial Accounting Standards Board (FASB) Concepts Statement No. 
6, Elements of Financial Statements (that is, believed on the basis of available evidence or logic but is 
neither certain nor proved). The task force believes that reasonably expected connotes a slightly greater 
than 50 percent chance of occurring. 
2
 A research and development (R&D) project is considered to have commenced when more than 
insignificant costs that qualify as R&D costs in accordance with FASB Statement of Financial Accounting 
Standards No. 2, Accounting for Research and Development Costs, have been incurred. 
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3.2.10 Whether an acquired intangible asset to be used in R&D activities has an 
alternative future use (see paragraphs 3.3.06 and 3.2.07) depends on specific facts and 
circumstances. Facts and circumstances that suggest the presence of an alternative 
future use include: (a) it is reasonably expected that the combined enterprise will use 
the intangible asset being acquired in its current condition in another currently 
identifiable R&D project to be commenced at a future date (for example, the acquired 
intangible asset represents base [or core] technology that is reasonably expected to be 
used in future R&D projects), or (b) a specific IPR&D project comprises a number of 
subprojects or parts, certain of which are complete and for which it is reasonably 
expected that the subprojects or parts will be used other than in a current R&D project 
(see paragraphs 3.3.58 and 3.3.59). Those circumstances suggest that the acquired 
intangible assets have alternative future uses.  
3.2.11 Facts and circumstances that suggest the absence of an alternative future 
use include intangible assets that represent incomplete specific IPR&D projects that are 
narrow in focus and for which the technology involved has the likely potential of being 
obsolete if the acquired specific IPR&D project fails or is terminated. Those 
circumstances suggest that if the specific IPR&D project were to be unsuccessful, 
management of the combined enterprise would abandon (or potentially block a 
competitor from, or both) the specific IPR&D project and direct its future R&D spending 
to areas using a different technology. Therefore, the specific IPR&D project as it existed 
at the date of the business combination would not have an alternative future use. 
3.2.12 However, if the combined enterprise expects to sell an acquired tangible 
or intangible asset associated with the acquired company’s R&D activities, the task 
force believes that the asset would be treated as an asset held for sale. The FASB 
and the Emerging Issues Task Force (EITF) have established criteria that should 
be satisfied to demonstrate commitment to a disposition (see FASB Statement No. 
121, Accounting for the Impairment of Long-Lived Assets and for Long-Lived 
Assets to Be Disposed Of, and EITF Issues No. 87-11, Allocation of Purchase Price 
to Assets to Be Sold, and No. 95-21, Accounting for Assets to Be Disposed Of 
Acquired in a Purchase Business Combination). The task force believes that an 
asset held for sale would not be accounted for under the guidance of FASB 
Statement No. 2 and FASB Interpretation No. 4; instead, the asset would be 
reported by the combined enterprise as an asset held for sale and recorded at an 
amount equal to its fair value, less cost to sell. 
3.3 EXPLANATORY COMMENTS 
3.3.01 Scope of R&D Activities 
3.3.02 Paragraphs 8 through 10 of FASB Statement No. 2 set forth broad guidelines 
on the activities whose costs are and are not to be classified as R&D. More particularly, 
paragraphs 9 and 10 identify activities that are and are not within FASB Statement No. 
2’s definition of R&D activities. These paragraphs are reproduced here (paragraph 
3.3.16 discusses R&D activities conducted for others): 
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9. The following are examples of activities that typically would be included 
in [R&D]…: 
a. Laboratory research aimed at discovery of new knowledge. 
b. Searching for applications of new research findings or other knowledge. 
c. Conceptual formulation and design of possible product or process 
alternatives. 
d. Testing in search for or evaluation of product or process alternatives. 
e. Modification of the formulation or design of a product or process. 
f. Design, construction, and testing of preproduction prototypes and models. 
g. Design of tools, jigs, molds, and dies involving new technology. 
h. Design, construction, and operation of a pilot plant that is not of a scale 
economically feasible to the enterprise for commercial production. 
i. Engineering activity required to advance the design of a product to 
the point that it meets specific functional and economic requirements 
and is ready for manufacture. 
10. The following are examples of activities that typically would be excluded 
from [R&D]…: 
a. Engineering follow-through in an early phase of commercial production. 
b. Quality control during commercial production including routine testing 
of products. 
c. Trouble-shooting in connection with break-downs during commercial 
production. 
d. Routine, on-going efforts to refine, enrich, or otherwise improve upon 
the qualities of an existing product. 
e. Adaptation of an existing capability to a particular requirement or 
customer’s need as part of a continuing commercial activity. 
f. Seasonal or other periodic design changes to existing products. 
g. Routine design of tools, jigs, molds, and dies. 
h. Activity, including design and construction engineering, related to the 
construction, relocation, re-arrangement, or start-up of facilities or 
equipment other than (1) pilot plants…and (2) facilities or equipment 
whose sole use is for a particular research and development project. 
i. Legal work in connection with patent applications or litigation, and the 
sale or licensing of patents. 
In addition to paragraph 10 of FASB Statement No. 2, other authoritative literature that 
limits the scope of activities that qualify as R&D activities includes— 
• Paragraph 4 of FASB Interpretation No. 6, Applicability of FASB Statement No. 2 to 
Computer Software, which states, “The Board’s intent in Statement No. 2 was that 
the acquisition, development, or improvement of a process by an enterprise for use 
in its selling or administrative activities be excluded from the definition of research 
and development activities.” 
• Paragraph 2 of FASB Statement No. 2, which excludes from its scope R&D activities that 
are conducted for others under a contractual arrangement (for which FASB Statement 
No. 68, Research and Development Arrangements, provides accounting guidance). 
• Statement of Position (SOP) 98-1, Accounting for the Costs of Computer Software 
Developed or Obtained for Internal Use, which provides that costs incurred to 
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develop internal-use software are not R&D costs unless they meet the limited 
exceptions provided in paragraph 18 of that SOP. Paragraph 12 of that SOP states 
that internal-use software has the following characteristics: (a) the software is 
acquired, internally developed, or modified solely to meet the entity’s internal needs 
and (b) during the software’s development or modification, no substantive plan exists 
or is being developed to market the software externally. The task force believes that 
the circumstances when a project to develop internal-use software would be 
accounted for as a specific IPR&D project are rare. (Also see EITF Issues No. 00-2, 
Accounting for Web Site Development Costs, and No. 00-3, Application of AICPA 
Statement of Position 97-2 to Arrangements That Include the Right to Use Software 
Stored on Another Entity's Hardware.) 
3.3.03 Questions and Answers3  
3.3.04 Question 1: Company A acquired Company X in a business combination. 
Company X produces a personal financial management software package and currently is 
marketing Version 4.2 of that product. Company X provides periodic upgrades to its 
customers who have subscribed to post-contract customer support—these releases are 
sometimes referred to in the industry by the term right of dot releases. At the acquisition date, 
development of Version 4.3 was underway and was approximately 60 percent complete. Do 
the efforts to develop Version 4.3 meet the scope requirements of R&D activities? 
3.3.05 Answer: No. Paragraph 10 of FASB Statement No. 2 provides examples of 
activities that typically are excluded from its definition of R&D. In describing activities 
that are not typically R&D, paragraph 10(d) says that “routine, on-going efforts to refine, 
enrich, or otherwise improve upon the qualities of an existing product” do not meet the 
definition of R&D. The task force believes that right of dot upgrades generally are used 
to identify and correct minor programming errors, or “bugs,” and do not significantly 
improve or extend the life of the existing product. The activities described with respect 
to the development of Upgrade 4.3 fall within the type of activities described in 
paragraph 10(d) of FASB Statement No. 2 and, therefore, are not R&D activities. The 
purchase price allocated to Version 4.2 should reflect the value of the improvements 
made through the efforts to develop Version 4.3 and would be capitalized as an 
intangible asset provided the asset meets the criteria in paragraph 39 of FASB 
Statement No. 141 for separate recognition apart from goodwill. In contrast, the task 
force believes that left of dot upgrades generally are used to identify significant 
enhancements to the features and functionality of an existing product. 
3.3.06 Question 2: Company A acquired Company X, a telecommunications company, 
in a business combination. At the acquisition date, Company X was developing new 
software to run its switches that are necessary for various telephone services (for example, 
voice mail and call forwarding) that it provides to its customers. Company X does not plan 
to sell, license, or market the software under development; rather, Company X plans to use 
the software internally to help provide the telephone services to its customers. Company A 
decided that the combined enterprise would continue the development of the new software. 
                                            
3
 The task force developed the following Q&As to provide guidance on the scope of FASB Statement No. 2 
and related accounting literature. 
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Do the efforts to develop the new software meet the scope requirements of an IPR&D 
project (that is, an asset to be used in R&D activities)? 
3.3.07 Answer: No. To qualify as IPR&D, the activities and costs should be R&D, as 
described in FASB Statement No. 2 and related guidance. SOP 98-1 provides that the 
costs related to the development of the new software that will be used internally are not 
R&D costs. In that case, the purchase price allocated to the internal-use software 
project should be capitalized (provided the asset meets the criteria in paragraph 39 of 
FASB Statement No. 141 for separate recognition apart from goodwill) and accounted 
for in accordance with the provisions of SOP 98-1. However, if Company X also were 
engaged in licensing software as an element of its switching equipment and had a 
substantive plan in existence or under development to externally market the acquired 
software under development and Company A intended to carry through on that plan, the 
activities and costs of the new software under development would qualify as R&D in 
accordance with FASB Statement No. 2 and the software development project would 
meet the scope requirements of an IPR&D project (that is, an asset to be used in R&D 
activities). Costs on that project incurred subsequent to the consummation of the 
business combination would be accounted for in accordance with the provisions of 
FASB Statement No. 86. 
3.3.08 Question 3: Company A acquired Company X in a business combination. 
Company X produces a well-known cardiovascular product to treat hypertension. 
Company X has been working on a process change to increase its production yields 
and create more efficiency in its manufacturing process. The process change is 
significant and considered to be nonroutine. Food and Drug Administration (FDA) 
approval of the process change is required due to the nature of the expected change 
and the approval had not been obtained at the acquisition date. Do the efforts to 
develop the process change meet the scope requirements of R&D activities? 
3.3.09 Answer: Yes. Paragraph 9 of FASB Statement No. 2 provides examples of 
activities that typically are included in R&D activities. The task force believes that 
because FDA approval of the process change is required, the process modifications fall 
within example 9(e), which specifically addresses modification of the formulation or 
design of a product or process. 
3.3.10 Control, Economic Benefit, and Measurability 
3.3.11 The task force notes that both Accounting Principles Board (APB) Opinion 
No. 16, Business Combinations (which is superseded by FASB Statement No. 141), 
and FASB Interpretation No. 4 were promulgated before the FASB developed its 
Concepts Statements. Consequently, the standards for accounting for assets acquired 
to be used in R&D activities did not explicitly consider the notions of control, economic 
benefit, and measurability contained in the Concepts Statements. The task force also 
notes that the FASB has indicated a possible future interest in reconsidering the 
requirements of FASB Statement No. 2 and FASB Interpretation No. 4. 
3.3.12 The task force noted that (a) the requirement that an asset acquired to be 
used in R&D activities that has no alternative future use is accounted for as if it were an 
asset, albeit only for purposes of allocating the purchase price, and (b) the FASB’s 
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Concepts Statements (No. 2, Qualitative Characteristics of Accounting Information; No. 
5, Recognition and Measurement in Financial Statements of Business Enterprises; and 
No. 6, Elements of Financial Statements) address characteristics of assets. The task 
force was particularly challenged by FASB Concept Statement No. 6’s definition of an 
asset representing “probable future economic benefits” in light of the FASB’s basis for 
conclusions in paragraph 39 of FASB Statement No. 2, which states: “There is normally 
a high degree of uncertainty about the future benefits of individual research and 
development projects, although the element of uncertainty may diminish as a project 
progresses.” The comments in the following paragraphs provide the task force’s bases 
for setting forth as a best practice that assets acquired to be used in R&D activities 
possess the characteristics of control and anticipated economic benefit and the attribute 
of being estimable with reasonable reliability. 
3.3.13 Control. The characteristics of control and economic benefit that are 
incorporated by the task force in the definition of assets acquired to be used in R&D 
activities are derived from the definition of an asset in paragraphs 25 and 26 of FASB 
Concepts Statement No. 6. That definition states the following: 
Assets are probable future economic benefits obtained or controlled by a 
particular entity as a result of past transactions or events…. An asset has 
three essential characteristics: (a) it embodies a probable future economic 
benefit that involves a capacity, singly or in combination with other assets, to 
contribute directly or indirectly to future net cash inflows, (b) a particular entity 
can obtain the benefit and control others’ access to it, and (c) the transaction 
or other event giving rise to the entity’s right to or control of the benefit has 
already occurred. 
3.3.14 With respect to control, examples of circumstances that provide evidence that 
the acquiring company obtains the benefit of and controls others’ access to an asset to 
be used in R&D activities include the following: 
• The combined enterprise has the ability to separate or divide, and sell, transfer, 
license, rent, or exchange its rights to the asset acquired to be used in R&D 
activities.  
• The combined enterprise has proprietary intellectual property rights, which it 
believes could be successfully defended if its rights thereto were to be legally 
challenged. 
Proprietary intellectual property that has not been patented or otherwise been legally 
protected may have been, or could be in the future, independently developed or 
duplicated by a limited number of third parties. Such a circumstance could give rise to 
more than one party having access to substantially the same intellectual property (for 
example, a nonexclusive license). The task force believes that such a circumstance 
does not violate the control characteristic merely because the third parties cannot be 
legally estopped from using their similar intellectual property or undertaking such 
development activities. However, the ability of third parties to duplicate an enterprise’s 
intellectual property, or their possession of similar intellectual property, would diminish 
its fair value. 
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3.3.15 The combined enterprise may control some but not all rights to the benefits of 
a particular asset. For example, assume the acquired company had the exclusive right 
to the exploitation and control of the results of a specific IPR&D project in the United 
States and an unrelated enterprise had the exclusive rights to non-U.S. exploitation of 
the results. The task force believes that the U.S. exploitation rights possessed by the 
combined enterprise would meet the control characteristic. 
3.3.16 Accounting for the costs of R&D activities conducted for others under a 
contractual arrangement is excluded from the scope of FASB Statement No. 2 and 
instead falls within the scope of FASB Statement No. 68. Therefore, assets acquired to 
be used in R&D activities do not include the ongoing benefit arising from the 
continuation of those R&D activities being conducted by the acquired company for 
others under a contractual arrangement, even if the combined enterprise might receive 
economic benefit from its participation in that arrangement. For example, a contractual 
R&D arrangement previously entered into by the acquired company might have 
provided that the acquired company will realize additional economic benefits based on 
the subsequent exploitation by the funding party of any assets that might result from the 
R&D efforts of the acquired company. The task force believes that such potential 
benefits constitute contingent consideration owed to the acquired company for having 
performed the contract R&D activities and do not constitute control of the benefits of the 
R&D. The potential benefit from such right may represent an intangible asset for 
purposes of applying the allocation provisions of FASB Statement No. 141. On the other 
hand, if an R&D arrangement grants the acquired company rights to exploit all or a part 
of the resulting technology, the task force believes that such rights would satisfy the 
control characteristic. 
3.3.17 Economic Benefit. A characteristic of an asset acquired to be used in R&D 
activities set forth herein is that it embodies an anticipated future economic benefit that 
involves an entity using such asset in its postcombination R&D activities. The task force 
acknowledges that an anticipated future economic benefit is less likely of occurring than 
a probable future economic benefit, which is part of the definition of an asset in FASB 
Concepts Statement No. 6 (as cited in paragraph 3.3.12 of this Practice Aid). However, 
the task force believes that many of the assets acquired to be used in R&D activities 
would not satisfy a requirement that there be a probable future economic benefit for 
many of the same reasons that the FASB concluded in FASB Statement No. 2 that R&D 
costs should not be capitalized as assets. 
3.3.18 In circumstances in which an alternative future use for an asset acquired to 
be used in R&D activities exists (see paragraph 3.2.06), the task force believes that 
such use would demonstrate a probable future economic benefit that would inure to the 
combined enterprise when the asset is consumed. Accordingly, that asset would be 
capitalized provided the asset meets the criteria in paragraph 39 of FASB Statement 
No. 141 for separate recognition apart from goodwill. If there is no alternative future use 
or if the alternative use is another current IPR&D project, the asset acquired to be used 
in R&D activities is similar to any R&D cost. The FASB cited in the basis for its 
conclusions in paragraph 45 of FASB Statement No. 2: “Although future benefits from a 
particular research and development project may be foreseen, they generally cannot be 
measured with a reasonable degree of certainty.” As a result, the FASB concluded that 
the cost of R&D should not be capitalized. 
  28 
3.3.19 Economic Benefit: Question and Answer4 
3.3.20 Question: Company A acquired Company X in a business combination. At the 
acquisition date, Company X was pursuing completion of ten in-process research and 
development projects. In evaluating Company X’s R&D activities during the due-diligence 
process before the acquisition date, management of Company A concluded that two of 
the in-process projects would not be pursued subsequent to the consummation of the 
business combination. Company A also concluded that there was no alternative future 
use for the two projects, nor did it have any expectation to sell the projects in their present 
incomplete states. Therefore, management of Company A concluded it would abandon 
further development of the two projects. Do the two projects have an anticipated 
economic benefit to Company A? 
3.3.21 Answer: No. The task force believes that specific IPR&D projects that (a) will 
not be used in the activities of the combined enterprise and (b) are believed to have no 
value on a stand-alone basis result in no economic benefit to the acquiring company. 
Therefore, Company A should not allocate any portion of its purchase price of Company 
X to the two projects. 
3.3.22 Measurability. The attribute of fair value being estimable with reasonable 
reliability, incorporated by the task force in the description of an asset acquired to be 
used in R&D activities, is derived from paragraph 23 of FASB Concepts Statement No. 
6, which states the following: 
To be included in a particular set of financial statements, an item must not only 
qualify under the definition of an element but also meet criteria for recognition 
and have a relevant attribute (or surrogate for it) that is capable of reasonably 
reliable measurement or estimate. Thus some items that meet the definitions 
may have to be excluded from formal incorporation in financial statements 
because of recognition or measurement considerations. [Emphasis added] 
3.3.23 Paragraph 76 of FASB Concepts Statement No. 5 provides that “information 
about some items that meet a definition may never become sufficiently reliable at a 
justifiable cost to recognize the item….” [Emphasis added] In citing a “definition,” FASB 
Concepts Statement No. 5 is referring to definitions of the elements of financial 
statements found in FASB Concepts Statement No. 3, which has since been 
superseded by FASB Concepts Statement No. 6, cited earlier. Paragraph 75 of FASB 
Concepts Statement No. 5 states, “To be reliable, information about an item must be 
representationally faithful, verifiable, and neutral.” Paragraph 89 of FASB Concepts 
Statement No. 2 states that verifiability:  
… means no more than that several measurers are likely to obtain the same 
measure. It is primarily a means of attempting to cope with measurement 
problems stemming from the uncertainty that surrounds accounting measures 
and is more successful in coping with some measurement problems than 
others. Verification of accounting information does not guarantee that the 
information has a high degree of representational faithfulness.… 
                                            
4
 The task force developed the following Q&A to provide guidance on economic benefit. 
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Paragraphs 72 through 74 of FASB Concepts Statement No. 7 address the relevance 
and reliability of present value measurements. 
3.3.24 The task force concluded that the measurement criteria for assets to be used in 
R&D activities and to be accounted for pursuant to FASB Interpretation No. 4 should be set 
at the level of “estimable with reasonable reliability.” The fact that the portion of the 
purchase price allocated to assets to be used in R&D activities is immediately charged to 
income does not obviate the requirement that such assets be estimable with reasonable 
reliability. There may be circumstances in which the fair value of an intangible asset to be 
used in R&D activities cannot be estimated with reasonable reliability for accounting 
purposes. In those circumstances, that asset would not be recognized separately in the 
financial statements; rather, it would become an element of reported goodwill. 
3.3.25 The task force believes that the existence of an independent valuation report, 
in and of itself, is not sufficient evidence that the fair value of an asset acquired to be 
used in R&D activities is estimable with reasonable reliability for accounting purposes. 
Valuations that are consistent with the best practices methodologies discussed in 
chapters 2 and 5 of this Practice Aid may not result in reasonably reliable estimates of 
fair value because the variability of the estimates underlying the valuation may be so 
great that different valuation specialists would estimate fair values that are not within a 
reasonable range. 
3.3.26 Circumstances in which the fair value of an asset acquired to be used in R&D 
activities can be estimated with reasonable reliability might include a specific IPR&D 
project for which the economic benefit of the product, service, or process anticipated 
from the R&D effort is sufficiently determinable so a reasonably reliable estimate of the 
future expected net cash flows can be made based on assumptions that are verifiable. 
For example, the expected attributes of a product under development may be 
sufficiently known, and the combined enterprise’s knowledge of the expected market 
based, in part, on its operating experience in those markets would allow the acquiring 
company to estimate with reasonable reliability the— 
• Size and duration of the market for the product. 
• Time and costs to commercialize and market. 
• Potential customers. 
• Share of market. 
• Selling price. 
• Production and related costs for the product.  
3.3.27 The task force believes that those circumstances would allow one to conclude 
that the fair value of the asset acquired to be used in R&D activities can be estimated 
with reasonable reliability. If the attributes listed above had been identified and 
contemporaneously documented, and the assumptions supported before the acquisition 
date, the task force believes that the likelihood that a reasonably reliable estimate of fair 
value could be determined is increased. The converse also would be true. 
3.3.28 In measuring the fair value of a specific IPR&D project that is anticipated to 
significantly improve an existing product, service, or process, the task force believes 
that the fair value is limited to the economic benefit derived from the significant 
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improvement. Therefore, as discussed in chapter 5 of this Practice Aid, the fair value of 
any such project would exclude the value of the base (or core) technology to which the 
improvements are to be made. The fair value of the base (or core) technology 
represents a separate intangible asset acquired that is to be allocated (based on its fair 
value) a portion of the cost of the acquired company provided the base (or core) 
technology meets the criteria in paragraph 39 of FASB Statement No. 141 for separate 
recognition apart from goodwill. 
3.3.29 In addition, the fair value of the specific IPR&D project excludes the value of 
the acquiring company’s existing assets that are unique to the acquiring company and 
that are anticipated to contribute to the economic benefits to be realized by the 
combined enterprise upon completion of the specific IPR&D project (referred to as 
buyer-specific synergies).5 See chapter 5 of this Practice Aid for a discussion of 
methodologies to be used in determining the fair value of a specific IPR&D project, base 
(or core) technology, and the effects of buyer-specific synergies. 
3.3.30 Measurability: Questions and Answers6 
3.3.31 Question 1: Company A acquired Company X in a business combination. Two 
months before the combination, Company X had initiated an IPR&D project that had 
progressed to the point that its substance could be demonstrated at the acquisition 
date. Nevertheless, because the time envisioned to complete the project was so long, 
management, in consultation with valuation specialists, concluded that, under the 
traditional present value approach, a discount rate of 70 percent was appropriate to 
reflect the completion and market risks in measuring the present value of expected 
future net cash flows. Does the use of such a large discount rate provide evidence that 
the fair value of the specific IPR&D project is not estimable with reasonable reliability? 
3.3.32 Answer: Not necessarily. If sufficient evidence exists to support the 
assumptions used to value the IPR&D project and the conclusion is that the valuation 
was reasonably reliable (and, as a result, verifiable), the task force believes that the use 
of a 70 percent discount rate is not evidence, by itself, that the resulting estimate of fair 
value is not reasonably reliable. See chapter 5 of this Practice Aid for best practices in 
selecting discount rates under the traditional present value approach. 
3.3.33 Question 2: Company A acquired Company X in a business combination. 
Company X is engaged in the biotechnology business. At the time of the acquisition, 
Company X had a compound in phase II clinical trials (efficacy trials in a small 
population of humans) for the indications of treatment of osteoporosis and breast 
cancer. Compounds in this stage of development for Company X have historically had 
approximately a 20 percent chance of ultimately receiving regulatory marketing approval 
by the FDA. Company A’s experience with the FDA approval process for similar 
compounds and that of other market participants allows it to reasonably estimate the 
time required for final FDA approval. Even though a specific manufacturing plan does 
not yet exist, Company A can make estimates, which it believes are reasonable, of the 
                                            
5
 Paragraph B174 of FASB Statement No. 141, Business Combinations, provides that an entity may use its 
estimates of cash flows if market participant assumptions are not available without undue cost and effort. 
6
 The task force developed the following Q&As to provide guidance on measurability. 
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costs to manufacture and sell the drug and how the drug will be priced based upon its 
and market participants’ experiences with other drugs. In the pharmaceutical industry, 
once the market has been identified, a company generally can determine the market 
size, the competition that exists or will exist in that market, and an estimate of the 
market share it may be able to obtain. Can Company A estimate with reasonable 
reliability the fair value of Company X’s specific IPR&D project?  
3.3.34 Answer: Yes. Because the potential markets for the product under 
development have been identified and future costs can be reasonably estimated, the task 
force believes that Company A should be able to estimate the fair value with reasonable 
reliability. The low probability of success is not evidence, by itself, that the resulting 
estimate is not reasonably reliable. The valuation of each of the projects should consider 
their individual stage of development, as discussed in paragraph 5.3.85. 
3.3.35 Question 3: Company A acquired Company X in a business combination. 
Company X is engaged in the development and marketing of software products. At the 
date of acquisition, Company X was developing a new version of an existing product 
that it believed would significantly extend the functionality and improve the operating 
characteristics of the current product. Nevertheless, the new version is still expected to 
process data for the same purpose as the present version and carry over much of the 
design characteristics of its present version. Does the value of the technological 
processes incorporated in the existing product and the institutional knowledge with 
respect to the design of that product represent base (or core) technology whose value 
would be excluded from the value of the specific IPR&D project to develop the new 
version of the software product?  
3.3.36 Answer: Yes. See chapter 5 of this Practice Aid for a discussion of best 
practices in the measurement of the fair value of the base (or core) technology. 
3.3.37 Question 4: Company A acquired Company X, a large company with operations in 
a variety of business segments, in a business combination. For the previous six months, 
Company X had been pursuing an R&D project to develop a “breakthrough” technology that 
would allow for the production of small-scale nuclear reactors suitable for residential use. A 
development plan that identified the anticipated significant technological hurdles had been 
prepared and some of those hurdles had already been overcome, as documented in minutes 
to the periodic status meetings among project managers and others in Company X. 
Accordingly, Company X concluded that the project had substance. However, due to the 
novel technologies that Company X hoped to develop and employ, it had not been able to 
reasonably estimate the costs to complete the project, the potential demand for the 
anticipated new product, and the manufacturing costs. Can the fair value of Company X’s 
specific IPR&D project be estimated with reasonable reliability under the multiperiod excess 
earnings methodology (as discussed in paragraph 5.3)?  
3.3.38 No. Though Company X’s specific IPR&D project has substance and is 
incomplete, the task force believes that the circumstances described would not permit 
the fair value of the project to be determined under the multi-period excess earnings 
methodology because any expected future net cash flows could not be estimated with 
reasonable reliability, in part because the assumptions used would not be verifiable. 
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3.3.39 Specific IPR&D Projects 
3.3.40 R&D projects are managed in a variety of ways and, as a result, it is not 
always clear when a specific project has substance or whether it has been completed. 
One way to view an R&D project is to consider it as having a life cycle, which in a basic 
form, might consist of four phases depicted below. Within the earlier phases, the 
attribute of substance gradually evolves to the point at which it can be demonstrated; 
within the later phases, the project reaches a point at which it is no longer considered 
incomplete. At some point, concurrent with or subsequent to a project having first 
demonstrated substance, the acquiring company likely will be able to estimate the fair 
value with reasonable reliability. Those four phases (more than one of which may be 
occurring simultaneously) are as follows: 
a. Conceptualization—This phase entails coming up with an idea, thought, new 
knowledge, or plan for a new product, service, or process, or for a significant 
improvement to an existing product, service, or process, or it may represent a 
decision by a company to focus its research activities within certain core 
competencies. Management might make an initial assessment of the potential 
market, cost, and technical issues for ideas, thoughts, or plans to determine 
whether the ideas can be developed to produce an economic benefit. 
b. Applied research—This phase represents a planned search or critical investigation 
aimed at the discovery of additional knowledge in hopes that it will be useful in 
defining a new product, service, or process that will yield economic benefits, or 
significantly improve an existing product, service, or process that will yield 
economic benefits. In addition, work during this phase assesses the feasibility of 
successfully completing the project and the commercial viability of the resulting 
expected product, service, or process. 
c. Development—This phase represents the translation of research findings or other 
knowledge into a detailed plan or design for a new product, service, or process, or 
for a significant improvement to an existing product, service, or process, and 
carrying out development efforts pursuant to the plan. 
d. Preproduction—This phase represents the business activities necessary to 
commercialize the asset resulting from R&D activities for the entity’s economic benefit. 
Managers of the R&D project may require, at various points (or gates) during the life 
cycle, an evaluation of the probability of success and the potential economic results. At 
each gate, a decision may be made about whether to continue funding the project. (See 
exhibit 3-1 for a further description of phases that are particular to the pharmaceutical 
industry in the United States.) 
3.3.41 A depiction of a project life cycle is as follows: 









3.3.42 A future product, service, or process is defined and its potential economic benefits 
are identified at some point within this life cycle after the project’s conceptualization. After 
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the time that a future product, service, or process has been defined and its potential 
economic benefits have been identified, a specific IPR&D project begins to demonstrate 
substance. This generally occurs when more than insignificant R&D efforts have been 
expended after the characteristics of the future product, service, or process have been 
defined and management has approved continued project funding. In addition, 
management has been able to make reasonably reliable estimates of the project’s 
completion date, consider the impact of potential competition, and make reasonably 
reliable estimates of costs to complete, sales volumes, average selling prices, and related 
costs over the anticipated economic life of the expected product, service, or process. The 
task force believes that at that time or at a later point, the project is far enough along to 
enable an entity to make a reasonably reliable estimate of its fair value. See paragraph 
3.3.44 for guidance on the attribute of substance. 
3.3.43 At some point before commercialization (that is, before earning revenue), and 
possibly before the end of the development or pre-production stages, the task force 
believes that the R&D project is no longer considered incomplete for accounting 
purposes (that is, ultimate completion of the project has occurred) and an asset 
resulting from R&D emerges from what was previously an asset used in R&D. See 
paragraph 3.3.54 for explanatory comments on the attribute of incompleteness. 
3.3.44 Specific IPR&D Projects—Substance 
3.3.45 The task force believes that any specific IPR&D project that has progressed 
beyond project conceptualization to a degree that enables its fair value to be estimated 
with reasonable reliability has substance. In contrast, if the acquired company has only 
articulated a concept, this does not constitute substantive activities, nor does it create a 
circumstance in which the acquiring company estimates the fair value of that concept 
with sufficient reliability to meet the measurability attribute that defines an asset to be 
used in R&D activities. 
3.3.46 In many circumstances, there will be written evidence of the specific IPR&D 
project’s economic and technical objectives (including identification of its technological, 
engineering, and regulatory risks) in the acquired company’s records. In addition, there 
will be periodic contemporaneously prepared evidence of the progress being made as 
the specific IPR&D project evolves to completion. That data will aid in verifying that the 
acquired IPR&D project had substance at the acquisition date. To the extent that the 
economic objectives originally set forth by the acquired company are significantly 
different from those reflected in the valuation of the IPR&D project by the acquiring 
company, best practices are to reconcile and explain those differences. 
3.3.47 Questions and Answers7 
3.3.48 Question 1: Company A, a pharmaceutical company, acquired Company X, a 
biotechnology company engaged in cancer research and development, in a business 
combination. Company X is developing a small molecule compound that is thought to 
have a therapeutic application in the cancer market. The company has incurred R&D 
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costs in (a) screening approximately 5,000 compounds, (b) identifying eight lead 
compounds, and (c) determining that they have the desired effect on the biological 
“target” (a part of the body, such as a protein, receptor, or gene; or something foreign to 
the body, such as a bacteria or virus that appears to play an important role in causing 
certain diseases), whose function is understood and has been validated. The eight 
compounds are considered potential drug development candidates and Company X has 
gathered sufficient scientific data to decide to advance these compounds to phase I 
clinical testing (that is, testing in humans). Based on Company X’s understanding of the 
biological target’s function and scientific data available in the public domain, Company X 
is able to make some general predictions on potential therapeutic benefits in treating 
several types of cancer and side effects of the compounds, if successful. The activities 
already undertaken by Company X have resulted in its reporting R&D expenses. A 
multi-tumor cancer drug represents a significant market opportunity. While no detailed 
market research has been conducted, market projections have been prepared based on 
patient population and cancer incidence rates. The complexity of the manufacturing 
process has not been thoroughly evaluated; however, manufacturing costs can be 
reasonably estimated based on the complexity of the synthesis process of the current 
lead compounds and raw material requirements.  Patent searches have been 
completed with no findings of any patents that would block Company X’s plans for 
further development and commercialization of the compounds.  In addition, Company X 
has filed for patent protection of these compounds. Have sufficient R&D activities been 
undertaken for this small molecule program, such that, at the acquisition date, the 
acquired IPR&D projects have substance and can be valued with reasonable reliability?  
3.3.49 Answer: Yes. However, the decision about whether fair value can be 
measured with reasonable reliability requires a significant amount of judgment.  The 
eight compounds that may lead to possible drug development candidates have 
progressed far enough through the R&D life cycle to have substance and Company X 
can estimate the fair value of these projects with reasonable reliability. Company X has 
selected a specific biological target whose function is understood and has been well 
validated. Company X has determined that the eight lead compounds have the desired 
effect on the biological target and do not interact with other tissues in the body. 
Consequently, it is reasonable to anticipate that these compounds may lead to a drug 
for treating cancer. Company X has gathered enough scientific data to decide to 
advance these compounds to phase I clinical testing. Market potential can be 
reasonably estimated because incidence of cancer, by tumor type, is well documented 
and tracked by several reputable independent organizations. Market share for a 
particular compound can be estimated by reviewing data currently available in the public 
domain that tracks patented programs, by biologic target, from preclinical through 
market launch. Thus, Company X can determine the number of competitors conducting 
research on a particular biologic target and estimate the potential order of entry given 
the competitors’ stages of development. Company X can also estimate price and 
revenue potential based on currently available drugs, incidence rates by specific tumor 
type, and therapeutic benefit. Manufacturing costs can be reasonably estimated based 
on the complexity of the synthesis process of the current lead compounds and raw 
material requirements. Since the potential revenues and costs can be reasonably 
estimated based upon data available in the public domain, the fair value of the eight 
compounds, albeit at an early-stage development, can be measured with reasonable 
reliability. While the facts in this example support the conclusion that the fair value of the 
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compounds can be measured with reasonable reliability, other situations with changes 
from the fact pattern presented here may result in a different conclusion. 
3.3.50 Question 2: Company A acquired Company X in a business combination. 
Company X designs and markets switches for sale to telecom companies, which use 
the switches to route telephone communications through their systems. Company X 
developed a routing technology for a switch that it believes will be pivotal in creating the 
next generation of switches to route Internet and video data over telephone systems 
(that is, it had completed the conceptualization and research phases of the project). 
Before the acquisition, Company X had surveyed several telecom companies to assist 
in designing the specifications of the proposed switch. In addition, Company X had a 
documented plan for development of the switches, which it expected would be complete 
in eighteen months. As of the date of the acquisition, the R&D project had been 
underway for two months. Have sufficient R&D activities been undertaken such that, at 
the date of acquisition, the specific IPR&D project has substance? 
3.3.51 Answer: Yes. As of the date of the acquisition, Company X had completed the 
conceptualization and research phases of the project and was partially through 
development of the new switch. As a result, the project satisfied the attribute of 
substance of an asset acquired to be used in R&D activities. The facts presented are 
insufficient to determine whether the measurability attribute can be satisfied. However, if 
the measurability attribute could be satisfied, the fair value of the project would be 
affected by the early stage of development. 
3.3.52 Question 3: Company A acquired Company X in a business combination. 
Company X was an established contract manufacturer of electronic components. An 
important aspect of its manufacturing process involved the extrusion of copper wire into 
extremely fine strands. The R&D department of Company X had targeted improvements 
in this aspect of the manufacturing process as one of its top priorities. The basic objective 
of such a project would involve significant improvements to the current process that would 
further reduce the diameter of the copper strands without significantly increasing 
manufacturing costs (for example, through lower yields of acceptable material or 
increased consumption of energy and indirect materials). As of the date of the acquisition, 
Company X’s R&D personnel had begun studying possible technological improvements 
to the extrusion process by researching relevant technical and academic material that 
was in the public domain. Company X’s R&D personnel also had conducted an all-day 
“brainstorming” session in which a number of theoretical approaches were debated. As a 
result of that meeting, a consensus on the most promising approach had been identified 
and a project plan was being drafted that would define expected timing, resource 
requirements, and key technical issues of the R&D project. Company X personnel were 
excited about the novel approach and believed that the project had a fairly high likelihood 
of ultimate success. Have sufficient R&D activities been undertaken such that, at the 
acquisition date, the specific IPR&D project has substance? 
3.3.53 Answer: No. At the date of the acquisition, Company X’s R&D project had 
only been conceptualized. Company X had not expended a more than insignificant 
effort in R&D activities to advance existing knowledge and technology toward the 
project objective. As a result, even though the project concept was promising, the 
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project lacked substance at the acquisition date and would not qualify as an asset to be 
recognized in the purchase price allocation. 
3.3.54 Specific IPR&D Projects—Incompleteness 
3.3.55 The attribute of incompleteness with respect to a specific IPR&D project 
acquired as part of a business combination suggests that there are remaining 
technological or engineering risks, or regulatory approvals. The task force notes that 
once an R&D project is complete, it represents an asset resulting from R&D activities, 
and the allocated portion of the purchase price representing its fair value would be 
capitalized by the combined enterprise provided the asset meets the criteria in 
paragraph 39 of FASB Statement No. 141 for separate recognition apart from goodwill. 
3.3.56 Factors or indicators that should be considered in evaluating whether 
activities making up a specific R&D project are incomplete at the acquisition date 
include both of the following: 
a. Circumstances in which the combined enterprise expects to incur more than de 
minimis future costs related to the acquired project that would qualify as R&D costs 
under FASB Statement No. 2 
b. Additional steps or milestones in a specific R&D project that remain for the 
combined enterprise, such as successfully overcoming the remaining risks or 
obtaining regulatory approvals related to the results of the R&D activities 
3.3.57 Examples of circumstances that the task force believes demonstrate that the 
ultimate completion of a specific R&D project would not have occurred at the date of 
acquisition include the following: 
• Tangible products that are not subject to governmental regulations—The acquired 
company’s project has not reached a level of completion such that “first customer 
acceptance” (or a similar demonstration of completion for those products not subject 
to first customer acceptance) of the product has occurred. The task force notes that 
obtaining customer acceptance for a new product often requires a demonstration of 
the product’s performance vis à vis planned operating measurements. Therefore, 
obtaining first customer acceptance evidences completion of the project. Upon 
achieving first customer acceptance (or a similar demonstration of completion for 
those products not subject to first customer acceptance), the combined enterprise 
would not incur additional costs that qualify as R&D pursuant to FASB Statement 
No. 2 to further develop the product. 
• Software to be sold, licensed, or otherwise marketed—Technological feasibility for 
the project has not been established under the criteria in paragraph 4 of FASB 
Statement No. 86. The task force notes that the risks of successful completion of a 
software project that has reached technological feasibility (and therefore is 
considered complete) are sometimes greater than for a hardware project just before 
first customer acceptance. However, in formulating the guidance for completion of a 
specific IPR&D project for the development of software, the task force looked to the 
requirements of FASB Statement No. 86. 
• Pharmaceutical products and processes related to right to market or use that are 
subject to governmental regulations—The acquired company’s product or process 
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has not been approved for marketing or production by the appropriate regulatory 
body. Approval for marketing for this purpose includes only the approval of the 
product to be marketed. For example, in the United States, the task force believes 
that only FDA approval of a product is sufficient for a project to be complete (FDA 
approval of a product for marketing also includes approval of the manufacturing 
process). Approval of the label or, where applicable, the pricing is not necessary for 
the project to be complete. 
3.3.58 There may be circumstances in which a specific IPR&D project comprises a 
number of subprojects that individually could be used by the combined enterprise in a 
manner that would create an anticipated economic benefit. If any of those subprojects are 
complete and it is anticipated that the combined enterprise will derive economic benefit 
from the discrete exploitation of those subprojects (that is, an alternative future use exists 
for the subprojects), then the fair values of the complete subprojects would represent 
assets resulting from R&D activities. As a consequence, the purchase price allocated to 
those projects would be capitalized and accounted for in accordance with the provisions 
of FASB Statement No. 142 provided the assets meet the criteria in paragraph 39 of 
FASB Statement No. 141 for separate recognition apart from goodwill. Such a 
circumstance is similar to that described in paragraph 39 of FASB Statement No. 86. 
3.3.59 For example, the acquired company may be in the process of developing a 
variety of software products that can be marketed both individually and in combination 
as an integrated suite of products (the suite). The development effort for certain of the 
individual products is complete and the development of the others is incomplete. 
Consequently, the development of the suite is incomplete. If it is anticipated that the 
combined enterprise will market the discrete products individually and include the 
discrete products as part of the suite, the task force believes that the purchase price 
allocated to any of the individual products whose development is complete should be 
capitalized as an asset resulting from R&D provided the asset meets the criteria in 
paragraph 39 of FASB Statement No. 141 for separate recognition apart from goodwill. 
In addition, the task force believes that the value of the completed component 
product(s) represents base (or core) technology, which is excluded from the 
measurement of the fair value of the suite.  
3.3.60 Questions and Answers8 
3.3.61 Question 1: Company X was acquired in a business combination and had an 
IPR&D project to develop the next generation of its microchip. The project was 
estimated to be 70 percent complete in terms of costs incurred. The technological and 
engineering hurdles remaining, though time-consuming and expensive, are not believed 
to be high-risk development issues and are not considered particularly difficult to 
accomplish. In fact, in similar previous development efforts, Company X consistently 
demonstrated that it could accomplish the remaining tasks once it got to a similar stage 
of completion. However, the remaining tasks are of the type described as R&D activities 
in paragraph 9 of FASB Statement No. 2, rather than of the type of activities described 
in paragraph 10 that are not considered R&D activities. Is the project incomplete? 
                                            
8
 The task force developed the following Q&As to provide guidance on incompleteness. 
  38 
3.3.62 Answer: Yes, because first customer acceptance of the microchip has not 
occurred. Even though the likelihood of success in achieving first customer acceptance 
may seem high based on Company X’s history, first customer acceptance has not 
occurred and additional qualifying R&D costs will be incurred. Consequently, completion 
of the project has not occurred at the date of acquisition.  
3.3.63 Question 2: Company A acquired Company X in a business combination. At 
the acquisition date, Company X had an R&D project in process to develop the next 
generation of its job scheduling software. Company X had delivered a working model of 
the software to several of its customers as part of the beta test stage. As of the 
acquisition date, engineers were working to incorporate improvements discovered as a 
result of the beta testing. Company A expects to complete the development and market 
any resulting product in a manner generally consistent with the plans of Company X that 
existed at the acquisition date. Is the project incomplete? 
3.3.64 Answer: No. The task force believes that when a project reaches 
technological feasibility as defined in FASB Statement No. 86, the project becomes an 
asset resulting from R&D. Because Company X had provided a working model of its 
software to several of its customers as part of the beta test stage, it met the 
technological feasibility criteria described in paragraph 4 of FASB Statement No. 86. As 
a result, a portion of the purchase price of the acquired company is allocated to the fair 
value of the project and capitalized provided the asset meets the criteria in paragraph 
39 of FASB Statement No. 141 for separate recognition apart from goodwill.  
3.3.65 Question 3: Company A acquired Company X in a business combination. At 
the acquisition date, Company X had an application to market a new drug pending FDA 
approval. Both Company A and X believe that Company X had completed all necessary 
tasks related to the filing (including having obtained satisfactory test results) and they 
believe that they will ultimately obtain FDA approval. Is the project incomplete? 
3.3.66 Answer: Yes. Industry experience shows that there are uncertainties about 
obtaining approval for a new drug upon filing with the FDA. FASB Statement No. 2 does not 
specifically address whether costs of obtaining FDA approval are R&D; however, the task 
force believes that such future expenditures satisfy the condition that, to be considered 
incomplete, additional R&D costs must be incurred by the combined enterprise. 
3.3.67 Question 4: Company X was acquired in a business combination and was 
involved in the design, manufacture, and marketing of consumer video communications 
devices. Company X had a successful product in the market and had been working on 
the next generation of the product, which involved significant improvements to features 
and functions. (These improvements have no alternative future use outside the new 
product.) Given the target market of young retail consumers, Company X planned to 
debut the new product at an upcoming trade show, followed shortly after by a 
nationwide marketing campaign. For competitive reasons, Company X did not allow 
prototypes of the product outside of its facilities, although it did use focus groups 
representing its target market demographics for feedback on design and features, 
product and performance quality, and marketing approaches. As of the acquisition date, 
Company X had approved the design and specifications of the latest prototype of new 
product as being ready for commercial manufacture. As a result, Company X’s 
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production facilities were preparing to begin mass production of product intended for 
commercial sale. However, Company X had yet to finalize specifications of the product 
shell (for example, color, ergonomic design, and brand graphics), which were still being 
tested with the focus groups. Commercial manufacturing had not yet begun and no 
products had been sold. Is the project incomplete? 
3.3.68 Answer: No. The R&D project related to the significant improvement of the 
existing product has been completed and there are no remaining R&D costs to be 
incurred. The remaining tasks before commercial manufacture and product launch do 
not involve technological or engineering risks, and the associated costs would not 
qualify as R&D. Although “first customer acceptance” has not occurred, Company X has 
demonstrated an equivalent internal milestone based on its product development 
practices and life cycle. 
3.3.69 Alternative Future Use 
3.3.70 Paragraph 11 of FASB Statement No. 2 specifies that the costs of intangible 
assets, materials and equipment, or facilities that are acquired or constructed for R&D 
activities and that have alternative future uses (in R&D activities or otherwise) should be 
capitalized (this is in accordance with FASB Statement No. 142). 
3.3.71 The task force recognizes that the determination of whether an asset 
acquired to be used in R&D activities has an alternative use (as discussed in paragraph 
3.2.07) is based on management intent because at least one potential future use could 
reasonably exist for most assets acquired. For example, the task force notes that the 
possibility exists for an enterprise to sell many of the assets acquired to be used in R&D 
activities; however, the task force believes that only an expectation of subsequent sale would 
relieve management from considering whether an asset has an alternative future use. 
3.3.72 The task force believes that an alternative future use that would require 
capitalization in post-combination financial statements is one that is capable of using the 
assets acquired as those assets exist at the acquisition date of the business 
combination. Consider a circumstance in which successful completion of an IPR&D 
project might give rise to additional R&D projects designed to significantly improve the 
just-completed product. Because those subsequent projects are contingent on the 
successful completion of the current project and would use the current R&D project in 
its future completed condition, the task force believes that they do not constitute an 
alternative future use at the acquisition date. 
3.3.73 The task force believes that management of a combined enterprise should 
search for alternative future uses in circumstances where (a) a significant portion of the 
purchase price is allocated to assets acquired to be used in R&D activities and (b) the 
allocation of purchase price to assets acquired to be used in R&D activities represents a 
material expenditure of the acquiring company. This belief is founded on the premise 
that contingency plans often are developed to maximize the return of assets acquired 
that have a material cost. However, the mere existence of a plan to use the assets 
acquired in an alternative manner does not represent an alternative future use unless 
the conditions in paragraph 3.2.07 are met. The task force believes that best practices 
for management of the combined enterprise are to document those considerations that 
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lead to its determination of whether there are or are not alternative future uses for 
assets acquired to be used in R&D activities. 
3.3.74 Questions and Answers9 
3.3.75 Question 1: Company A acquired Company X, a software company, in a 
business combination. Before being acquired, Company X had two specific IPR&D 
projects underway. Project 1 is a word-processing package to be used in hand-held 
computing devices, and Project 2 is an advanced version of that project that incorporates 
significant additional features and functionality. Project 2 is dependent on the successful 
completion of Project 1. Is Project 2 an alternative future use for Project 1? 
3.3.76 Answer: No. Since Project 2 builds off Project 1, and is therefore contingent 
upon successful completion of Project 1, the task force believes that it is not an 
alternative future use for Project 1 because Project 2 will only use the completed Project 
1, and thus Project 2 would not have used Project 1 as it existed at the acquisition date. 
Any allocation of purchase price to the fair value of Project 2 would exclude the value 
that will be derived through use of the Project 1 technology. However, the task force 
believes that the progress made in Project 1 through the date of the consummation of 
the business combination would represent base (or core) technology with respect to 
Project 2, the value of which would be excluded from the measurement of the fair value 
of Project 2. 
3.3.77 Question 2: Company A acquired pharmaceutical Company X in a business 
combination. Company X owns a license that gives it the exclusive right to develop and 
market a certain compound for the treatment of various diseases. At the time of the 
acquisition, the compound was in early stage clinical trials as a drug for treating certain 
cancers. The project met all of the criteria for an asset used in R&D activities. It is 
believed the same compound also might be effective in treating a type of cardiovascular 
disease. The cancer treatment projects were in early stage testing but had progressed 
to the point that the fair value could be estimated with reasonable reliability. However, 
human studies for toxicity (safety) of the compound were not yet completed. If the 
results of those studies are negative, the project will be abandoned and the compound 
would not be considered for use in a development project to address cardiovascular 
disease. Should the potential use of the license rights to the compound for a project 
addressing cardiovascular disease represent an alternative future use? 
3.3.78 Answer: No. The task force believes that studies for toxicity represent a 
contingency that must be resolved before an alternative future use is reasonably 
expected. Unless the compound successfully completes the toxicity studies for the 
indication for cancers, it will not be considered for use in treating any other disease. The 
risk of failing the toxicity tests for the treatment of cancers would be considered in 
estimating the fair value of the specific IPR&D project. However, there would be an 
alternate future use if favorable toxicity results had already been obtained and it were 
reasonably expected that the combined company would pursue the project to address 
cardiovascular disease. If favorable toxicity results were obtained subsequent to the 
acquisition date and the combined company then decided to pursue the cardiovascular 
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indication, it would not constitute an alternative future use because the project would 
have progressed to a state that was different from what existed at the acquisition date. 
3.3.79 Question 3: Company A acquired custom software Company X in a business 
combination. Before being acquired, Company X custom-designed software packages 
based on specifications provided by its customers. Company X retained the rights to a 
specific custom software package it recently had designed for one of its customers with 
the intent of externally marketing that software. The custom software package had been 
programmed to run on a proprietary operating system with interfaces to the customer’s 
legacy systems. Company X intended to modify the software so that it would be 
integrated into a widely used enterprise resource planning (ERP) package marketed by 
Company B. Company A planned to pursue a project after the acquisition to modify the 
Company X software so that it could be integrated into its own ERP software that 
competes with that of Company B. However, Company A did not plan to pursue 
modification of the Company X software to work with Company B’s package. Is the 
Company B modification of the software package an alternative future use for the 
acquired software? 
3.3.80 Answer: No. The task force believes that an alternative future use is one that 
is reasonably expected to occur. Because Company A did not have the intent to pursue 
the Company B modification of the software package, that potential use, which was the 
intended use by legacy Company X, is not an alternative future use. Company A would 
still need to evaluate, however, whether (a) any of the technology represented by the 
custom version of the software project represented base (or core) technology and (b) it 
had another alternative future use for the custom software package. 
3.3.81 Question 4: Company A acquired Company X in a business combination. 
Company X has one product, a transdermal patch for the delivery of drugs. The patch 
has been approved by the FDA for the delivery of Drug A, and Company X has been 
selling that product for two years. In addition, Company X has commenced clinical trials 
for delivery of Drug B via transdermal patch in anticipation of applying to the FDA for 
approval for such use. It is expected that significant R&D costs will be incurred to 
customize the transdermal patch technology to accommodate the unique characteristics 
of Drug B before obtaining FDA approval for delivery of Drug B. Those actions are 
underway and are approximately 50 percent complete, but the FDA has not approved 
delivery of Drug B. Does the marketing of the patch for delivery of Drug A, while the 
project to obtain FDA approval for delivery of Drug B is underway, constitute an 
alternative future use for the transdermal patch? 
3.3.82 Answer: No. The characteristics of Drugs A and B are different and the design 
of a transdermal patch for each drug must reflect those different characteristics. 
Therefore, the patch for Drug B will not use the design of the patch for Drug A as it 
existed at the consummation of the business combination. However, the task force 
believes that the technological processes and institutional knowledge represented by the 
transdermal patch used for the delivery of Drug A that currently is marketed would 
represent base (or core) technology, the value of which should be excluded from the 
measurement of the fair value of the IPR&D project for use of the patch to deliver Drug B. 
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3.3.83 Question 5: Company A acquired Company X in a business combination. 
Company X has developed a compound for a new drug. Company A expects that its 
only use for the compound will be in four of its currently active IPR&D projects for other 
indications in addition to continuing Company X’s project for the initial indication. Do 
Company A’s four currently active IPR&D projects constitute alternative future uses for 
Company X’s project to develop the compound? 
3.3.84 Answer: No. Company X’s compound is expected to be used only in 
Company A’s currently active IPR&D projects and not in future IPR&D projects. 
Therefore, the task force believes that Company A should allocate the amount of 
purchase price assigned to Company X’s compound to all of the IPR&D projects, and 
those amounts should be immediately charged to income. However, if any of Company 
A’s four projects had instead been planned future projects (instead of currently active 
projects) and the future projects were reasonably expected to occur, the planned future 
project(s) would have been an alternative future use, and the fair value of Company X’s 
compound would be capitalized provided the asset meets the criteria in paragraph 39 of 
FASB Statement No. 141 for separate recognition apart from goodwill. 
3.3.85 Question 6: Company A, a pharmaceutical company, acquired Company X in 
a business combination. Company X’s assets include a library of molecules for high-
throughput screening of drug candidates. Company X is using portions of the library in 
its existing specific IPR&D projects and it is reasonably expected that other portions will 
be used in currently identified future projects. Should the fair value of this library be 
capitalized because it has an alternative future use? 
3.3.86 Answer: Yes, provided the asset meets the criteria in paragraph 39 of FASB 
Statement No. 141 for separate recognition apart from goodwill. The library of 
molecules for high-throughput screening of drug candidates is a tool used in the R&D 
process that is being used in current specific IPR&D projects and is reasonably 
expected to be used in different future R&D projects. While portions of the library are 
being used in current specific IPR&D projects, it is reasonably expected that the library 
also will be used in several different currently identified future R&D projects. The task 
force believes that the library represents an asset resulting from R&D activities. 
3.3.87 Question 7: Company A acquired Company X in a business combination. 
Company X’s assets include worldwide exploitation rights to Web-based access 
technology. The rights supported an existing specific IPR&D project to develop a 
product for exploitation in the United States. Company A does not have the resources to 
exploit the potential product in foreign countries and, therefore, it reasonably expects 
that it will sell the exclusive rights to exploitation in countries outside the United States. 
Should the fair value of the non-U.S. exclusive exploitation rights be capitalized? 
3.3.88 Answer: Yes, provided the asset meets the criteria in paragraph 39 of FASB 
Statement No. 141 for separate recognition apart from goodwill. The expected sale of 
the non-U.S. exclusive rights for exploitation in foreign countries is an intangible asset 
that is separable and would be treated as an asset held for sale. The task force believes 
that the fair value of the non-U.S. exclusive exploitation rights to the Web-based access 
technology should be capitalized and accounted for in accordance with the provisions of 
FASB Statements No. 141 and No. 142. The specific IPR&D project with respect to the 
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development of a project for the U.S. market would be accounted for in accordance with 
the best practices herein. 
3.3.89 Question 8: Company A acquired Company X in a business combination. 
Company X previously had purchased a unique piece of medical testing equipment for 
use only in a specific IPR&D project. The combined enterprise will continue to pursue 
the IPR&D project, and Company A reasonably expects that the combined enterprise 
will use the equipment only in the specific IPR&D project. The combined enterprise can 
measure the fair value of the equipment and related salvage value with reasonable 
reliability. How should Company A account for the portion of the purchase price 
allocated to the medical testing equipment?  
3.3.90 Answer: The task force believes that Company A should immediately expense 
the amount allocated, less salvage value, to the medical testing equipment because the 
equipment does not have an alternative future use. Paragraph 11(a) of FASB Statement 
No. 2 says, in part: 
The costs of materials, equipment, or facilities that are acquired or constructed 
for a particular research and development project and that have no alternative 
future uses and therefore no separate economic values are research and 
development costs at the time the costs are incurred. 
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EXHIBIT 3-1 
Phases of Development in the Pharmaceutical Industry∗  
DISCOVERY RESEARCH PHASE—TWO TO FOUR YEARS 
This is the earliest phase of the new drug research and development process. In the 
discovery research phase scientists attempt to identify, from the literally millions of 
molecules existing in the world, one that has a desired effect against a given disease or 
illness. This whole process begins with the identification of a biological “target” that 
appears to play an important role in causing the disease or illness in question. This 
target could be something that is a part of the body itself, such as a protein, receptor, or 
gene; or it could be something normally foreign to the body, such as a bacteria or virus. 
The process of identifying lead molecules (or leads) is a trial-and-error process in which 
tens of thousands of different molecules are tested or screened to see if they have a 
desirable impact on the target. For example, if the target is a particular bacteria that 
causes infection, those molecules that kill or inhibit the bacteria would be considered 
leads and scientists go on to the next phase of development. The probability of any one 
lead actually making it through the rest of the drug development process and becoming 
a product is extremely low. 
EARLY DEVELOPMENT PHASE—FOUR TO SIX YEARS 
The drug development phase is all about taking a lead molecule, refining it, learning 
how to manufacture it, and testing it for safety and efficacy. The initial testing takes 
place in animals and looks for toxicity and other potential safety issues that might 
preclude ever introducing the compound into humans. Standard predictive models 
are used to project these findings from animals into potential toxicity and dosing 
levels for humans. The first human tests (phase I) are conducted in a very small 
group of healthy volunteers to assess the safety and the potential dosing range. 
After a safe dose has been established, the drug is administered to a still relatively 
small population of sick patients (phase II) to look for initial signs of effectiveness in 
treating the targeted disease. In parallel to this animal and human testing, scientists 
are also developing a manufacturing process that will allow the molecule to be 
manufactured in a safe, efficient, and economical way. Long-term animal studies 
continue to test for potential toxicology issues. The early development phase is a 
very high-risk part of the overall process in which the vast majority of leads fail to 
move on to the next phase of the process. Those molecules that do show some 
initial signs of efficacy move on to the final phase of the research and development 
process, known as the product phase. 
PRODUCT PHASE—THREE TO FIVE YEARS 
Those molecules that move on to the product phase (phase III) have already 
demonstrated safety and preliminary efficacy and therefore have a much higher 
likelihood of success. The drug is now tested in much larger patient populations to 
                                            
∗
 As mentioned in paragraph 3.3.40. 
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prove efficacy in a more rigorous and statistically significant way. These trials are 
generally global in nature and are designed to generate all of the data necessary for 
inclusion in the regulatory submission documents. Often these studies will involve a 
comparison of the new drug with existing competitive therapies, with placebo, or 
both. All of the data is compiled and submitted to regulatory agencies around the 
world. Often there will be several exchanges of questions and answers with the 
regulators, and then, it is hoped, the drug is approved for marketing. 
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CHAPTER 4 
ACCOUNTING AND DISCLOSURE OF ASSETS ACQUIRED THAT ARE 
TO BE USED IN R&D ACTIVITIES 
4.1 ACCOUNTING QUESTIONS AND ANSWERS 
4.1.01 The IPR&D Task Force identified the following questions as those where the 
accounting in financial statements for transactions involving the application of Financial 
Accounting Standards Board (FASB) Interpretation No. 4, Applicability of FASB 
Statement No. 2 to Business Combinations Accounted for by the Purchase Method, 
appears to reflect diversity in practice. 
4.1.02 Question 1: In recording the purchase of a business, is discretion provided in 
the timing for recording the allocation of purchase price to assets acquired to be used in 
research and development (R&D) activities? For example, if information is not available 
to make a reasonable allocation in the period that the business combination closes, can 
an acquiring company employ some form of suspense accounting? 
4.1.03 Answer: No. Paragraph 48 of FASB Statement of Financial Accounting 
Standards No. 141, Business Combinations, provides guidance on when an acquiring 
company should record the allocation to assets acquired to be used in R&D activities in 
connection with recording the purchase of a business: “the date of acquisition ordinarily 
is the date assets are received and other assets are given, liabilities are assumed or 
incurred, or equity interests are issued.” In addition, paragraph B183 of FASB 
Statement No. 141 (which retains the guidance of paragraph 36 of FASB Statement No. 
38, Accounting for Preacquisition Contingencies of Purchased Enterprises), provides 
that some allocations at the purchase balance sheet date are necessarily tentative.  
The Board recognizes that completion of the allocation process that is required 
by Opinion 16 may sometimes require an extended period of time. For 
example, appraisals might be required to determine replacement cost of plant 
and equipment acquired, a discovery period may be needed to identify and 
value intangible assets acquired, and an actuarial determination may be 
required to determine the pension liability to be accrued. 
If a business combination is consummated toward the end of an acquiring 
enterprise’s fiscal year or the acquired enterprise is very large or unusually 
complex, the acquiring enterprise may not be able to obtain some of the data 
required to complete the allocation of the cost of the purchased enterprise for 
inclusion in its next annual financial report.  In that case, a tentative allocation 
might be made using the values that have been determined and preliminary 
estimates of the values that have not yet been determined. The portions of the 
allocation that relate to the data that were not available subsequently are 
adjusted to reflect the finally determined amounts, usually by adjusting the 
preliminary amount with the corresponding adjustment of goodwill. 
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4.1.04 The existence of assets to be used in R&D activities in a business 
combination involving software, electronic devices, and pharmaceutical companies is 
commonplace and the guidance in paragraph 48 of FASB Statement No. 141 should be 
followed. Therefore, the task force believes that an acquiring company should make an 
allocation to assets acquired to be used in R&D activities based on its then best 
estimate at the same time it makes other allocations of the purchase price (that is, at the 
date of acquisition). 
4.1.05 Best practices suggest that the acquiring company often is able to determine 
its final allocation to assets acquired to be used in R&D activities in the same 
accounting period that the business combination is consummated based on the due 
diligence it performs before or immediately after agreeing to the terms of the acquisition. 
Exceptions may be acquisitions of very large companies with significant R&D activities 
and hostile takeover situations. In those circumstances, the task force believes that best 
practice would be for the acquiring company to (a) record its best estimate within the 
range of possible fair values of the assets acquired to be used in R&D activities for 
purposes of its preliminary allocation, (b) disclose the range of significant estimates, and 
(c) consider the disclosure requirements of paragraphs 12 through 19 of Statement of 
Position (SOP) 94-6, Disclosure of Certain Significant Risks and Uncertainties, related 
to significant estimates.   
4.1.06 If the initial allocation to assets acquired to be used in R&D activities is 
preliminary, paragraph 51(h) of FASB Statement No. 141 requires disclosure of reasons 
why a purchase price allocation is not final and, in subsequent periods, the nature and 
amount of material adjustments to the initial allocation.  The “allocation period” ends 
when the acquiring company is no longer waiting for information it has arranged to 
obtain and is known to be available or obtainable. The allocation period generally 
should not exceed one year.  
4.1.07 The task force believes that changes in the preliminary allocation to assets 
acquired to be used in R&D activities subsequent to the issuance of financial 
statements or interim information in the allocation of purchase price should then be 
evaluated by determining whether (a) the originally reported allocation was the result of 
a preliminary evaluation of an ongoing data-gathering and evaluation process, which in 
management’s opinion represented good faith best estimates based on the data then 
available, and (b) the evaluation process is finalized in a reasonable period of time 
subsequent to the acquisition, given the nature of the assets acquired to be used in 
R&D activities. If an acquiring company meets both conditions, it should record any 
adjustments by adjusting the preliminary amount of assets acquired to be used in R&D 
activities (with a corresponding adjustment to goodwill), and it should treat the 
adjustments as a change in accounting estimate in the period of change. If an acquiring 
company does not meet both of these conditions, it would report the adjustment as a 
correction of an error. 
4.1.08 The Securities and Exchange Commission (SEC) staff had stated in Staff 
Accounting Bulletin Topic No. 2.A.7 (which was issued before FASB Statement No. 
141) that the acquiring company should disclose the circumstance related to allocation 
of purchase price that is pending additional adjustments in the financial statements, 
including in financial statements that are part of Forms 8-K and 10-Q filings. Absent 
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disclosure of an open allocation period, it is the SEC staff’s view that the purchase price 
allocation is presumed to be final. 
4.1.09 Question 2: How should an acquiring company apply in-process R&D 
(IPR&D) accounting requirements to initial investments in common stock that are to be 
accounted for using the equity method, including circumstances in which the acquiring 
company’s lack of control precludes access to reliable information on which to base a 
determination of the existence of IPR&D projects, estimate their fair value with 
reasonable reliability, or both? 
4.1.10 Answer: Paragraph 19(b) of Accounting Principles Board (APB) Opinion No. 
18, The Equity Method of Accounting for Investments in Common Stock, requires that 
the difference between the cost of an investment and the amount of underlying equity in 
net assets of an investee should be accounted for as if the investee were a consolidated 
subsidiary. Accordingly, the task force believes the value related to the investor’s 
proportionate interest in assets acquired to be used in R&D activities that have no 
alternative future use should be charged to income in the period that the acquiring 
company makes its equity investment in common stock, assuming the acquiring 
company can satisfy the attribute of being able to estimate the fair value with 
reasonable reliability. 
4.1.11 Paragraph 19(n) of APB Opinion 18 (as amended by FASB Statement No. 
142) states: 
The carrying amount of an investment in common stock of an investee that 
qualifies for the equity method of accounting as described in subparagraph (m) 
may differ from the underlying equity in net assets of the investee. The 
difference should affect the determination of the amount of the investor’s share 
of earnings or losses of an investee as if the investee were a consolidated 
subsidiary. However, if the investor is unable to relate the difference to specific 
accounts of the investee, the difference shall be recognized as goodwill and 
not be amortized in accordance with Statement No. 142. [Footnote reference 
in paragraph 19(n) omitted]  
4.1.12 Paragraph 4 of FASB Interpretation No. 35, Criteria for Applying the Equity 
Method of Accounting for Investments in Common Stock, provides examples of 
indications that an investor may be unable to exercise significant influence over the 
operating and financial policies of an investee. For example, paragraph 4(d) provides 
the following indication that the equity method may not be appropriate:  
The investor needs or wants more financial information to apply the equity 
method than is available to the investee’s other shareholders (for example, the 
investor wants quarterly financial information from an investee that publicly 
reports only annually), tries to obtain that information, and fails. 
Nevertheless, the task force believes that an investee’s sensitivity to maintain 
confidentiality with respect to the nature of its IPR&D projects may result in a 
circumstance in which an investor that has significant influence cannot obtain needed 
information to estimate the fair value of the investee’s IPR&D with reasonable reliability. 
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Consequently, while the task force believes that an acquiring company’s inability to 
determine fair value of assets acquired to be used in R&D activities would preclude 
recording a charge to income for those assets, that circumstance would not, of itself, 
preclude the use of the equity method of accounting. 
4.1.13 The task force believes that the answer to question 1 of this chapter also 
applies to the allocation of the purchase price to an equity investment. 
4.1.14 Question 3: How should an acquiring company classify an IPR&D charge in 
its statement of cash flows? 
4.1.15 Answer: Best practices suggest that an acquiring company should report its 
cash acquisition of assets to be used in R&D activities as an investing outflow in its 
statement of cash flows in the line item identifying payments for the purchase of a 
company, net of cash acquired. The acquisition of assets to be used in R&D activities 
would be reported in this fashion irrespective of whether acquired through a business 
combination or a purchase of specific assets. In this regard, an acquiring company 
should treat assets acquired to be used in R&D activities similar to how it reports other 
acquired assets in the statement of cash flows. 
4.1.16 In addition, when arriving at cash flows from operating activities under the 
indirect method of reporting cash flows, best practices suggest that an acquiring 
company should add back to net income the costs of assets acquired to be used in R&D 
activities that are charged to income. That adjustment is necessary to eliminate from 
operating cash flows those cash outflows of assets acquired to be used in R&D 
activities that are reflected in investing activities. 
4.1.17 Question 4: Subsequent to a business combination, but before the final 
allocation of the purchase price, the combined enterprise abandons an IPR&D project 
that existed at the acquisition date and met the definition of an asset to be used in R&D 
activities. Should any portion of the purchase price be allocated to the IPR&D asset in 
the final allocation? 
4.1.18 Answer: The task force believes that whether a portion of the purchase price 
should be allocated to the IPR&D asset in the final allocation depends on the 
circumstances giving rise to the decision to abandon the project. If the abandonment 
decision was based on circumstances that existed at the acquisition date (that is, 
circumstances analogous to a Type I subsequent event, as discussed in Statement on 
Auditing Standards [SAS] No. 1, Codification of Auditing Standards and Procedures 
[AICPA, Professional Standards, vol. 1, AU sec. 560], “Subsequent Events”), the task 
force believes that the abandoned IPR&D project should not be included in the final 
allocation of the purchase price. An example of such circumstances might be if 
management of the acquiring company had not had the opportunity to fully investigate 
the project as part of its due diligence procedures before the acquisition and, 
subsequent to the acquisition and before significant additional R&D costs had been 
incurred, determines that the expected economic benefits and associated risks of 
completion do not warrant continued funding of the project. 
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4.1.19 However, if the abandonment decision was based on circumstances that 
arose subsequent to the acquisition date (that is, circumstances analogous to a Type II 
subsequent event), the task force believes that the fair value of the IPR&D project 
should be included in the final allocation of purchase price. An example of such 
circumstances might be if tests of the results of post-acquisition development efforts are 
not promising and lead to the conclusion that the technological hurdles to successful 
completion cannot be realistically overcome. Another example might be if, subsequent 
to the acquisition, a competitor introduces a product with performance and pricing 
characteristics that are superior to those envisioned for the planned product.  
4.1.20 Question 5: Should subsequent events after the final allocation of the 
purchase price cause the allocation to be revised (for example, a specific IPR&D project 
to which value was assigned is subsequently abandoned or significantly reduced in 
scope, or actual results are significantly different than the projections used to value the 
IPR&D project)?  
4.1.21 Answer: No. Generally accepted accounting principles (GAAP) do not permit 
an acquiring company to consider previously unknown events that occur subsequent to 
the final determination of fair value of assets acquired to be used in R&D activities. For 
example, a decision made subsequent to the final allocation to abandon a project or 
subsequent factors that are the result of circumstances that developed after the final 
allocation have no impact on the determination of fair value as of the acquisition date of 
a business combination. Additionally, consistent with internally developed R&D that is 
subsequently abandoned or reduced in scope, or where actual results are significantly 
different from projections, such events do not affect the determination of the amounts 
already reported as having been expended for the acquired IPR&D project. As a result, 
the allocation of the purchase price of the business combination should not be revised. 
4.1.22 Question 6: Company A acquired Company X in a business combination. At 
the initiation of the combination, Company X was working on one project that was in the 
R&D stage. At the acquisition date, Company X had completed the R&D project. Should 
Company A allocate any portion of the purchase price to assets acquired to be used in 
R&D activities? 
4.1.23 Answer: No. Paragraph 35 of FASB Statement No. 141 states, in part: “an 
acquiring entity shall allocate the cost of an acquired entity to the assets acquired and 
liabilities assumed based on their estimated fair values at date of acquisition.” Because 
the R&D project was complete at the date of acquisition, it represents an asset resulting 
from R&D activities that should be capitalized as an intangible asset, provided that it 
meets the criteria in paragraph 39 of FASB Statement No. 141 for separate recognition 
apart from goodwill.  
4.2 DISCLOSURE 
4.2.01 In considering best practices for disclosure of assets acquired in a business 
combination to be used in R&D activities, the task force observed that the disclosures 
required by GAAP and, for SEC registrants, Regulations S-K and S-X are somewhat 
limited. For example, FASB Statement No. 2, Accounting for Research and 
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Development Costs, requires disclosure only “of the total research and development 
costs charged to expense in each period for which an income statement is presented.” 
4.2.02 The task force also observes that FASB Statement No. 141 does not require 
disclosure of valuation methods, and assumptions or qualitative information about 
assets acquired. Paragraphs 51 through 57 of that Statement address required 
disclosures for a business combination. 
4.2.03 The task force notes that the SEC staff has requested public registrants to 
disclose additional information about charges for IPR&D acquired in business combinations 
in their financial statements and in management’s discussion and analysis (MD&A). In 
January 1999, the SEC staff sent a letter to selected public company chief financial officers 
setting forth certain expectations for disclosures about IPR&D, among other things. The 
task force notes that the SEC staff’s letter was not specific about which disclosures should 
be included in the financial statements and which disclosures should be included in MD&A. 
Excerpts of that letter related to acquired IPR&D charges follow:  
We understand that you will report significant charges in 1998 for asset write-
downs, restructuring activities, or acquired in-process research and 
development. In connection with our focus on transparent financial reporting 
and potential earnings management issues, we may select your 1998 annual 
report for review. For your consideration as you prepare that filing, this letter 
identifies commonly requested MD&A and financial statements disclosures 
that may be applicable in whole or part to the kinds of charges you incurred. 
………. 
Acquired In-Process Research & Development 
Disclose: 
• Specific nature and fair value of each significant in-process research and 
development project acquired 
• Completeness, complexity and uniqueness of the projects at the 
acquisition date 
• Nature, timing and estimated costs of the efforts necessary to complete the 
projects, and the anticipated completion dates 
• Risks and uncertainties associated with completing development on 
schedule, and consequences if it is not completed timely 
• Appraisal method used to value projects 
• Significant appraisal assumptions, such as— 
— period in which material net cash inflows from significant projects are 
expected to commence; 
— material anticipated changes from historical pricing, margins and 
expense levels; and 
— the risk adjusted discount rate applied to the project's cash flows. 
• In periods after a significant write-off, discuss the status of efforts to 
complete the projects, and the impact of any delays on your expected 
investment return, results of operations and financial condition 
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4.2.04 In determining whether entities should provide additional disclosures about 
IPR&D, the task force identified the following general considerations: 
• Financial statement disclosures need be provided only about items that are 
qualitatively or quantitatively material—individually or in the aggregate. 
• Disclosures about IPR&D should be considered in the context of the financial 
statements taken as a whole. The extent of disclosures about IPR&D should not give 
undue emphasis to IPR&D when research and development is a relatively minor 
aspect of the overall financial activities of the company. 
• To the extent that contemplated disclosures about IPR&D include forward-looking 
information, a public company should consider the legal implications of including 
those disclosures in the financial statements rather than outside the financial 
statements, such as in MD&A. The task force noted that the safe harbor for forward-
looking information adopted in the Private Securities Litigation Reform Act of 1995 
does not extend to financial statement disclosures. 
• Nonpublic companies should consider making the disclosures that a comparable 
public company would make. 
4.2.05 Financial Statements. Paragraph 51(g) of FASB Statement No. 141 requires 
disclosure of the amount of purchased R&D assets acquired and written off in the period 
in which a material business combination is completed and the line item in the income 
statement in which amounts written off are aggregated. For each acquisition having an 
associated material IPR&D charge, best practices suggest that an acquiring company 
disclose the following in the footnotes to the financial statements (both in the interim 
period of acquisition and in the annual financial statements of the year of acquisition):  
• The portion of the purchase price assigned to each individually material project 
• The technique used in each acquisition to value material assets acquired to be used 
in R&D activities 
4.2.06 The task force developed the following sample footnote disclosures as an 
illustration of the disclosure requirements of paragraph 51 (e) and (g) of FASB 
Statement No. 141 and best practices for a significant acquisition. (Appendix C of FASB 
Statement No. 141 provides illustrations of some of its disclosure requirements.) 
NOTE WW. SIGNIFICANT ACCOUNTING POLICIES—RESEARCH AND 
DEVELOPMENT EXPENSES 
 Company A incurred research and development expenses of $X, $Y, 
and $Z million in 2000, 1999, and 1998, respectively, including amounts 
assigned to acquired in-process technology of $200 million in 2000. The value 
assigned to acquired in-process technology was determined by identifying 
those acquired specific in-process research and development projects that 
would be continued and for which (a) technological feasibility had not been 
established at the acquisition date, (b) there was no alternative future use, and 
(c) the fair value was estimable with reasonable reliability. 
NOTE XX. ACQUISITIONS 
On October 5, 2000, Company A consummated its acquisition of Company X in a 
transaction accounted for as a business combination. Company X was engaged in 
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licensing, implementing, and supporting business network software systems, and 
had a well-established global service and support team. The aggregate purchase 
price of $1 billion for Company X’s equity consisted of approximately $400 million 
in cash and the issuance of 4 million shares of Company A common stock with a 
market value of approximately $600 million. In addition, short-term liabilities with a 
fair value of $300 million and long-term liabilities with a fair value of $700 million 
were assumed by Company A. The results of operations of Company X and the 
estimated fair value of the assets acquired and liabilities assumed are included in 
Company A’s financial statements from the date of acquisition. 
The purchase price was allocated to the tangible and intangible assets 
acquired and liabilities assumed based on Company A’s estimates of fair value 
at the acquisition date. The purchase price exceeded the amounts allocated to 
the tangible and intangible assets acquired and liabilities assumed by $785 
million, and this excess was classified as goodwill.  
The following table shows the allocation of the purchase price for the 
acquisition of Company X: 
Value Assigned to Assets & Liabilities 
Balance Sheet Category (in millions)  Acquired 
Current assets  $ 100 
Property, plant and equipment   650  
Acquired in-process R&D   200  
Intangible assets:  
Developed technology  175  
Customer list   25  
Trademarks 40  
Goodwill  785 
Other assets 25 
Short-term liabilities   (300)  
Long-term liabilities   (700) 
Net assets  $ 1,000 
 
Approximately $200 million of the purchase price represents the estimated fair 
value of acquired in-process R&D projects that had not yet reached 
technological feasibility and had no alternative future use. Accordingly, this 
amount was immediately expensed in the Consolidated Statement of Income 
upon the acquisition date. The value assigned to purchased in-process 
technology comprises the following projects: Project A ($100 million), Project B 
($70 million), and others ($30 million).  
The estimated fair value of these projects was determined by employment of a 
discounted cash flow model. The discount rates used take into account the 
stage of completion and the risks surrounding the successful development and 
commercialization of each of the purchased in-process technology projects 
that were valued.  
[Note: Required pro forma disclosures have been omitted.] 
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4.2.07 MD&A. The task force notes that the objectives and requirements of MD&A 
as stated in the instructions in Regulation S-K include the following: 
• The purpose of MD&A is to provide to investors and other users information relevant 
to an assessment of the financial condition and results of operations of the registrant 
as determined by evaluating the amounts and certainty of cash flows from 
operations and from outside sources. The information provided need only include 
that which does not clearly appear in the registrant’s financial statements. 
• MD&A should focus specifically on material events and uncertainties known to 
management that would cause reported financial information not to be necessarily 
indicative of future operating results or of future financial condition. This would 
include descriptions and amounts of (a) matters that would have an impact on 
future operations and have not had an impact in the past, and (b) matters that have 
had an impact on reported operations and are not expected to have an impact 
upon future operations. 
Registrants are encouraged, but not required, to supply forward-looking information. 
This is to be distinguished from presently known data that will affect future operating 
results, such as known future increases in costs. This latter data may be required to be 
disclosed. Any forward-looking information supplied is expressly covered by the safe 
harbor rule for projections. 
4.2.08 The task force also notes the following considerations that could influence 
management’s consideration of disclosures to be included in MD&A regarding IPR&D: 
• IPR&D charges may materially affect the total amount of R&D expense, income from 
continuing operations, or trends in those amounts. 
• IPR&D charges may cause reported financial information not to be necessarily 
indicative of future operating results. 
• Purchased R&D projects represent a known event that may produce uncertainty that 
could reasonably be expected to materially affect future operating results, due to 
additional R&D expenses expected to be incurred to complete the projects and 
changes in revenue and profitability from changes in the product sales mix. 
• Purchased R&D projects may represent a material demand on liquid resources to 
fund completion of the projects. 
• Qualitative information about management’s objectives in material acquisitions of 
businesses and intangibles may be helpful in understanding the financial statements 
“through the eyes of management.” 
• The SEC staff informed the task force that the staff believes that the letter to 
selected public company chief financial officers (see paragraph 4.2.03) continues to 
be relevant. That letter does not specify which of the commonly requested 
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VALUATION OF ASSETS ACQUIRED  
5.1 INTRODUCTION AND OVERVIEW  
5.1.01 Acquiring assets in a business combination requires ascertaining the cost of 
the acquired company (that is, purchase price) and assigning that cost to the assets 
acquired and liabilities assumed. The acquiring company should assign a portion of the 
purchase price to the assets acquired and liabilities assumed usually equal to their fair 
values at the date of acquisition. Tangible and intangible assets that meet the criteria in 
paragraph 39 of Financial Accounting Standards Board (FASB) Statement No. 141, 
Business Combinations, for separate recognition apart from goodwill should be 
assigned an amount; assets acquired to be used in research and development (R&D) 
activities generally represent intangible assets that also should be assigned a portion of 
the purchase price based on their fair values if they meet that criterion. Examples of 
assets acquired to be used in R&D activities include patents, software copyrights, base 
(or core) technology, developed product technology, specific in process R&D (IPR&D) 
projects, and technical drawings or manuals.1 The acquiring company undertakes 
procedures to specifically identify and value assets acquired to be used in R&D 
activities if either of the following conditions exists at the date of acquisition: 
• The acquired company was conducting R&D activities. 
• The acquired company has other assets that will be used in R&D activities by the 
combined enterprise. 
5.1.02 Valuations may be used as an aid in determining the fair values of assets 
acquired and liabilities assumed. A valuation specialist, engaged to perform a valuation 
of assets acquired in a business combination for the purpose of assisting management 
of the combined enterprise in the allocation of purchase price, should consider the best 
practices set forth in this Practice Aid. This chapter of the Practice Aid provides best 
practices related to the valuation of assets acquired in a business combination, with an 
emphasis on the valuation of assets acquired to be used in R&D activities, including 
specific in-process R&D (IPR&D) projects.  
5.1.03 The section of this chapter starting with paragraph 5.2 sets forth what the 
IPR&D Task Force believes are best practices in the acceptance, administration, and 
reporting of a valuation engagement in connection with the allocation of purchase price 
pursuant to generally accepted accounting principles (GAAP). The objective of that 
valuation is to estimate the fair value (as that term is defined by GAAP—see chapter 1) 
of the assets acquired and liabilities assumed, including assets acquired resulting from 
and to be used in R&D activities. The valuation specialist should perform appropriate 
procedures to estimate the fair value. 
                                            
1
 The Financial Accounting Standards Board (FASB) recently issued FASB Statement of Financial Accounting 
Standards No. 141, Business Combinations, which provides guidance on which intangible assets should be 
recognized apart from goodwill in the allocation of purchase price in a business combination.  
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5.1.04 The section of this chapter starting with paragraph 5.3 sets forth best 
practices on the application of the multi-period excess earnings methodology. The multi-
period excess earnings methodology is the most common method used by valuation 
specialists in estimating the fair value of assets acquired to be used in R&D activities, 
including specific IPR&D projects. 
5.2 PROCEDURES TO BE FOLLOWED BY VALUATION SPECIALISTS 
5.2.01 An acquiring company initially should decide whether it possesses sufficient 
expertise in-house to appropriately identify and value the assets acquired. In many 
cases, the expertise may not be available in-house, resulting in the need for the 
acquiring company to engage an independent valuation specialist to perform the 
valuation of the assets acquired. An acquiring company that engages an independent 
valuation specialist to perform a valuation would expect that the valuation specialist’s 
work will comply with the requirements of Statement on Auditing Standards (SAS) No. 
73, Using the Work of a Specialist (AICPA, Professional Standards, vol. 1, AU sec. 
336), so that the independent auditor may rely on the work of the independent valuation 
specialist. See chapter 6 of this Practice Aid for guidance on using the work of a 
specialist pursuant to SAS No. 73. Whether the valuation is prepared in-house or by an 
independent valuation specialist, the task force believes that the valuation specialist 
should follow the best practices set forth in this Practice Aid. 
5.2.02 Acceptance of Engagement 
5.2.03 The valuation specialist should consider several factors before accepting or 
performing a valuation engagement. These factors include the following: 
• The purpose of the valuation. The valuation specialist should consider the purpose 
of the engagement. The valuation methods employed by the valuation specialist will 
be determined by the reasons for the engagement because certain concepts, 
approaches, and standards of value may be required for certain types of 
engagements. For example, engagements that entail the valuation of assets 
acquired in a business combination are engagements to provide asset valuations 
that assist in forming the basis for purchase price allocations pursuant to FASB 
Statement No. 141, FASB Interpretation No. 4, Applicability of FASB Statement No. 
2 to Business Combinations Accounted for by the Purchase Method, and related 
guidance. Therefore, the valuation specialist should be familiar with, and his or her 
valuation report should be consistent with, the authoritative accounting literature as it 
relates to assets acquired in a business combination. 
• The valuation specialist’s competency to perform the engagement. The person 
performing the valuation should have demonstrated competence to perform the 
valuation. This competence is demonstrated by the valuation specialist’s prior 
experience in performing asset valuations (including assets acquired to be used in 
R&D activities), in connection with purchase price allocations pursuant to FASB 
Statement No. 141. The valuation specialist also would be expected to possess an 
appropriate understanding of the— 
 Industry in which the acquired company operates and its trends and conditions.  
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 Operations of the acquired and acquiring companies (including their products, 
marketing and distribution channels, technologies, and manufacturing processes). 
 Market participants (see paragraphs 1.1.04 and 1.1.05 for guidance on the 
effects of market participants on the valuation). 
• Willingness to be identified as an expert. Valuation specialists often undertake 
engagements for public registrants and render reports summarizing their findings and 
conclusions. These engagements may cause valuation specialists to be considered 
“experts” in the meaning of Section 7 of the Securities Exchange Act of 1933 (the 1933 
Act). In current practice, when work is performed solely to assist company management 
in estimating the fair value of assets acquired in a business combination, and neither 
the valuation specialist’s name nor his or her work is referred to in a 1933 Act filing, the 
valuation specialist generally would not be referred to in the filing as an expert. 
Therefore, the valuation specialist would not sign a consent as an expert. However, on 
occasion, the Securities and Exchange Commission (SEC) staff has requested 
valuation specialists to be referred to as experts in filings with the SEC. The task force 
believes that valuation specialists, in the case of engagements with public companies, 
should be prepared to support their valuation study in discussions with the SEC staff 
and willing to be referred to as an expert in filings with the SEC before accepting and 
completing a valuation engagement. 
• The proper identification of the assets to be valued. An important consideration in 
the valuation process is the identification of what will be valued. Therefore, the 
valuation specialist should be familiar with, and the valuation report should be 
consistent with, the criteria in paragraph 39 of FASB Statement No. 141 for separate 
recognition apart from goodwill.  Valuation engagements that entail the valuation of 
assets acquired to be used in R&D activities would identify the specific assets and 
IPR&D projects to be valued along with all the contributing assets. See paragraph 
5.3.33 for guidance on the characteristics and attributes of assets acquired to be 
used in R&D activities and paragraph 5.3.54 for guidance on contributory assets. 
• The proper date at which to value the assets. In this case, the assets acquired 
resulting from and to be used in R&D activities are valued as of the acquisition date, 
as defined in paragraph 48 of FASB Statement No. 141, of the business combination. 
See paragraph 4.1.03 for guidance on the definition of the acquisition date. 
• The appropriate premise or standard of value to be used. In the context of allocating 
purchase price to assets acquired in a business combination, the valuation of assets 
acquired to be used in R&D activities, including specific IPR&D projects, should be 
consistent with the concept of fair value as that term is defined by GAAP. See 
chapter 1 of this Practice Aid for guidance on the GAAP concept of fair value. 
• The appropriate approaches and methodologies for estimating value. The task force 
believes that this chapter sets forth best practices in the use of appropriate valuation 
methodologies to be applied in the valuation of assets acquired to be used in R&D 
activities, including specific IPR&D projects. See chapter 2 of this Practice Aid for a 
general discussion of valuation approaches to estimating fair value of assets acquired. 
• The relevant valuation standards and codes of ethics. Independent valuation 
specialists are subject to the standards and codes of ethics set forth by numerous 
professional organizations to which they belong. If valuation specialists hold 
themselves out as certified public accountants (CPAs) or partners, principals, or staff 
of AICPA member firms, they also should follow rules governing CPAs (particularly 
the Consulting Standards found in Professional Standards, vol. 2, CS sec. 100.). 
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• The type of report to be issued. The results of the valuation of assets acquired to be 
used in R&D activities, including specific IPR&D projects, should be documented in a 
written report, supported by appropriate exhibits and appendixes. A key requirement 
of a report prepared by an independent valuation specialist is that it contain sufficient 
information so it can be subjected to audit procedures outlined in SAS No. 73 (see 
chapter 6 of this Practice Aid). A limited scope valuation engagement or calculation is 
where the prospective financial information is not investigated by the valuation 
specialist in determining its propriety for use in the valuation. The task force believes 
that a limited scope valuation engagement or calculation would not be sufficient for the 
independent auditor to reduce the nature, timing, and extent of his or her audit 
procedures relating to the valuation of the assets acquired. See paragraph 5.2.06 for 
guidance on the contents of a valuation report. 
• The possibility of a conflict of interest or the appearance of a conflict of interest. A 
conflict of interest or the appearance of a conflict would include situations in which the 
client has the ability or appearance of an ability (through employment, ownership, 
contractual right, family relationship, or otherwise) to directly or indirectly control or 
significantly influence the valuation specialist. For example, the task force believes that 
a direct financial interest by a valuation specialist (or his or her firm, or principal owners 
of the firm) in the acquiring company or the acquired company would constitute a 
conflict of interest, which would necessitate disclosure in the valuation report. The task 
force believes that a valuation report prepared by a valuation specialist who is the 
subject of an actual or perceived conflict of interest may be precluded from being 
treated as the work of a specialist, as that term is used in SAS No. 73 (see paragraphs 
6.3.28 through 6.3.32). (Also see Discussion Memorandum 99-3, Appraisal and 
Valuation Services, issued by the Independence Standards Board.) 
5.2.04 Engagement Letters  
5.2.05 The task force believes that independent valuation specialists should be 
engaged by clients using some form of written agreement (that is, an engagement letter). 
An engagement letter is a document that defines the terms and scope of the valuation 
engagement as agreed upon with the client. The engagement letter helps avoid 
misunderstandings and, therefore, is in the interests of both the independent valuation 
specialist and the client. An engagement letter usually would include the following: 
• The objective or purpose of the valuation engagement. In this case, the objective of 
the valuation engagement is the performance of a valuation of assets acquired with 
the resultant fair value used to assist management of the acquiring company in the 
allocation of purchase price pursuant to FASB Statement No. 141, FASB 
Interpretation No. 4, and related guidance. 
• The date of the valuation. In this case, the assets acquired to be used in R&D 
activities are valued as of the acquisition date, as defined in paragraph 48 of FASB 
Statement No. 141, of the business combination.  
• The nature and scope of the procedures to be performed.  
• An identification of the assets to be valued. 
• A definition of the premise or standard of value (it is also customary to include the 
definition in the final written report). In this case, the premise/standard of value is fair 
value, as that term is defined by GAAP. See chapter 1 of this Practice Aid for 
guidance on the GAAP concept of fair value. 
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• The form of the report to be delivered. 
• The timing of the engagement. 
• The fees to be charged for the engagement. 
• A list of limiting conditions and restrictions on the use of the report by the party or 
parties that it is intended for. Valuation specialists would be expected to make the 
valuation report and the related supporting documentation available to the acquiring 
company’s independent auditors in connection with their audit of the allocation of 
purchase price. 
• An outline of what will be expected of the client in the engagement, such as providing 
the valuation specialist with the appropriate prospective financial information, and 
signing a representation letter at the conclusion of the engagement. 
• Other terms and conditions, as necessary. 
5.2.06 Contents of a Valuation Report 
5.2.07 The following discussion outlines the task force’s conclusions regarding the 
content of a well-documented valuation report. The valuation specialist’s report would 
not constitute an examination, compilation, or an agreed-upon procedures assignment 
as described in Statement on Standards for Attestation Engagement No. 10, Revision 
and Recodification (AICPA, Professional Standards, vol. 1, AT sec. 301, “Financial 
Forecasts and Projections”). Nonetheless, the valuation specialist will perform 
procedures necessary to satisfy himself or herself that prospective financial 
information (that is, a forecast of expected future cash flows, or PFI) is objectively 
verifiable (as evidenced by validating procedures), reliable, relevant, and useful to the 
valuation process. Best practices suggest (and some valuation standards of practice 
require) that the valuation specialist state in the report that he or she does not provide 
assurance on the achievability of the prospective results because events and 
circumstances frequently do not occur as expected; differences between actual and 
expected results may be material; and achievement of the prospective results is 
dependent on actions, plans, and assumptions of the responsible party (that is, the 
acquiring company’s management). 
5.2.08 Transmittal or cover letter. This section of the report (if prepared in this 
format) usually would include a signature of the valuation firm or individual. It would 
summarize the engagement, including information contained in the engagement letter, 
such as— 
• Objective of the valuation.  
• Purpose and function of the valuation.  
• Date as of which the assets are valued.  
• Premise or standard of value.  
• Summary description of the assets valued.  
• Scope of the assignment.  
• Any limiting conditions relating to the performance of the engagement, the use of the 
report, or both.  
Additional language may include a summary of findings or conclusions and a reference 
to the attached valuation study. The task force believes that there should not be any 
language in the report that is contradictory to the performance of best practices set forth 
in this Practice Aid. For example, PFI provided by management that is accepted by the 
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valuation specialist without having been subjected to validating procedures by the 
valuation specialist would contradict the performance of best practices set forth in this 
Practice Aid. Examples of validating procedures are outlined in paragraph 5.2.19.  See 
Exhibit 5-2.1 for an example of a transmittal letter. 
5.2.09 Table of contents and list of exhibits/appendixes. These typically are provided 
for ease of use by the reader. 
5.2.10 Certification. Most valuation standards of practice require that the valuation 
specialist provide a signed certification. For example, for those specialists subject to 
Uniform Standards of Professional Appraisal Practice (USPAP), Standard 10, Business 
Appraisal, Reporting, provides appropriate wording for the certification.  
5.2.11 Limiting conditions. Most standards of practice require a statement of those 
conditions that limit the activities of the valuation specialist and the use of the ultimate 
report. For example, section 8.3 of the American Society of Actuaries (ASA) Code of 
Ethics and Principles of Appraisal Practice lists mandatory limiting conditions; many 
valuation specialists have added language based on specific issues.  
5.2.12 Introduction or executive summary. This is an optional section used to 
increase the user-friendliness of the report; it often repeats a summary of findings or 
conclusions as well as other details mentioned in the Transmittal or Cover Letter 
section, as discussed in paragraph 5.2.08.  See Exhibit 5-2.2 for an example of an 
introduction or executive summary. 
5.2.13 The objective or purpose of the valuation engagement. See paragraph 5.2.05. 
5.2.14 History and nature of the company’s business and its assets. This is a 
background section that demonstrates the valuation specialist’s knowledge of the 
acquired company and identifies the assets to be valued. A description of the subjects 
that would be covered in this section includes the acquired company’s business; key 
events affecting the acquired company; competition, including identification of key 
markets and market participants; technology; management; structure of the acquired 
company; organization of the acquired company; ownership; and physical facilities of 
the acquired company. 
5.2.15 Analysis of the company’s industry. This section demonstrates the valuation 
specialist’s knowledge of the industry in which the acquired company participates and it 
identifies the key markets and market participants whose data will be used in analyzing 
the PFI. Key sources of industry data would be listed in this section. Competition would 
be a key topic of discussion in this section. This section is sometimes merged with the 
section described in paragraph 5.2.13.  See Exhibit 5-2.3 for an example of an analysis 
of the company’s industry. 
5.2.16 Analysis of the local, regional, and national economy affecting the company. This 
section demonstrates that the valuation specialist has an awareness of the current economic 
trends and conditions that may affect the acquired company’s operations. Some of the issues 
that are discussed in this section include: economic growth, interest rates, manufacturing 
capacity utilization, product demand, labor, and local and regional conditions. 
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5.2.17 Financial analysis of the company. This section demonstrates the valuation 
specialist’s knowledge of the historical financial performance of the acquired company. 
This section serves, in part, as a basis for review of the PFI for the acquired company. 
Generally, an analysis of three to five years of historical financial data is summarized, 
including growth trends, ratio analysis, and common-sizing of selected financial data.  
See Exhibit 5-2.4 for an example of the financial analysis of the company. 
5.2.18 General description of valuation approaches/methodologies. This section 
provides an overview of the valuation methods to be applied and demonstrates that 
the valuation specialist understands the applicable approaches and methodologies 
and best practices outlined in this Practice Aid. Generally, an overall description of 
the cost, market, and income approaches is provided, as well as specifics of the 
methods used for the valuation of assets acquired, including assets acquired to be 
used in R&D activities. In all but very rare circumstances, the multi-period excess 
earnings or another commonly accepted discounted cash flow methodology would 
be used for the valuation of intangible assets acquired to be used in R&D activities, 
including specific IPR&D projects. See Exhibit 5-2.5 for an example of a general 
description of valuation approaches. 
5.2.19 Valuation analysis. This is the most important section of the report and would 
expand on the background sections described above. This section would include a 
discussion of the following: 
• A description of the process used to identify assets for valuation and methodologies 
to be employed. See exhibit 5-2.5 for an example of a description of assets valued.   
• A description of how assets acquired to be used in R&D activities are classified into 
appropriate subcomponents (for example, base [or core] technology, developed product 
technology, and IPR&D projects). Sufficient, objective, verifiable evidence would be 
presented to demonstrate that the valuation specialist has considered the relevant 
accounting guidance on assets acquired to be used in R&D activities regarding— 
 Control. 




 Alternative future use. 
This evidence would be derived from review of factual data and interviews with 
management and market experts. Chapter 3 of this Practice Aid describes these 
bulleted items. 
• A listing of company data sources; documents received, read, and analyzed; 
interviews performed; and industry data sources used, if not mentioned elsewhere, 
and those market participants considered in the development of assumptions. This 
section’s purpose is to demonstrate that the valuation specialist has considered the 
appropriate data and has the necessary supporting documents in his or her work 
files. The supporting documentation and work files would be made available to 
management or the independent auditor upon request. 
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• For each asset valued, the following topics would be covered: 
 Assets valued pursuant to a cost approach. Sources of data (for example, 
acquiring company, acquired company, market participants), nature of costs 
(reproduction versus replacement), method of cost aggregation (that is, actual 
application of approach), treatment of obsolescence, treatment of taxes, 
treatment of amortization tax benefit, and circumstances that lead to selection of 
the cost approach as opposed to other approaches. The task force notes that the 
cost approach is rarely used in the valuation of intangible assets acquired to be 
used in R&D activities. 
 Assets valued pursuant to a market approach. Sources of comparable data 
(acquiring company, acquired company, market participants), adjustments 
to comparable data, application of actual method, discounts or adjustments 
to value indications, and circumstances that lead to selection of the market 
approach as opposed to other approaches. The task force notes that with 
the exception of certain assets within limited industries (for example, 
pharmaceuticals), the market approach is rarely used in the valuation of 
intangible assets. 
• Assets valued pursuant to an income approach. In the case of the multi-period 
excess earnings or another commonly accepted discounted cash flow methodology: 
 Sources of PFI (acquiring company, acquired company, financial advisers, or 
market participants) 
 Procedures performed to allow the valuation specialist to rely on and use the PFI  
 Adjustments made to PFI 
 Procedures performed (such as revenue splitting)  
 Sources of data and procedures performed to reflect technology migration and 
the existence and separate valuation of base (or core) technology and other 
contributory assets 
 Development of appropriate tax rates, discount rates, and contributory asset charges  
 Actual application of the method, including calculation of the amortization tax benefit 
See exhibit 5-2.6 for an example of assets valued pursuant to an income approach. 
In the case of the relief from royalty method (the task force notes that the use of this 
method in valuing specific IPR&D projects should be rare, as discussed in paragraph 
2.1.15):  
 Revenue forecasts (acquiring company, acquired company, financial advisers, or 
market participants) 
 Procedures performed to allow the valuation specialist to rely on the revenue forecasts 
 Sources of royalty or license rates (for example, internal company comparable 
data, external market comparable data, and publicized sources) 
 Development of discount rates and tax rates  
• An affirmation that the valuation will be used in the allocation of purchase price in 
accordance with GAAP. 
 69 
5.3 APPLICATION OF MULTI-PERIOD EXCESS EARNINGS METHOD TO 
ACQUIRED INTANGIBLE ASSETS 
5.3.01 Overview 
5.3.02 The multi-period excess earnings method is the most common method used 
by valuation specialists in estimating the fair value of intangible assets acquired to be 
used in R&D activities, including specific IPR&D projects, for purposes of allocating 
purchase price pursuant to FASB Statement No. 141, FASB Interpretation No. 4, and 
related guidance.  
5.3.03 The principle behind the multi-period excess earnings method is that the 
value of an intangible asset is equal to the present value of the incremental after-tax 
cash flows attributable only to that intangible asset. 
5.3.04 The application of the multi-period excess earnings method generally involves 
the following overall steps: 
1. Select the PFI that best reflects the final purchase price. 
2. Evaluate and document the key assumptions relating to the elements that make up 
the PFI and ascertain that the PFI reflects management’s good-faith best estimates. 
3. Eliminate synergies (that is, acquiring company and acquired company assumptions 
that are not consistent with assumptions used by market participants) from the 
selected PFI resulting in the “adjusted PFI.”  Also see paragraph 1.1.15. 
4. Identify assets acquired, including assets to be used in R&D activities. 
5. Confirm the existence of assets acquired to be used in R&D activities, including 
specific IPR&D projects. 
6. Eliminate effects of non-IPR&D activities from the PFI resulting in the “final PFI.” 
7. Apply contributory asset charge for assets that contribute to the generation of the cash 
flows (that is, apply contributory asset charges to the cash flows). 
8. Calculate the present value of the cash flows using a discount rate appropriate for the 
specific asset acquired being valued. 
9. Compute the related income tax benefits resulting from the amortization of the asset 
acquired for income tax purposes. 
10. Evaluate the overall reasonableness of the asset’s fair value relative to the other 
assets acquired and the overall purchase price. 
5.3.05 To summarize the multi-period excess earnings method, the fair value of an 
intangible asset acquired is estimated by deducting expected costs, including income 
taxes (as described in paragraph 5.3.97), from expected revenues attributed to that 
asset to arrive at after-tax cash flows. Such revenues and costs should reflect the 
assumptions that would be used by market participants. From after-tax cash flows, 
after-tax contributory asset charges are deducted (see paragraph 5.3.54) to arrive at 
incremental after-tax cash flows. These remaining cash flows are discounted to present 
value (see paragraph 5.3.68) and then summed. The calculation of the value of the 
amortization tax benefit (see paragraph 5.3.97) is added to the sum of the present 
values of incremental after-tax cash flows to arrive at the fair value of the intangible 
asset acquired. See exhibit 5-2 for a comprehensive example of a valuation analysis of 
intangible assets acquired to be used in R&D activities. The final step is the 
determination of the overall reasonableness of the asset’s fair value. 
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5.3.06 Step 1—Select the Prospective Financial Information That Best Reflects 
the Final Purchase Price 
5.3.07 Before consummation of a business combination, various PFI alternatives 
frequently are prepared. From the perspective of the acquired company, PFI often exist 
as a result of reports and analyses that management had prepared as part of ongoing 
management of technology projects and overall business operations. PFI also may 
have been prepared by the acquired company or its advisers as part of the selling effort 
(for example, offering memoranda). From the perspective of the acquiring company, PFI 
may have been prepared as part of due diligence procedures or as part of an overall 
process to determine acceptable purchase price ranges. The PFI may encompass 
various alternatives, including optimistic, base case, pessimistic scenarios, or all three. 
All PFI produced by parties to the transaction (as well as by their advisers) should be 
evaluated by the valuation specialist to understand the underlying assumptions and the 
differences between the sets of assumptions. 
5.3.08 The PFI alternative that best reflects the final purchase price is the logical 
starting point for the valuation specialist. The valuation specialist should prepare an 
information request to assist in evaluating which PFI alternative best represents the 
alternative that was used in negotiating the final purchase price. The following 
information, for example, would be requested: 
• Historical financial statements of the acquired company for an appropriate period of 
time (for example, the most recent five years) 
• Transaction documents (that is, the purchase agreement and related exhibits) 
• Press releases and other public disclosures of the transaction 
• PFI prepared by the acquired company 
• PFI prepared by the acquired company’s advisers 
• PFI prepared by the acquiring company 
• PFI prepared by the acquiring company’s advisers 
• PFI prepared for lenders 
• Reports of outside analysts, market experts, governmental agencies, or other third 
parties, that relate to the transaction 
• Board of directors’ presentations prepared for the acquired company 
• Board of directors’ presentations prepared for the acquiring company 
• Technical analysis that relates to the acquired company’s products or technologies 
(whether it be prepared by the acquiring company, acquired company, or a third party) 
• Sales or marketing materials used to sell the acquired company’s products and services 
• Data on patents held by the acquired company 
• Acquired company’s analysis of its specific IPR&D projects, including analysis 
supporting management’s approval of the projects and periodic status reports 
• R&D budget of the acquired company 
• Historical R&D expenditures by the acquired company 
• Product road map or other similar detail of the acquired company’s expected evolution 
from current products and technologies to future products and technologies 
• Licensing agreements that exist for either the development of technologies or 
ultimate marketing of product manifestations 
• Identification of market participants and relevant market participant data  
• Government or industry publications  
• Market surveys 
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• Engineering studies  
• General economic indicators  
• Industry statistics  
• Trends and patterns developed from the acquired company’s operating history (for 
example, life cycles of prior generations of products and rate of changes in average 
selling prices) 
• Internal data and analyses, accompanied by their supporting objective evidence  
5.3.09 Not all of these data sources will be available in a given transaction. At a 
minimum, the valuation specialist should collect data that would have been considered 
by the acquiring company and acquired company in performing their due diligence and 
agreeing upon a final purchase price. The valuation specialist also would consider 
significant changes that may have occurred between the date when the acquiring 
company and acquired company came to final terms and the acquisition date of the 
business combination. Upon collecting the relevant data, the valuation specialist should 
interview appropriate members of the acquiring and acquired companies’ management 
teams (if relevant and applicable). Management should be in a position to state its 
reliance on such data when corroborative or explain its lack of reliance when contrary. 
The functional departments represented in such queries would include: scientific (that 
is, R&D), marketing, sales, finance, accounting, and operations. See paragraph 5.3.26 
for additional information to be obtained during these interviews with management. 
5.3.10 The valuation specialist should understand and document the process by 
which the PFI was prepared. To the extent that management or its advisers have a 
process for preparing PFI, the valuation specialist will be able to readily find the support 
for the PFI and determine its suitability for use in the valuation analysis. Best practices 
suggest that significant differences (and their underlying reasons) between the PFI used 
in the valuation of the acquired company and the final PFI that was presented to the 
acquiring company’s board of directors or management (as appropriate) by the 
acquiring company, acquired company, or their financial advisers should be 
documented and reconciled. The task force believes that the valuation specialist should 
select the PFI that best represents the alternative that was used in negotiating the final 
purchase price and, therefore, is most representative for purposes of determining the 
fair value of the acquired company. 
5.3.11 The task force believes that management of the acquiring company should 
take responsibility for the completeness and accuracy of the PFI alternative selected for 
use in the valuation analysis. Management would represent to the valuation specialist 
that the PFI represents management’s best estimate of the most likely expected 
outcome of the economic benefits resulting from the assets acquired. Management also 
would be expected to provide the valuation specialist with data supporting the key 
assumptions used in the preparation of the PFI, including identification of any expected 
synergies. The valuation specialist does not simply accept PFI from management 
without investigating its suitability for use in the valuation analysis. The valuation 
specialist is responsible for evaluating the methodology and assumptions used by 
management in preparing the PFI and concluding whether the PFI is appropriate for use 
in valuing the assets acquired.  
5.3.12 At this point, the valuation specialist and management should reach 
agreement on the PFI alternative that best represents the alternative that was used in 
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negotiating the final purchase price and, therefore, is most representative for purposes 
of determining the fair value of the acquired company. If the valuation specialist and 
management cannot agree on the appropriate PFI alternative, the valuation specialist 
would disclose the nature of its disagreement in its valuation report and the effect, if 
quantifiable, on the value assigned to the assets acquired. Pursuant to some 
professional standards of conduct, the valuation specialist also would need to consider 
the possibility of resigning from the engagement if the valuation specialist concludes 
that the management-prepared PFI is not appropriate. 
5.3.13 Step 2—Evaluate and Document the Key Assumptions Relating to the 
Elements That Make Up the PFI and Ascertain That the PFI Reflects 
Management’s Good-Faith Best Estimates 
5.3.14 The next step for the independent valuation specialist would be to evaluate 
the methodology and assumptions used by management in preparing the PFI and 
concluding whether the methodology and assumptions are appropriate for use in the 
valuation analysis. The following represents specific elements of PFI for the valuation 
specialist to verify and suggested sources of objective evidence that support each 
material assumption underlying the specific elements of PFI: 
• Revenue. The valuation specialist’s assessment of PFI begins with an analysis of 
the key assumptions related to revenue from current products and revenue that is 
expected to result from both specific IPR&D projects and R&D projects not yet 
commenced, including estimated number of units expected to be sold, estimated 
selling prices throughout the selling period, estimated market penetration, and 
estimated market share. Year-over-year unit growth (or decline) rates over the 
product(s) life cycle(s) (that is, the period of years over which revenue is expected to 
be received for a given technology or related product offering) and the 
reasonableness of average per-unit selling prices during the period should be 
evaluated by the valuation specialist, giving due consideration to expected 
competitors’ reactions, anticipated technological developments, and historical trends. 
Historical financial data of the acquired company is a common source of objective 
evidence to support the assumptions in the PFI regarding revenue. Industry data, 
data from public filings of market participants, and reports generated by market 
research firms and industry analysts also may be sources of objective evidence to 
support revenue assumptions in PFI. Once these key assumptions relating to 
revenue are understood by the valuation specialist, management should be queried 
on its support for material assumptions. 
• Costs of sales. Historical financial data of the acquired company is a common source of 
objective evidence to support the assumptions in the PFI regarding cost of sales. 
Industry data, data from public filings of market participants, and reports generated by 
market research firms and industry analysts also may be sources of objective evidence 
to support cost of sales assumptions in PFI. Valuation specialists should understand the 
difference between company-wide costs of sales and specific product-by-product costs 
of sales because costs of sales may change over a product’s life cycle and likely will 
differ from product to product. Valuation specialists should query management about 
past experience with prior product offerings and compare the trend of costs of sales for 
prior product offerings with those contained in the PFI. 
• Sales and marketing expense. Historical financial data of the acquired company is a 
common source of objective evidence to support the assumptions in the PFI 
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regarding sales and marketing expense. Industry data, data from public filings of 
market participants, and reports generated by market research firms and industry 
analysts also may be sources of objective evidence to support sales and marketing 
expense assumptions in PFI. Product launch costs should be included in PFI if 
product development activities are expected to lead to the introduction of new 
product offerings. Product launch costs commonly are incurred during the 
introduction of new product offerings and can differ dramatically from routine sales 
and marketing expense. Objective evidence may be gathered from the acquired 
company’s prior experience with previously launched product offerings or from 
industry and market participant’s data. 
• General and administrative expense. Historical financial data of the acquired 
company is a common source of objective evidence to support the assumptions in 
the PFI regarding general and administrative expense. Industry data, data from 
public filings of market participants, and reports generated by market research firms 
and industry analysts also may be sources of objective evidence to support general 
and administrative expense assumptions in PFI. 
• Technical support expense. Historical financial data of the acquired company is a 
common source of objective evidence to support the assumptions in the PFI 
regarding technical support expense. Industry data, data from public filings of market 
participants, and reports generated by market research firms and industry analysts 
also may be sources of objective evidence to support technical support expense 
assumptions in PFI. 
• R&D expense. Historical financial data of the acquired company is a common source 
of objective evidence to support the assumptions in the PFI regarding R&D expense. 
Industry data, data from public filings of market participants, and reports generated 
by market research firms and industry analysts also may be sources of objective 
evidence to support R&D expense assumptions in PFI. 
• Tax expense. See paragraph 5.3.97 for guidance on the impact of income taxes on 
the determination of fair value of assets acquired. 
• Required levels of net working capital. PFI may include expectations regarding 
working capital needs for the acquired company. Historical levels of working capital, 
combined with industry experience available from the public filings of market 
participants, typically serve as the best evidence of required levels of working 
capital. Such levels will further serve as an input to the calculation of future 
contributory asset charges in the valuation analysis. See paragraph 5.3.54 for 
guidance on contributory asset charges. 
• Required levels of tangible assets. PFI may include expectations regarding tangible 
asset needs for the acquired company. Historical levels of tangible assets, combined 
with industry experience available from the public filings of market participants, typically 
serve as the best evidence of required future levels of tangible assets. Such levels will 
further serve as an input to the calculation of contributory asset charges in the valuation 
analysis. See paragraph 5.3.54 for guidance on contributory asset charges. 
• Required levels of intangible assets. PFI typically does not include expectations 
regarding intangible asset needs for the business in aggregate because companies 
often do not budget purchases of intangible assets. Levels of other intangible assets 
calculated as a result of the valuation process associated with allocating the 
purchase price, combined with industry experience available from the public filings of 
market participants, typically serve as the best evidence of required levels of 
intangible assets. Such levels will further serve as an input to the calculation of 
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contributory asset charges in the valuation analysis. See paragraph 5.3.54 for 
guidance on contributory asset charges. 
5.3.15 To the extent that the valuation specialist, in his or her judgment, does not 
receive sufficient support for particular PFI assumptions, the valuation specialist should 
investigate other client records as well as external sources in an effort to locate 
corroborating objective support for each material assumption. If conflicting data exists, 
the task force believes that the valuation specialist should challenge management to 
further support its assumptions or change those assumptions to be consistent with the 
objective evidence.  
5.3.16 At this point the valuation specialist would have completed his or her 
evaluation of the methodology and assumptions used by management in the 
preparation of the PFI that best reflects the final purchase price. The valuation specialist 
and management should reach agreement on the methodology and assumptions used 
in the preparation of the PFI alternative that best reflects the final purchase price. If the 
valuation specialist and management cannot agree on the appropriate methodology and 
assumptions used in the preparation of the selected PFI, the valuation specialist would 
disclose the nature of the disagreement in the valuation report and the effect, if 
quantifiable, on the value assigned to the assets acquired. Pursuant to some 
professional standards of conduct, the valuation specialist also would need to consider 
the possibility of resigning from the engagement if the valuation specialist concludes 
that the management-prepared PFI is not appropriate. 
5.3.17 Step 3—Eliminate Synergies From the Selected PFI, Resulting in the 
Adjusted PFI2  
5.3.18 At this point in the valuation process, the assumptions used in the preparation 
of the selected PFI may include assumptions that are specific to the acquiring company 
and not necessarily those of market participants. Therefore, the next step in the multi-
period excess earnings analysis is to remove from the selected PFI the cash flows 
attributed to synergies.3 Valuation methods for measuring assets should be consistent 
with the objective of measuring fair value, as that term is defined by GAAP. Those 
methods would incorporate assumptions that market participants would use in their 
estimates of values, future revenues, and future expenses. If the acquiring company 
pays the owners of the acquired company any significant consideration for synergistic or 
strategic benefits in excess of those expected to be realized by market participants, the 
valuation specialist would identify those excess benefits and remove them from the 
selected PFI. (Those excess benefits ultimately will be included in the portion of the 
purchase price allocated to goodwill.) The ultimate assumptions included in the selected 
PFI that are used to assign cost to the assets acquired should reflect the best estimate 
of how market participants would benefit from use of the assets acquired.  Also see 
paragraph 1.1.15 for guidance on strategic or synergistic value. 
                                            
2
 Synergies are acquiring company and acquired company assumptions that are not consistent with assumptions 
used by market participants. 
3
 Paragraph B174 of FASB Statement No. 141 provides that an entity may use its estimates of cash flows if 
market participant assumptions are not available without undue cost and effort. 
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5.3.19 During the data collection and management interview process, the valuation 
specialist should identify, document, and evaluate the reasonableness of the synergistic 
revenues and cost savings identified by management of the combined enterprise. 
Management of the combined enterprise should be queried on what unique operating 
efficiencies or revenue enhancements are expected to be experienced by the combined 
enterprise that would not be expected to be experienced by market participants. Once 
identified, those synergistic revenues (that is, revenue enhancements) and cost savings 
should be eliminated from the selected PFI.  
5.3.20 Synergies unique to the combined enterprise should not be used in estimating 
the fair value of any asset acquired. Adjustments to the selected PFI can be 
accomplished by revising the revenue growth or cost savings rates from those used in 
the selected PFI to those of market participants.  
5.3.21 Example–eliminating cost synergies. Company A acquired Company X in a 
business combination. Selling costs for Company X are 40 percent of revenues, and the 
rate representative of performance of market participants is 30 percent of revenues. 
Due to the unique size and efficiency of its distribution channel, selling costs for 
Company A are 20 percent (also the rate used by Company A in its PFI alternative that 
was used to negotiate the final purchase price). Selling costs in the PFI would be 
adjusted up to 30 percent, the rate representative of market participants, to eliminate a 
synergy specific to the acquiring company.  
5.3.22 Example–eliminating revenue synergies. Company A acquired Company X in a 
business combination. Company X’s product complements Company A’s product. Upon 
acquisition, Company A’s combined product offering will be unique in the market, and 
Company A believes that it can derive 10 percent more in revenues from both products 
than it or market participants could if they were to sell either product on a separate stand-
alone basis. The PFI should exclude all revenues attributable to Company A’s preexisting 
product, and the incremental 10 percent increase in revenues derived from Company X’s 
product, which resulted from having a combined product offering. 
5.3.23 Example–eliminating income tax synergies. Company A acquired Company X 
in a business combination. Company A currently does not pay income taxes because of 
net operating loss carryforwards. Company A does not expect to pay income taxes in 
the foreseeable future due to the size of the net operating loss carryforwards. In the PFI 
that Company A provides to the valuation specialist for use in valuing certain assets 
acquired to be used in R&D activities, management of Company A does not include any 
expected income tax payments resulting from the cash flows attributable to the acquired 
assets. In other words, in the PFI prepared by Company A’s management, the present 
value of the expected future cash flows attributed to the acquired assets is the same on 
a pretax basis as on an after-tax basis because no income tax payments are expected. 
5.3.24 The valuation specialist would adjust the PFI to include an estimate of the 
expected tax payments that market participants would be expected to pay on the 
expected future cash flows attributable to the acquired assets. The “favorable” tax 
attributes of Company A is a synergy and, therefore, is eliminated from the PFI used to 
value the acquired assets. See paragraph 5.3.97 for guidance on the impact of income 
taxes on the multi-period excess earnings method. 
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5.3.25 At this point the valuation specialist would have adjusted the selected PFI so 
the assumptions underlying the selected PFI would reflect the assumptions expected to 
be experienced by market participants (adjusted PFI). The next step in the analysis is to 
identify which assets acquired are to be valued by the valuation specialist. 
5.3.26 Step 4—Identify Assets Acquired, Including Assets to Be  
Used in R&D Activities 
5.3.27 At the outset of the valuation analysis, the valuation specialist and 
management should identify all assets acquired that can be subjected to valuation 
procedures (including all contributory assets, as discussed in paragraph 5.3.54). Many 
assets already will be identifiable from the balance sheet of the acquired company 
based on historical transactions. These assets typically include working capital items, 
such as cash, accounts receivable, inventory, and prepaid expenses. Also, tangible 
assets commonly appear on historical balance sheets at historical cost less 
accumulated depreciation. Intangible assets appear less frequently because they 
typically result from prior business combinations or asset acquisitions by the acquired 
company. Historical balance sheets often do not include intangible assets that were 
developed internally by the acquired company. All assets acquired will require analysis 
to determine their fair value in the current transaction. 
5.3.28 During the analysis of historical financial data, the valuation specialist would 
interview management of the acquiring and acquired companies, including those 
responsible for marketing and technology development. During those interviews, the 
valuation specialist would collect company data relating to product offerings, channels 
of distribution, facilities, operations of the acquired company, and R&D efforts underway 
by the acquired company. The purpose of those interviews would be to ascertain the 
existence of other intangible assets not readily apparent from a reading of the historical 
financial data. The valuation specialist generally would have made reference to a list of 
potential intangible assets, such as that referenced in paragraph 5.3.60 (which 
references appendix A of FASB Statement No. 141) of this Practice Aid, in conducting 
the interviews of management. A common inquiry to management is “What is your 
perception of the assets you acquired?” or, alternatively, “What is your perception of the 
assets you sold?” 
5.3.29 In the context of an acquisition of a technology-based company, assets 
acquired to be used in R&D activities often are part of the finalized list of assets to be 
valued. Therefore, the valuation specialist’s inquiry of management also would include a 
discussion regarding the identification and classification of assets acquired to be used in 
R&D activities. The valuation specialist also would review the following information in 
evaluating management’s identification and classification of assets acquired to be used 
in R&D activities: 
• Presentations to the board of directors 
• Offering memoranda 
• Due diligence reports 
• Press releases (including those of the acquired company before the business combination) 
• Web site materials 
• Analysts reports 
• Industry reports 
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5.3.30 Ultimately, the valuation specialist should agree with management on a 
specific listing of assets to be valued, based on the facts and circumstances of the 
specific transaction, and the experience of management and the valuation specialist.4 
5.3.31 The remainder of this chapter will focus on estimating the fair value of assets 
acquired to be used in R&D activities, including specific IPR&D projects, using the multi-
period excess earnings methodology. 
5.3.32 Step 5—Confirm the Existence of Assets Acquired to Be Used in R&D 
Activities, Including Specific IPR&D Projects 
5.3.33 Once the existence of assets acquired to be used in R&D activities has been 
preliminarily established, the valuation specialist should evaluate and document his or her 
conclusion that the identified assets meet the definition of assets acquired to be used in 
R&D activities. Considerations in reaching such a conclusion would include an analysis of 
the characteristics and attributes of assets to be used in R&D activities, including specific 
IPR&D projects, which are discussed in detail in chapter 3 of this Practice Aid. 
• Scope of IPR&D projects. An IPR&D project is the result of activities undertaken 
before the acquisition date, the costs of which qualify as R&D costs pursuant to 
FASB Statement No. 2, Accounting for Research and Development Costs, and 
related guidance. See paragraph 3.3.01 for guidance on the scope of R&D activities. 
• Control. The valuation specialist should conclude and document that the acquiring 
company has purchased assets to be used in R&D activities that the acquiring 
company obtains the benefit of and controls others’ access to. See paragraphs 
3.2.02 and 3.3.13 for guidance on the definition of control. Evidence that indicates 
that the acquiring company has met the control characteristic would include— 
 Existence of patents, software copyrights, or regulatory approval. 
 Ability to sell, lease, license, franchise, or use the assets.  
 Qualitative data that indicates that the company has what it believes are 
defendable intellectual proprietary rights to the assets. 
• Economic benefit. The valuation specialist should conclude that the assets acquired 
to be used in R&D activities are anticipated to produce an economic benefit. See 
paragraphs 3.2.02 and 3.3.17 for guidance on the definition of economic benefit. 
Evidence to be considered includes the existence of the acquired company’s 
business plans for commercial exploitation of the technology through product 
offerings that were developed when it initially considered funding the project and 
thereafter when considering whether to continue funding the project, forward-looking 
statements made by management regarding anticipated economic benefits of the 
technology, and external market or industry data that support the significance of the 
potential economic benefits or substantiates the existence of an unserved or 
underserved market for product offerings related to the technology project. Parallel 
efforts to develop similar technologies by competitors also would corroborate the 
existence of anticipated economic benefit. 
                                            
4
 See footnote 1.
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• Measurability. The valuation specialist should conclude and document that the value of 
the assets acquired to be used in R&D activities is estimable with reasonable reliability. 
See paragraphs 3.2.03 and 3.3.22 for guidance on the definition of measurability. The 
valuation specialist generally would review the business plans that address the 
exploitation of the technology through product offerings. These business plans should be 
supportable by historical data of the acquired company, other current company records, 
opinions of market experts either internal or external to the company, external 
publications, the opinion of external industry analysts, or a combination of these. The fact 
that assets acquired to be used in R&D activities are anticipated to have economic benefit 
does not, in and of itself, indicate that such benefit is estimable with reasonable reliability. 
Sufficient objective, verifiable evidence to support the assumptions used in the 
measurement process must exist to compute a reasonably reliable estimate of the fair 
value to be assigned to the assets acquired to be used in R&D activities. 
• Substance. The valuation specialist should conclude and document that an R&D 
project has been advanced to a sufficient stage to be deemed to have substance. 
See paragraphs 3.2.04 and 3.3.45 for guidance on the definition of substance. 
Evidence to be considered includes— 
 The stage of completion of the project as evidenced in the acquired company’s 
records, such as periodic status reports of specific IPR&D projects. 
 The treatment and emphasis given to the project in the company’s product road 
map for the technology. 
 The acquired company’s R&D budget.  
 The acquired company’s R&D planning documents and related status reports.  
 R&D costs incurred by project and estimated costs to complete the project. 
 Press releases by the acquired company.  
 Presentations to the board of directors.  
 Offering memoranda.  
 Due diligence reports.  
 Web site materials.  
 Assessments made by market research firms and industry analysts. 
• Incompleteness. The valuation specialist should conclude and document that the 
technology project is incomplete as of the acquisition date. See paragraphs 3.2.04 
and 3.3.54 for guidance on the definition of incompleteness. Evidence to be 
considered includes— 
 The stage of development as indicated by the development milestones attained 
and yet to be reached. 
 Remaining technological, engineering, or regulatory risks to be overcome. 
 Remaining development costs to be incurred.  
 Remaining time to be spent to reach completion.  
 Probability of successful completion. 
Such analysis also will be useful in determining the impact of stage-of-completion on 
the selection of an appropriate discount rate under the traditional approach. (See 
paragraph 5.3.81 for guidance on selection of an appropriate discount rate.) 
• Alternative future use. The valuation specialist should conclude and document 
whether the assets acquired to be used in R&D activities have an alternative future 
use. See paragraphs 3.2.06 and 3.3.69 for guidance on the definition of alternative 
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future use. If assets acquired to be used in R&D activities (recognized separate and 
apart from goodwill) have an alternative future use, the allocated fair value of those 
assets would be accounted for pursuant to FASB Statements No. 141 and No. 142, 
Goodwill and Other Intangible Assets. If assets acquired to be used in R&D activities 
(recognized separate and apart from goodwill) do not have an alternative future use, 
the allocated fair value of those assets would be charged to expense as of the date 
of acquisition.  
5.3.34 Once the existence of assets acquired to be used in R&D activities 
(recognized separate and apart from goodwill) has been established, the valuation 
specialist should remove from the adjusted PFI activities unrelated to assets acquired to 
be used in R&D activities, including ancillary revenues. Once removed, the remaining 
cash flows included in the adjusted PFI will represent the expected future cash flows to 
be used as the basis for estimating the fair value of assets acquired to be used in R&D 
activities, including specific IPR&D projects. 
5.3.35 Step 6—Eliminate Effects of Non-IPR&D Activities From the PFI 
Resulting in the Final PFI  
5.3.36 If cash flows attributable to activities that are unrelated to assets acquired to be 
used in R&D cannot be removed from the adjusted PFI (because those cash flows are 
not largely independent of the cash flows attributable to assets acquired to be used in 
R&D activities), a contributory asset charge would be used to remove the benefits of net 
after-tax cash flows associated with the activities that are unrelated to assets acquired 
to be used in R&D. Maintenance, consulting, service, and other ancillary revenues and 
costs also would be eliminated from the adjusted PFI at this step. The task force 
believes that ancillary revenues and costs should be excluded from the valuation 
analysis of assets acquired to be used in R&D activities because ancillary revenues and 
costs do not represent cash flows resulting directly from the assets acquired to be used 
in R&D activities. Ancillary revenues and costs are an indirect benefit. While there might 
be a conceptual basis for including the ancillary revenues and costs in the valuation 
analysis, the task force believes that it is unlikely that the ancillary revenues’ 
contribution to the value of the assets acquired to be used in R&D activities would be 
significant, after taking into consideration assumptions used by market participants and 
applying appropriate expenses and contributory asset charges. 
5.3.37 Example—IPR&D bundled with non-IPR&D. Company A acquired Company 
X in a business combination. At the acquisition date of the business combination, 
Company X was developing a software product. Company A plans to sell a solution that 
will bundle the software product (IPR&D) under development acquired from Company X 
with computer hardware (non-IPR&D) purchased from a third party. The solution is 
expected to be sold for a single price, and Company A concludes that it cannot reliably 
remove the revenues and costs associated with reselling the computer hardware from 
the PFI attributable to the software product under development. Using an estimate of 
the value of identifiable assets committed to the hardware reselling business (including 
net working capital, tangible assets, and intangible assets), a contributory asset charge 
is calculated and charged against the combined after-tax cash flow of the solution for 
the use of those assets representing the business of hardware resale. The remaining 
after-tax cash flows would be attributable to the software product under development. 
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5.3.38 At this point, the remaining cash flows included in the adjusted PFI represent the 
expected future cash flows that will be used as the basis for estimating the fair value of 
assets acquired to be used in R&D activities, including specific IPR&D projects (final PFI). 
5.3.39 PFI attributable to assets acquired to be used in R&D activities. The forecast of 
future expected revenues and expenses included in the final PFI would extend only for the 
estimated useful life of the related assets acquired. Thus, the fair value of assets acquired to 
be used in R&D activities should not include the value inherent in gaining a market position 
that may be retained after the value of the assets acquired to be used in R&D activities has 
been exhausted. Except for a few specific industries (for example, pharmaceutical), best 
practices suggest that the estimated life typically would be presumed to not extend beyond 
five to seven years, unless there is objectively verifiable evidence to support a longer life for 
the technologies. In many cases, the estimated life would be shorter than five to seven years, 
which should be considered an outer limit for software and hardware technologies. However, 
for pharmaceutical industries, the life of a patent compound that will be marketed as a drug 
upon successful completion of development generally would be the patent life or the period of 
market exclusivity, if longer. The pattern of cash flows (for example, growth rates and 
profitability) would follow patterns that would be expected by market participants. 
5.3.40 The final PFI should be further allocated into various subcomponents of the 
assets acquired to be used in R&D activities. These subcomponents of the assets acquired 
to be used in R&D activities may include patents, software copyrights, base (or core) 
technology, developed product technology, specific IPR&D projects, technical drawings or 
manuals, and general intellectual know-how. Each subcomponent generally would be 
separately identified and valued (provided that subcomponent meets the criteria in 
paragraph 39 of FASB Statement No. 141 for separate recognition apart from goodwill). 
5.3.41 A current product’s attributes and characteristics (known as functionality) are a 
result of the functionality of prior versions or releases of the product (referred to as base or 
core technology) and the functionality that was added as a result of the release of the current 
product (referred to as developed product technology). As future versions of the products are 
released, the revenue generated by those future products also will be a result of research 
and development that is undertaken in the future (referred to as future R&D or future 
technology). The forecast of expected future revenue is based on sales of products. At times, 
there is a direct correlation between a technology project and a new product offering. When 
the subcomponents of assets acquired to be used in R&D activities are used by many 
product offerings, or when the subcomponents will be used over numerous 
generations of product offerings, the valuation specialist should go through a process 
of assigning a portion of the revenue stream from each product offering to the 
subcomponents. The allocation of the cash flows to the subcomponents would consider 
the relative contribution of developed product technology, current R&D projects, future 
technology, and base (or core) technology over successive releases of products that 
incorporate these subcomponents (the process of allocating the cash flows is referred to 
as technology migration). The contribution of each subcomponent of technology will be 
based on the specific facts and circumstances. The following factors would be 
evaluated in determining the contribution of each subcomponent of technology: 
• Historical cost to develop the subcomponent 
• Dates that the development of the subcomponent began and was completed 
• Economic useful life of the subcomponent 
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• Relative complexity of technical issues addressed and resolved by the subcomponent 
• Whether the subcomponent represents unique or proprietary technology, or an 
alternative solution to other technologies in the marketplace 
• Whether the subcomponent is (or could be) protected by patents 
• Difficulty of designing around the patented technology of the subcomponent 
• Whether the technology in the subcomponent allows the company to charge 
premium prices for the product 
5.3.42  Figure 5.3.42 illustrates the contribution of the technology subcomponents to 
the forecast of expected future revenue included in the final PFI. In year 1 (the year 
immediately following the acquisition), a significant portion of the forecasted expected 
future revenue is attributed to the developed product technology (that is, the products that 
existed at the date of acquisition) with assistance from the base (or core) technology, 
whereas in year 5, a significant portion of the forecasted expected future revenue is 
attributed to R&D that is expected to be performed subsequent to the date of acquisition. 
5.3.43 The allocation of value to the subcomponents (that is, technology migration) 
may be reflected in the final PFI as either— 
• Adjustments to revenues and costs to eliminate everything but revenues and costs 
associated with a specific IPR&D project (known as revenue splitting).  
• Contributory asset charges related to developed product technology and base (or 
core) technology (charges that decrease over time) and future technology (charges 
that increase over time). 
5.3.44 The revenue-splitting method may be appropriate in circumstances where a 
company has numerous separable businesses; products or services; or in the case of 
technology, numerous subcomponents, such as base (or core) technology, developed 
product technology, in-process technology, and future technology. When the assets 
acquired (or some subset thereof) produce measurable economic benefit only in 
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combination with one another, the task force believes that the best way to isolate 
individual asset values is through a revenue splitting exercise. The splitting of revenues 
in this fashion for technology may be a preferable alternative to applying contributory 
asset charges (or economic rents) for the use of base (or core) or developed 
technologies. Contributory asset charges can be used in situations where the fair value 
of contributory assets can be separately estimated.  
5.3.45 Example—technology migration. Company A acquired Company X in a 
business combination. Company X releases annually a major new version of its 
software products. At the acquisition date of the business combination, Company X has 
under development the second release of a software product (that is, Version 2 or V2). 
Historically each release has doubled the functionality of the product, and Company A 
expects this to continue. The relative contributions over multiple releases (that is, the 
technology migration) are estimated as follows: 
 PFI Year 
 1 2 3 4 5 
Developed product technology 
(Version 1) 
100% 50% 25% 12.5% 6% 
In-process technology (Version 2) 0% 50% 25% 12.5% 6% 
Future technology  0%  0%  50%  75%  88% 
 100% 100% 100% 100% 100% 
      
5.3.46 Upon acquisition, Company A concludes that Version 2 qualifies as an IPR&D 
project. Accordingly the percentage of annual forecasted revenues attributable to the 
IPR&D subcomponent of the project (that is, Version 2) would be only 50 percent of the 
forecasted revenues for year 2 (the year in which Version 2 is initially released), 25 
percent of the forecasted revenues for year 3, and so on. In the example above, the 
revenue split does not include an allocation to base (or core) technology; therefore, the 
cash flows attributable to the R&D project would include a contributory asset charge 
associated with the base (or core) technology used by or incorporated in the R&D 
project. A number of factors would need to be considered in estimating the relative 
contributions of the subcomponent technologies, including the number of lines of code 
added or changed, and the functionality of the product that was added or changed by 
each subcomponent. The valuation specialist gathers the underlying support for the 
percentage allocations based on interviews with management from various departments 
including R&D, marketing and sales, finance, and operations. Outside verification is 
obtained through industry data and the valuation specialist’s experience with similar 
companies and technologies. 
5.3.47 The terms base technology and core technology are often used 
synonymously. The basic definition reflects the existence of underlying technology that 
has value through its continued use or re-use in many products or many generations of 
a singular product (that is, a product family). This base (or core) technology of a 
company may be represented by, for example, a portfolio of patents, a library of 
potential candidates for therapeutic drugs, or a superior manufacturing capability. The 
existence of base (or core) technology is dependent on facts and circumstances. In 
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some cases, companies “in-license” technology that serves as a core or base for their 
product development efforts. In other cases, base (or core) technology may not exist at 
all, as each new product is developed from a new or novel technology platform. 
5.3.48 The concept of technology migration also indicates technology re-use from 
one generation of a product to the next. In that circumstance where technology 
migration is present, some would describe today’s developed product technology (that 
is, technology manifested in current product offerings) as tomorrow’s base (or core) 
technology (through its re-use in future product offerings). In this circumstance, 
especially when the re-usable technology has a one-to-one correspondence to a 
product family, the delineation between what may be referred to as developed product 
technology and base (or core) technology may blur.  
5.3.49 Even when using a valuation model that splits revenues or profits, it may be 
necessary to set up a separate category for base (or core) technology because it 
derives its economic value from its use with many products or product families, as well 
as ongoing developmental efforts. It no longer exhibits, strictly speaking, the one-to-
one correspondence that a single-product technology migration model might indicate. 
The consideration of a simulated royalty is one alternative to a “revenue split” model, 
as it effectively “profit-splits” the income stream. That royalty also can be applied 
against future revenues to capture continued re-use of the base (or core) technology. 
It is important to note that, in a valuation model that splits revenues or profits, care 
must be taken to ensure that proper consideration is given to all completed 
technology, both base (or core) and developed product technology. If the split includes 
a category that properly comprises both base (or core) and developed product 
technology, no further disaggregation is necessary. However, if the split of revenue or 
profits considers only the migration of developed product technology, it is necessary to 
provide for a separate category comprising base (or core) technology to the extent 
that base technology exists. 
5.3.50 From a GAAP perspective, the use of two categories of technology 
(base/developed and in-process) versus three categories of technology (base, 
developed, and in-process) is significant if the categories of base and developed 
product technology exhibit different amortizable useful lives (because the value of both 
technologies is capitalized and amortized, provided each category meets the criteria in 
paragraph 39 of FASB Statement No. 141 for separate recognition apart from goodwill). 
However, if the useful lives are the same, developed product technology and base (or 
core) technology may be combined into one category in a valuation model which “splits” 
revenues or profits. 
5.3.51 The remainder of this section of the chapter focuses on the application of the 
multi-period excess earnings method in the valuation of a specific IPR&D project. 
5.3.52 Revenue attributable to the IPR&D subcomponent. At this point the valuation 
specialist has become satisfied that the revenue expectations specifically attributable to 
a specific IPR&D project have been isolated on an appropriate basis.  
5.3.53 Expenses attributable to the IPR&D subcomponent. Expenses to be attributed to 
the IPR&D subcomponent should include costs of sales, selling and marketing expenses, 
general and administrative expenses, maintenance R&D costs (including only ongoing 
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charges to debug or maintain technology, once completed), costs to complete technology, 
any one-time roll-out or launch costs, contributory asset charges, and income taxes. 
Unrelated expenses, including costs of financing, should not be deducted in arriving at 
after-tax cash flows. All expense levels should reflect that which would be expected to be 
experienced by market participants, as opposed to a specific party to the transaction. 
• Technical support expense attributable to IPR&D. In many industries, technical 
support is provided as part of product sales or in exchange for product maintenance 
fees. To the extent that such fee revenues are appropriately not included in the 
expected future cash flows attributable to specific IPR&D projects, it would not be 
appropriate for the associated expense to be included in the expected future cash 
flows. If, however, such technical services are incapable of being unbundled from 
the product sale, the appropriate level of expense should be reflected in the PFI.  
See paragraph 5.3.35 for guidance on the elimination of non-IPR&D activities, 
including ancillary revenues. 
• R&D expense attributable to IPR&D. In the case of a project that is categorized as an 
asset to be used in R&D, there is generally a significant up-front expense related to R&D 
costs to complete. Also, there are typically ongoing expenses that may be incurred by the 
R&D staff, subsequent to project completion that may relate to maintenance, debugging, 
post-market approval surveillance, and other activities. The product roadmap of the 
acquired company, combined with R&D budgeting documents, will serve as primary 
source material evidencing appropriate levels of costs to complete and ongoing 
expenditures. A useful cross-check is to sum all project costs-to-complete and ongoing 
expenditures per year and compare to the total R&D budget or R&D expense as a 
percentage of sales historically for the acquired company, acquiring company, or both, 
and for the market participants, when relevant data is available. 
• Tax expense attributable to IPR&D. Objective evidence to support particular 
assumptions used in the PFI include historical financial data, industry data, and 
statutory rates. Care should be taken not to reflect specific tax circumstances of the 
acquired company, acquiring company, or both, in choosing the effective tax rate, 
such as net operating loss carry-forwards, penalties, and special payments. Industry 
data demonstrating the effective tax rate experienced by market participants should 
be carefully considered and compared with company-specific data and statutory 
rates. See paragraph 5.3.97 for guidance on the impact of income taxes on the 
determination of fair value of assets acquired. 
5.3.54 Step 7—Apply Contributory Asset Charge for Assets That Contribute to 
the Generation of the Cash Flows  
5.3.55 As noted previously, the application of the income approach to the valuation 
of intangible assets acquired typically is performed using the multi-period excess 
earnings method. The fundamental premise of the multi-period excess earnings 
method is that the value of an intangible asset is equal to the present value of the net 
cash flows attributable to the subject intangible asset. The net cash flows attributable 
to the subject asset are those in excess of fair returns on all the assets that are 
necessary to the realization of the cash flows. These assets include not only assets 
purchased in the instant transaction, but all assets required to realize the cash flows. 
The acquiring company already may own some of these assets or may need to 
purchase them in a separate transaction, if they are necessary to generate the 
expected future cash flows in the aggregate. The contributory asset charges would be 
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based on the fair value of the contributing assets (for example, fixed assets and 
customer list). After-tax cash flows of each intangible asset are charged after-tax 
amounts representing a return of and a return on these contributory assets based on 
the fair value of such contributory assets. 
5.3.56 These fair returns are frequently called contributory asset charges, capital 
charges, or economic rents. They represent the contribution of other assets to the 
overall value realized for a particular intangible asset (for example, an IPR&D project).5  
5.3.57 The principle behind a contributory asset charge is that each IPR&D project 
“rents” or “leases” from a hypothetical third party all the assets it requires to produce the 
cash flows resulting from its development, that each project rents only those assets it needs 
and not the ones that it does not need, and that each project pays the owner of the assets a 
fair return on (and of, when appropriate) the fair value of the rented assets. Thus, any net 
cash flows remaining after such charges are attributable to the subject IPR&D project. 
5.3.58 For self-constructed assets, such as customer lists, the cost to replace them 
(that is, the return of value) typically is included in normal operating costs and, therefore, 
already is factored into the PFI as part of the operating cost structure. Likewise, the return 
of fixed assets can be included in a cost structure as depreciation or amortization. 
Because this component of return is already deducted from the subject revenues, the 
returns charged for these assets would include only the required return on the investment 
and not the return of the investment in those assets. Where returns of the asset are not 
included in the operating cost structure, a return on and of value would be charged. 
5.3.59 Types of contributory assets.6 Capital charges should be made for all assets 
(including elements of goodwill) that contribute to the realization of the expected future cash 
flows. Similarly, capital asset charges would not be made for assets that do not contribute to 
the expected future cash flows (for example, land held for investment should not be considered 
as a basis for a charge if it is not necessary for the generation of expected future cash flows). 
5.3.60 Assets make a contribution to the expected future cash flows by supporting 
the realization of those cash flows. Examples of assets that may be charged for and the 
type of contributions that they make include— 
• Working capital—Realizing cash flows from the commercialization of a new product 
or service requires working capital for investment in receivables, inventory, and other 
short-term assets. Whereas certain projects may have negative working capital 
balances, the expectation is that a positive working capital balance is associated 
with each project over the medium to long term. Working capital makes a 
contribution to the project by allowing and supporting the normal business cycle. 
                                            
5 See Gooch & Grabowski, 1976, and Gooch, 1993. 
6
 The word asset is used loosely in the context of contributory assets. The task force recognizes that FASB 
Statement No. 141 results in no allocation of purchase price to intangibles that do not meet the criteria in paragraph 
39 of FASB Statement No. 141 for separate recognition apart from goodwill (some of which are described here as 
“contributory assets”). Regardless of whether an intangible is a separately recognized asset for financial reporting 
purposes, best practices suggest that “contributory asset” charges include charges for certain intangibles that do not 
meet the criteria in paragraph 39 of FASB Statement No. 141 for separate recognition apart from goodwill.  
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• Fixed assets—Fixed assets allow for the physical production of products; the 
workspace for the marketing, sales, and logistics functions for both tangible and 
intangible products; and the facilitation of general management functions and corporate 
overhead. Although the exact nature of the contribution of a particular desk to a specific 
IPR&D project is most likely unknowable, a reasonable estimation would be used (for 
example, an allocation of fixed asset charges on the basis of revenue). 
• Intangible assets—In addition to the above, business combinations may include other 
assets. Paragraph A14 of FASB Statement No. 141 lists examples of intangible assets that 
meet the criteria for recognition as a separate asset apart from goodwill, including: 
marketing-related intangible assets; customer-related intangible assets; artistic-related 
intangible assets; contract-based intangible assets; and technology-based intangible 
assets. In addition, certain intangibles may make a contribution to expected future cash 
flows even if they are not recognizable under FASB Statement No. 141. For example— 
 Workforce-based assets—Intangibles that relate to the value of the established 
employees or workforce of a company: 
Assembled workforce and trained staff 
Nonunion status, strong labor relations, and favorable wage rates 
Superior management or other key employees 
Technical expertise 
Ongoing training and recruiting programs 
5.3.61 As with working capital and fixed assets, a return should be charged for the use of 
each asset as appropriate. However, a careful analysis would be made to determine 
which assets contribute to which projects. Many contributory assets benefit most or all 
projects, including current technologies. The total return earned by an asset should be 
spread over the projects that benefit from that asset. The aggregate return calculated 
for a contributory asset should be allocated to the individual projects acquired. A project 
that uses twice as much of a contributory asset than another project should incur twice 
the capital charge. When objective use information is available, it forms the basis of a 
capital charge allocation. In the absence of reliable data, a reasonable assumption is 
used. Capital charges generally are allocated to projects based on the relative revenue 
of each project. When an asset is not expected to contribute to a particular project, its 
return is not charged against that project (its return is, however, charged against all of 
the projects to which it does make a contribution).  
5.3.62 Basis for determining charges. Contributory asset charges should be based 
on the concept that the owner of that asset should reasonably expect to get a return on 
and of the fair value of the asset that is commensurate with the risk of that asset and the 
returns earned by market participants on similar assets. The fair value of the asset may 
not be the same as the current carrying value or the value recorded in the allocation of 
the purchase price. 
5.3.63 The fair value of contributory assets may be expected to change over time. For 
example, working capital may be assumed to remain a constant percentage of sales and, 
therefore, would be expected to change as the estimate of future sales changes. It should 
be noted that a technology-based business may have high scalability relative to working 
capital, fixed assets, and possibly other assets (for example, a software company may be 
able to grow revenue ten-fold without significantly increasing its fixed assets). 
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5.3.64 The following table provides examples of assets typically charged for and the 
basis for determining the fair return, and it presumes the return of the asset is reflected in 
the operating costs when applicable (for example, depreciation expense). The capital asset 





Working capital Short-term lending rates for market 
participants (for example, working capital 
lines or short-term revolver rates) 
Fixed assets (for example, property, 
plant, and equipment) 
Financing rate for similar assets for market 
participants (for example, terms offered by 
vendor financing), or rates implied by 
operating leases, capital leases, or both 
(typically segregated between returns of [that 
is, recapture of investment] and returns on). 
Workforce (which is not recognized 
separate from goodwill), customer lists, 
trademarks, and tradenames 
Weighted average cost of capital (WACC) 
for young, single-product companies (may 
be lower than discount rate applicable to a 
particular project—see paragraph 5.3.90). 
Patents WACC for young, single-product companies 
(may be lower than discount rate applicable 
to a particular project—see paragraph 
5.3.90). In cases where risk of realizing 
economic value of patent is close to or the 
same as risk of realizing a project, rates 
would be equivalent to that of the project. 
Other intangibles, including base (or 
core) technology 
Rates appropriate to the risk of the subject 
intangible. When market evidence is 
available it should be used. In other cases, 
rates should be consistent with the relative 
risk of other assets in the analysis and 
should be higher for riskier assets. 
 
5.3.65 Contribution for unallocated purchase price.7 The general principle of 
contributory asset charges is to provide a return on the fair value of all assets necessary 
for the realization of the cash flows. In deciding whether a contributory charge for 
elements of goodwill is appropriate, the valuation specialist first would determine if the 
other assets, including intangibles, represent all the assets necessary to support those 
particular cash flows. Generally, the allocation of value to acquired intangibles and the 
consideration of other intangibles (that is, intangibles from sources other than the 
subject purchase, such as the acquiring company’s existing intangibles) would provide 
all of the necessary contributory asset charges. 
                                            
7 
 See footnote 4. 
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5.3.66 However, if the identification of other assets explains only a small portion of 
the consideration, further analysis is required. The valuation specialist should 
determine the likely sources of the unidentified value and their relationship to the 
subject asset. Significant unidentified value may be attributable to a synergistic or 
market premium paid by the buyer (this value would not, under the fair value premise, 
be associated with the individual assets). If the valuation specialist believes that the 
unidentified amount is a synergistic premium, it is not an asset that is required to 
realize the subject cash flows. 
5.3.67 Period of charge. Returns should be charged over the period that the subject 
project requires such assets. In the case where a project requires an asset that has an 
economic life of three years but the project has a life of six years, the capital asset 
charge would be over the entire six years. The assumption is that the investment in that 
asset is replaced over time as the asset is amortized and that the subsequent new 
investment requires the same type of return that the original investment required. It 
should be noted that the continuation of charges over the life of the project (versus the 
asset life) prevents the unreasonable situation where the later project cash flows are 
“free” money (that is, are not reduced by capital charges). 
5.3.68 Step 8—Calculate the Present Value of the Cash Flows Using a Discount 
Rate Appropriate for the Specific Asset Acquired Being Valued 
5.3.69 As noted previously, the most common method used by valuation 
specialists to estimate the fair value of an intangible asset is the multi-period 
excess earnings method. Under this method, the future after-tax net cash flows 
expected to arise from the ownership of an identified intangible asset are 
discounted to their present value using an after-tax discount rate. In applying the 
multi-period excess earnings method, valuation specialists most often rely on a 
best estimate of future cash flows, which are discounted at a single, all-in interest 
rate. An issue addressed by the task force is whether this technique for estimating 
fair value is acceptable under GAAP.  
5.3.70 Before FASB Concepts Statement No. 7, Using Cash Flow Information and 
Present Value in Accounting Measurements, guidance about the appropriate use of 
present value techniques in accounting was limited and not always consistent.  
5.3.71 The task force observes that the technique typically used in the application of 
the multi-period excess earnings method is similar to the traditional approach, as 
described in FASB Concepts Statement No. 7. The acceptability of the traditional 
approach from the viewpoint of GAAP is found in several references in the accounting 
literature. Although perhaps more suited for measuring the fair value of assets with 
contractual cash flows, the task force notes that the traditional approach is one 
measurement alternative described in FASB Statement No. 121, Accounting for the 
Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of. That 
Statement provides guidance about estimating the fair value of long-lived assets, 
including intangible assets, following a determination that an impairment in an asset 
should be recognized. Specifically, paragraph 7 of FASB Statement No. 121 notes that 
in the absence of a market price for a long-lived asset: 
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The estimate of fair value shall consider prices of similar assets and the 
results of valuation techniques to the extent available in the circumstances. 
Examples of valuation techniques include the present value of estimated 
future cash flows using a discount rate commensurate with the risks involved, 
option-pricing models, matrix pricing, option-adjusted spread models, and 
fundamental analysis. [Emphasis added] 
5.3.72 Paragraph 9 of FASB Statement No. 121 provides guidance about 
estimating cash flows for purposes of measuring impairment, requiring that it should 
be the “best estimate based on reasonable and supportable assumptions and 
projections.” The FASB acknowledged in paragraph 89 of that Statement that the 
language in paragraph 9 allows the use of either a single most likely estimate or a 
range that considers the probability of possible outcomes. The latter alternative 
(described in FASB Concepts Statement No. 7 as the expected cash flow approach) 
is discussed more fully in the following paragraphs. In reaching this conclusion, the 
FASB determined that it was more useful to permit techniques that were currently 
available and to allow for the use of new techniques that may be developed in the 
future rather than to prescribe specific techniques.  
5.3.73 The task force reasoned that if the traditional approach was acceptable in 
estimating the fair value of similar assets under FASB Statement No. 121, the income 
approach used by valuation specialists was an acceptable technique to estimate the fair 
value of intangible assets acquired in a business combination accounted for under 
FASB Statement No. 141.8 
5.3.74 In FASB Concepts Statement No. 7, the FASB concludes that fair value is 
the objective in using present value in measurements at initial recognition and fresh 
start measurements of assets. Although acknowledging that the simplicity of the 
traditional approach has caused it to enjoy a broad acceptance in practice, the 
FASB describes the expected cash flow approach as generally a superior 
measurement technique. This approach uses expected cash flow measurements 
discounted at the risk-free rate of interest. The FASB notes that the improvement in 
the measurement capabilities of the expected present value (which is the result of 
the expected cash flow approach) is particularly true in situations involving the 
complexities encountered in measuring the fair value of nonfinancial assets, 
including intangible assets. 
5.3.75 Expected cash flow is defined as “the sum of probability-weighted 
amounts in a range of estimated amounts; the estimated mean or average.” For 
example, if the population of future cash flow outcomes was $10, $100, and 
$1,000, which had probabilities of occurring of 10 percent, 40 percent, and 50 
percent, respectively, the expected cash flow is $541 ([$10 x 10%] + [$100 x 40%] 
+ [$1,000 x 50%]). If it is assumed for the purposes of this example that all the 
outcomes would occur one year from today, the expected present value of the 
cash flow is $515.24 using a discount rate (risk-free rate of return) of 5 percent 
                                            
8 The proposed FASB Statement, Accounting for the Impairment or Disposal of Long-Lived Assets and for 
Obligations Associated with Disposal Activities, addresses the appropriate use of present value techniques when 
measuring the fair value of an asset or asset group. The task force recommends that entities follow the 
developments of that proposed Statement. 
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($541/[1 + .05]). Note that in this example, the best estimate of future cash flow 
as is used in the traditional approach is $1,000 because it is the most likely 
outcome based on probabilities. To arrive at the same present value amount (that 
is, $515.24) using the traditional approach, the rate necessary to discount the best 
estimate of $1,000 would be approximately 94 percent. This example illustrates 
one of the principal differences between the traditional approach and the expected 
cash flow approach. That is, the expected cash flow approach focuses on the 
variations in the amount and timing of estimated cash flows and their relative 
probability of occurrence, whereas the traditional approach attempts to capture 
those same factors by focusing on the selection of an interest rate that is 
commensurate with the risk. To employ the latter approach requires that a similar 
asset with similar cash flow characteristics exists in the marketplace and the rate of 
return implicit in its market price may be measured. For many unique nonfinancial 
assets, including IPR&D, the task force observes that comparable items in the 
market may be very difficult to identify.  
5.3.76 FASB Concepts Statement No. 7 notes that the following five elements of a present 
value measurement, taken together, capture the economic differences between assets: 
a. An estimate of the future cash flow, or in more complex cases, series of future cash 
flows at different times 
b. Expectations about possible variations in the amount or timing of those cash flows 
c. The time value of money, represented by the risk-free rate of interest 
d. The price for bearing the uncertainty inherent in the asset or liability 
e. Other, sometimes unidentifiable, factors including illiquidity and market imperfections 
5.3.77 In selecting a discount rate to determine the present value of future cash 
flow under the expected cash flow approach, in theory, only the third element (risk-
free rate of return) is needed because elements b, d, and e are incorporated in the 
cash flows. In practice, it may be more practical to adjust the risk-free rate of return 
to compensate for systemic risks (see paragraph 69 of FASB Concepts Statement 
No. 7) rather than attempting to adjust estimates of future cash flows for these risks. 
Adjustments to the discount rate are needed for elements b, d, and e in applying the 
traditional approach.  
5.3.78 The FASB notes that many CPAs routinely do not use the expected cash flow 
approach and, therefore, may be reluctant to depart from the apparent simplicity of the 
traditional approach, arguing the high level of subjectivity involved in assigning 
probabilities to cash flow outcomes. However, the FASB observes that the subjectivity is 
no greater than that involved in selecting a discount rate under the traditional approach. 
The FASB also notes the explicit assessment of the probabilities associated with the 
possible cash flow outcomes provides computational transparency compared with 
selecting a discount rate commensurate with the risks. 
5.3.79 The task force notes that the use of probability-adjusted cash flows is more 
commonplace in the pharmaceutical, insurance, natural resource, and other industries 
in which management has developed a reasonable basis for estimating relative 
probabilities. Accordingly, the task force believes the expected cash flow approach 
should be used by companies with relevant historical experience to estimate the fair 
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value of intangible assets, including IPR&D. Exhibit 5-1 includes an example of the 
application of the expected cash flow approach in a pharmaceutical setting. 
5.3.80 The task force notes that FASB Concepts Statement No. 7 states, “Like 
any measurement, the application of an expected cash flow approach is subject to 
a cost-benefit constraint. In some cases, an entity may have access to 
considerable data and may be able to develop more than general statements about 
the variability of cash flows without incurring considerable cost.” The task force 
expects that, in practice, the traditional approach will continue to serve as the 
method that often will be used to estimate the fair value of an intangible asset 
acquired, including assets acquired to be used in R&D activities. Nevertheless, the 
task force encourages the discipline embodied in explicitly addressing the 
variability in the timing and amount of cash flows. 
5.3.81 Selection of discount rates. The following paragraphs describe the process for 
selecting discount rates for valuing specific IPR&D projects under the traditional approach. 
5.3.82 GAAP prescribes that, under the traditional approach, the appropriate 
discount rate used to determine present value is the rate commensurate with the risk. 
That is, in addition to the time value of money (risk-free rate of return), the discount rate 
should include the premium that market participants command for bearing the 
uncertainties in the estimates of future cash flows from the IPR&D project.  
5.3.83 Estimates of future cash flows from new product launches are subject to a 
variety of risks or uncertainties, including— 
• Time to market. 
• Market and customer acceptance. 
• Viability of technology. 
• Regulatory approval. 
• Competitor response. 
• Price/performance characteristics.  
5.3.84 Unlike business investment projects involving the launch of previously 
developed products, the cash flow estimates for an IPR&D project have the added 
uncertainty associated with the completion of the development effort (that is, whether 
the development effort will result in the new knowledge or technology that is a 
necessary first step to achieving the cash flows anticipated from its commercialization). 
In addition, the relative success of the development effort and the timing of the 
development project’s completion have a significant effect on the subsequent risks and 
uncertainties associated with its commercialization. Accordingly, the task force believes 
that risk premiums for IPR&D projects should be significantly higher than projects 
involving the application of existing knowledge or technology. 
5.3.85 The task force believes that the risk premium should decrease as a project 
successfully proceeds because the uncertainty about accomplishing the necessary first 
step, and as a result each subsequent step, diminishes. Accordingly, the uncertainty 
about the cash flows that are estimated to arise from commercialization of a successful 
project should decline as the project proceeds. Unfortunately, observable markets for 
the risk premiums that are charged by market participants to fund IPR&D projects do 
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not exist, let alone provide insight on how those premiums are likely to vary as progress 
to completion of projects is made. In the absence of a market, identification of 
observable rates charged in similar or comparable risk situations is the next best 
approach. Many times, however, the search for specific comparables may prove 
unsatisfactory. It is in this context that valuation specialists often find themselves when 
valuing specific IPR&D projects acquired as part of a business combination. 
5.3.86 The task force concluded that practice could be improved by providing fences 
(or ranges) within which discount rates for specific IPR&D projects are presumed to fall. 
Where the selected rate falls in that range is influenced by the stage of completion of 
the project. The task force cautions valuation specialists that very early stage projects 
may not have progressed to the point that reasonably reliable estimates of cash flows 
from the commercial exploitation of the development effort can be made. The task force 
believes that valuation specialists should be skeptical about whether the fair value of 
acquired IPR&D projects that have had only limited activity can be estimated with 
reasonable reliability. 
5.3.87 For acquired IPR&D projects that the valuation specialists have 
concluded are estimable with reasonable reliability, the task force observed that the 
projects often have risk profiles similar to early stage development enterprises 
funded by venture capital financing. The task force noted that venture capital 
continues to be an important source of R&D funding. As such, it provides an 
observable market for the cost of capital used to fund R&D activities. The task 
force noted that venture capital financing was better characterized as equity 
financing, because commercial lending, at least in the early stages of development, 
is unlikely. 
5.3.88 The task force identified two publications that provide guidance about the 
rates of return commanded by venture capital investors at various stages of an entity’s 
development. A summary is set forth in table 5.3.88. 
Table 5.3.88 
Rates of Return 
Stage of Development Plummer 9 Scherlis and Sahlman10 
Start-up 50%–70% 50%–70% 
First Stage or “Early Development” 40%–60% 40%–60% 
Second Stage or “Expansion” 35%–50% 30%–50% 
Bridge/IPO 25%–35% 20%–35% 
 
                                            
9
 Plummer, James L., QED Report on Venture Capital Financial Analysis (Palo Alto: QED Research, Inc., 1987). 
10 Scherlis, Daniel R. and William A. Sahlman, A Method for Valuing High-Risk, Long Term, Investments: The 
Venture Capital Method (Boston: Harvard Business School Publishing, 1987). 
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5.3.89 As described in the publications referenced in table 5.3.88, start-up stage 
investments typically are made in companies that are less than a year old. The 
venture funding is to be used substantially for product development, prototype testing, 
and test marketing. Early development stage investments are made in companies that 
have developed prototypes that appear viable and for which further technical risk is 
deemed minimal, although commercial risk may be significant. Companies in the 
expansion stage have usually shipped some product to customers (including beta 
versions). Bridge/IPO stage financing covers such activities as pilot plant construction, 
production design and testing, as well as bridge financing in anticipation of a later 
initial public offering.  
5.3.90 The task force concluded that in developing a range of discount rates to 
be used in valuing IPR&D under the traditional approach, the rate of return 
expected for start-up investments could be used as the upper boundary for the 
selection of a discount rate for early stage IPR&D projects. The task force 
concluded that, once an IPR&D project is complete, a premium over the weighted 
average cost of capital (WACC) observable for young, single-product companies in 
the acquired company’s industry segment could be used to approximate a market 
discount rate for projects with similar risks. For practical purposes, the task force 
observes that the use of the WACC without the premium may be a reasonable 
approach. These rates would serve as the lower boundary for discount rates used 
for completed R&D projects (that is, developed product technology). The task force 
noted that young, single-product companies in the same industry segment are 
more likely to exhibit risk characteristics similar to completed IPR&D projects. The 
task force believes that an IPR&D project should be thought of as an early stage 
entity, even if it is actually being conducted by an established or diversified entity. 
Therefore, the best way to estimate an appropriate discount rate for assets to be 
used in R&D activities, including specific IPR&D projects, would be to determine 
the WACC of several early stage entities that intend to provide the same or similar 
products or services. The task force noted that it was inappropriate to use the 
WACC of a large or diversified entity for valuing IPR&D because the goal of 
valuation is to approximate the rates of returns required by market participants on 
the project assets. Entities whose value is based partially on such items as 
established brand names, significant financial resources, or a diversified (and thus 
less risky) product line will generally have a lower WACC, reflecting these less 
risky operations. 
5.3.91 The task force also observed that the WACCs for such young, single 
product companies are not unlike the rates commanded by venture capital investors 
for bridge/IPO investments. In developing anecdotal evidence for this observation, 
the task force considered WACCs for young, public companies (market capitalization 
less than $250 million) in industry segments for which IPR&D projects are often 
identified (that is, Internet software and services, biotechnology, and networking and 
communication devices). The results of this test (which may change as market 
conditions change in the future) are shown in table 5.3.91. 
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Table 5.3.91. 
Weighted Average Cost of Capital in Young, Public Companies 




















Biotechnology 62 19.3% 19.3% 19.2% 
Internet Software and Services 20 29.3% 28.1% 25.6% 
     
* The returns computations use a size-adjusted capital asset pricing model,11 assuming a risk-free rate of 
6%, a market premium of 7.8%, and size adjustment of 3.3%. Betas were retrieved from Hoover’s Online 
by selecting all companies in the indicated sub-industry with a market capitalization less than or equal to 
$250 million. The capital asset pricing model and basic input data (long-term treasury rate, MRP, size 
adjustments) were taken from Ibbotson Associates: Stocks, Bonds, Bills, and Inflation 1998 Yearbook: 
Market Results for 1926-1997, pp.162–165. 
** Excludes the smallest and largest 5% of observed returns from the computation. 
 
                                            
11 In developing the statistics in this table, the task force made use of the size-adjusted Capital Asset 
Pricing Model (CAPM). CAPM is one of several asset return models. The use of the CAPM in the task 
force’s report is not intended to proscribe the use of other widely accepted approaches to estimating an 
entity’s cost of equity capital. Rather, the task force chose to use a version of the CAPM to illustrate the 
goals of arriving at an estimated weighted average cost of capital (WACC) when valuing in-process 
research and development because of its broad acceptance in the finance community. The task force 
notes that debt financing is not commonly used to finance the entities that the task force believes are 
appropriate proxies. This simplifies the WACC estimation to estimating the required return on equity of 
proxy entities. The formula used, together with an explanation of the variables used, is as follows: 
Ke = rf + β x (rm - rf) + P 
Each of these inputs is discussed in further detail below. 
Risk-free Rate (rf): The risk-free rate is the return on government securities with a term similar to that of the 
investment being valued. 
Market Risk Premium (MRP = rm – rf): The market risk premium (MRP), also known as the equity risk premium, 
is defined as the additional rate of return over the risk-free rate that is expected by investors from 
investments with systematic risk equal to the “market” portfolio. The market portfolio can be thought of as 
a broadly diversified investment portfolio, often thought of as the return on an index such as the S&P 500. 
Beta (ß): The theory and application of beta as a modifier of the MRP are well documented and widely 
accepted. Beta is a measure of the risk of an entity’s stock relative to the risk of a diversified portfolio (the 
MRP). Rather than explain the nature of how to estimate beta, the task force notes that there are many 
available sources of betas. Because the estimation procedure is not controversial, those sources may 
normally be relied on. 
Size Premium (P): Research has shown that small companies have larger betas than large companies. 
The adjustment is necessary because small stocks outperform large stocks, even after adjusting for the 
systematic risk (beta) of small stocks. This phenomenon is widely known as the size effect. 
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5.3.92 The task force’s conclusions about the expected behavior of discount rates 
over the life of an IPR&D project and the presumed lower boundary from which discount 
rates may be selected for young, single-product companies are illustrated in figure 5.3.92. 
 
 
5.3.93 Paragraph 39 of FASB Statement No. 2 states, “There is normally a high 
degree of uncertainty about the future benefits of individual research and development 
projects, although the element of uncertainty may diminish as a project progresses 
[emphasis added].” Accordingly, the selection of the discount rate in the range between 
the upper and lower boundary would be based in part on stage of completion. That is, 
earlier stage projects would be closer to the upper boundary, whereas a project nearing 
completion would be expected to be closer to the lower boundary. As progress toward 
completion is made, the task force expects discount rates would behave in a “step” 
fashion, reflecting the reduction of risk as progress is achieved. That is, even though 
development activities may be taking place, technological or engineering risk may not 
be reduced until a particular hurdle has been accomplished. 
5.3.94 One reasonable approach to determine the point in the range of discount 
rates that would be selected for a particular project would be to analyze each 
performance step, milestone, or task in the project and assign a weight to those steps, 
milestones, or tasks based on their relative technical complexity. It would not be 
expected that each step or task would necessarily reduce technological risk in the same 
proportion. If, for example, the cumulative weighting for steps or tasks completed at the 
acquisition date indicates that half of the technological complexity had been solved, the 
rate to be selected should fall at or above the rate in the midpoint of the range for stage 
of completion. 
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5.3.95 Paragraph 47 of Statement of Position (SOP) 81-1, Accounting for 
Performance of Construction-Type and Certain Production-Type Contracts, notes that 
stage of completion (or progress toward completion) generally is best measured by 
output measures in circumstances in which a reliable measure can be established. 
Output measures (for example, milestones, units produced or delivered, and value 
added) measure progress directly. Where output measures are not reliable, input 
measures or efforts expended should be used as an indirect measure of progress. 
5.3.96 As figure 5.3.92 also illustrates, discount rates may vary for reasons other 
than stage of completion (that is, at each stage of completion there may be a range of 
discount rates). Where in this range of discount rates a particular IPR&D project falls 
requires the consideration of a variety of factors and ultimately, the application of 
judgment. Some of the factors that should be considered and their impact, at least 
directionally, on the judgment reached are as follows: 
• Industry segment. Industries or subsegments within an industry may be characterized by, 
for example, rapid technological or competitive change. The task force believes that the 
discount rates for companies in those industries or subsegments would be at the higher 
range of possible rates. For example, within the software industry, products of enterprise 
software developers may be characterized by structured development projects for software 
that are expected to have long useful lives (for example, five to seven years). In contrast, 
products of Internet software developers would be expected to have shorter useful lives. A 
discount rate selected for IPR&D projects of enterprise software developers would be 
expected to be lower than Internet software developers.  
• Nature of expected product, service, or process to be developed. The development of a 
new product, service, or process would be expected to have greater commercial risks 
than a significant improvement to a product that has achieved commercial success. 
• Length of time to complete the project. The longer the development horizon, the greater 
the risk that the expected market for the new product, service, or process will change. 
• History of the company bringing products to commercial success. The more experience 
the company has with successfully completing development of products and bringing 
those products to market, the lower the risks about the company’s ability to assess the 
status of the project and the greater the likelihood of commercial success. 
• Competitive position. If the IPR&D project is expected to introduce a product that will 
be the first to market, expectations about commercial success may be higher than a 
project that will result in a follow-on product. 
5.3.97 Step 9—Compute the Related Income Tax Benefits Resulting From the 
Amortization of the Asset Acquired for Income Tax Purposes 
5.3.98 The task force believes that the valuation of an intangible asset would include 
(a) the expected tax payments resulting from the cash flows attributable to the intangible 
asset and (b) the tax benefits resulting from the amortization of that intangible asset for 
income tax purposes.12 Including the tax effects in the valuation is common in the 
                                            
12
 As noted in paragraph 41 of FASB Concepts Statement No. 7, Using Cash Flow Information and Present 
Value in Accounting Measurements, “interest rates used to discount cash flows should reflect assumptions that 
are consistent with those inherent in the estimated cash flows.” That is, assumptions about taxes and discount 
rates should not result in double counting their effects. 
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income and cost approaches. It is not typical in the market approach because any tax 
benefits already would be factored into the quoted market price through the negotiation 
of market participants during the bid-and-ask process. 
5.3.99 When the business combination is structured as an asset sale for tax 
purposes (as opposed to a stock sale), practice typically includes the associated tax 
benefits in the valuation of the assets acquired because it is assumed that the assets 
acquired will be amortized for both book and tax purposes. When a stock sale occurs 
without a corresponding change in the bases of assets acquired and liabilities assumed 
for tax purposes, some have argued that no tax benefit should be included in the 
valuation of the intangible assets acquired because the buyer will not amortize the 
intangible assets acquired for income tax reporting purposes.  
5.3.100 Before FASB Statements No. 96 and No. 109, Accounting for Income Taxes, 
the net-of-tax approach was used in assigning values to assets acquired and liabilities 
assumed in a business combination. Under the net-of-tax approach, the future tax 
effects of differences between fair values and tax bases and timing of those tax effects 
(that is, discounting) were considered in assigning values to assets acquired and 
liabilities assumed. Thus, before FASB Statements No. 96 and No. 109, deferred tax 
assets and liabilities were not recognized in a business combination.13 FASB Statement 
No. 109 prohibits the net-of-tax approach and requires assets acquired and liabilities 
assumed to be recorded at their “gross” fair value. 
5.3.101 Paragraph 129 of FASB Statement No. 109 states: 
Paragraph 89 of APB Opinion 16 stated that “. . . the fair value of an asset to 
an acquirer is less than its market or appraisal value if all or a portion of the 
market or appraisal value is not deductible for income taxes.” The Board 
believes that the net result is the same whether amounts assigned to the 
individual assets acquired and liabilities assumed are pretax or net-of-tax. For 
example, assume that the (a) pretax market or appraisal value of depreciable 
assets acquired in a purchase business combination is $1,000, (b) tax basis of 
those assets is zero, and (c) enacted tax rate is 40 percent for all years. If net-
of-tax, the assigned value of those assets would be $600. If pretax, the 
assigned value of those assets would be $1,000, and there would be a $400 
deferred tax liability. Under either approach, the net result of allocating the 
purchase price is the same. The Board concluded that the amounts assigned 
to assets and liabilities in a purchase business combination should not be net 
of any related deferred tax liability or asset. 
In either case, the acquired intangible asset in this example would be assigned a cost of 
$1,000 for financial reporting purposes. 
5.3.102 This issue should not be confused with the need to apply taxes to pretax income 
streams to apply a particular valuation method, such as a discounted cash flow method. A 
willing buyer would factor into the amount that it would be willing to pay the seller to acquire 
                                            
13
 See EITF Issue No. 96-7, “Accounting for Deferred Taxes on In-Process Research and Development Activities 
Acquired in a Purchase Business Combination.”
 
 98 
the seller’s business all incremental cash flows that inure to the benefit of that buyer. Those 
incremental cash flows would be reduced by expected income tax payments using 
appropriate tax rates. The task force believes that the determination of fair value would take 
into account future income taxes that a market participant purchasing the asset would be 
expected to pay, without regard to how the transaction is structured for income tax reporting 
purposes (that is, whether the transaction is structured to result in a change in bases of 
assets acquired and liabilities assumed for income tax reporting purposes). The task force 
also believes that the fair value of an intangible asset would include the value of the tax 
benefit resulting from the amortization of that asset because FASB Statement No. 109 
requires that the cost assigned to an acquired intangible asset be the same whether the 
asset is acquired piecemeal or in a nontaxable business combination in which the asset 
had no corresponding tax basis. If the value of the tax benefit resulting from the 
amortization of that asset were not included in the fair value of the intangible asset, it would 
have the impact of stating that asset on the balance sheet “net of tax.” The task force 
believes that only after the fair value is determined would the asset’s assigned value be 
subjected to the deferred tax accounting requirements of FASB Statement No. 109. That is, 
the deferred tax calculation is performed only after the determination of fair value is made. 
5.3.103 Question 1: If Company A acquires the assets of Company X in a transaction 
structured as an asset acquisition for income tax reporting purposes, and the allocation 
of purchase price for financial reporting purposes includes an intangible asset that is 
valued using a discounted cash flow method, would the expected future income taxes to 
be paid resulting from the pretax expected future cash inflows to be generated by the 
acquired intangible asset be deducted from the pretax cash flows in calculating the fair 
value of the acquired intangible asset? 
5.3.104 Answer: Yes. As discussed in paragraph 5.3.102, the application of the 
discounted cash flow method would capture after-tax cash flows resulting from 
ownership of the subject asset being valued. 
5.3.105 Question 2: Assume the same set of facts as in 5.3.103. In addition, the 
acquired intangible asset is deductible for income tax reporting purposes on a straight-
line basis over a fifteen-year life. Company A values the acquired intangible assets 
using a discounted cash flow technique with a 45 percent discount rate. Because the 
transaction was structured as an asset acquisition, there is a change in the bases of the 
assets acquired for income tax reporting purposes. Further assume the following 
regarding the acquired intangible asset: 
 
    Year 1       Year 2     Year 3 
Estimated:    
Pre-tax cash flows $1,000 $1,000 $1,000 
Income taxes @40% 400 400 400 
After-tax cash flows 600 600 600 
Present-value factor @45% .6897 .4756 .3280 
Present value of estimated after-tax cash flows 414 285 197 
Sum   $ 896 
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The estimated income tax benefit that results from amortization of the intangible asset for 
income tax reporting purposes is $381 ([$896+381]*40%), using a market participant 
assumed 40 percent income tax rate. The present value of those estimated income tax 
benefits is $56, using a discount rate of 45 percent and a fifteen-year life for income tax 
reporting purposes. Should the fair value allocated to the intangible be $896, representing 
its value before consideration of tax deductibility, or $952, representing the value assuming 
the acquired intangible asset is amortizable for income tax reporting purposes? 
5.3.106 Answer: $952. As discussed in paragraph 5.3.98, the valuation of an 
intangible asset would include the tax benefits resulting from the amortization for 
income tax reporting purposes of that intangible asset. 
5.3.107 Question 3: Assume the same facts as paragraphs 5.3.103 and 5.3.105, 
except that the transaction was structured as a stock acquisition for income tax 
reporting purposes (that is, a nontaxable business combination). Because the 
transaction was structured as a stock acquisition instead of an asset acquisition, no 
change occurs in the bases of the assets acquired for income tax reporting purposes. 
The specific intangible asset under analysis has no tax basis. Should the fair value 
allocated to the intangible asset be $896, representing its value without assuming tax 
deductibility (that is, reflecting that no tax benefits will result from the asset), or $952, 
representing the value assuming the acquired intangible asset is amortizable for income 
tax reporting purposes irrespective of the asset’s actual tax attributes? 
5.3.108 Answer: $952. As discussed in paragraph 5.3.98, the valuation of an 
intangible asset would include the tax benefits resulting from the amortization of that 
intangible asset for income tax reporting purposes. In addition, as discussed in 
paragraph 5.3.102, the tax benefits associated with the amortization of that intangible 
asset would be included in the valuation of the intangible asset without regard to 
whether the transaction was structured as a taxable (that is, change in tax bases of 
assets acquired) or nontaxable business combination (that is, no change in tax bases of 
assets acquired). 
5.3.109 Step 10—Evaluate the Overall Reasonableness of the Asset’s Value 
Relative to the Other Assets Acquired and the Overall Purchase Price 
5.3.110 The valuation specialist should reconcile the individual asset valuations to an 
overall business enterprise valuation of the acquired company to ensure consistency of 
assumptions. Feedback should be solicited from management and their advisers to 
establish that the valuation analysis “hangs together.” To the extent that differences of 
opinion exist, they should be reconciled and documented in an objective and 
supportable fashion. 
5.3.111 A business enterprise valuation assists the valuation specialist in concluding 
on the appropriateness of PFI. The determination of business enterprise value is 
beyond the scope of this Practice Aid. 
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EXHIBIT 5-1 
Pharmaceutical IPR&D Valuation Example: Expected Cash Flow Approach∗ 
Pharma Inc. acquired ABC Company, a developer, manufacturer, and marketer of 
pharmaceutical products. One of the assets acquired in the business combination was a 
research and development (R&D) project involving a compound that has possible 
application in the treatment of certain cancers. At the acquisition date, the compound 
was entering Phase II Clinical Testing in preparation for possible approval by the U.S. 
Food and Drug Administration. Two possible indications (tumor types) for the 
compound, that is, colorectal and prostate, were under development. The probabilities 
of success at each phase based on historical experience are given in the following 
table. The probability of success for each indication is independent of the probability of 
success for the other, and neither indication has an alternative future use. 
Development Phase Probability of Advancing 
Phase II 15% 
Phase III 75% 
 
Based on these indicators, the probabilities of reaching a commercial launch for each 
indication is 11.25 percent (15% x 75% = 11.25%). 
The after-tax development costs for each indication are $5 million for Phase II and $50 
million for Phase III. It is estimated that it will take one year to complete each phase, 
with all costs assumed to occur at the beginning of the period. The estimated cash flows 
following a commercial launch for the two indications (assuming an eight-year 
commercial life) are summarized in the following table. All amounts are in millions of 
dollars after income taxes. The computation of the net present value (NPV) of those 
cash flows is discounted using the risk-free rates of return applicable to the period (for 
simplicity, this has been assumed to be a single rate of 6 percent throughout the yield 
curve).1 The NPV amounts are computed to the start date of the remaining development 
effort. For each indication, the probability of a high market potential is 30 percent and a 
low market potential is 70 percent. The estimates for the probability of success were 






                                            
∗
 As mentioned in paragraph 5.3.79. 
1
 The use of the risk-free rates in this example is not intended to imply that the price for bearing uncertainty is 
captured solely in the expected cash flows. As discussed in paragraph 62 of Financial Accounting Standards 
Board (FASB) Concepts Statement No. 7, Using Cash Flow Information and Present Value in Accounting 
Measurements, the estimate of fair value should include the price that market participants are able to receive for 
bearing the uncertainty of the cash flows. 
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 Post-Launch Year  
 1         2       3       4      5      6      7       8       NPV 
Colorectal          
High -61 43 122 195 281 305 329 342 975 
Low -50 35 80 100 160 180 190 190 554 
Prostate          
High -68 47 135 217 311 339 366 379 1082 
Low -56 39 90 105 166 190 205 210 593 
 
The following tree diagrams show the present value of the cash flows and related 















The probability-weighted present value of cash flows for the colorectal indication equals 
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The probability-weighted present value of cash flows for the prostate indication equals 
$71.2 million. 
Because the probabilities and values associated with the two indications are 
independent of one another, the expected present value for the compound is the sum of 
the expected present value for each indication, or $135.7 million. 
An example of the computations associated with the amounts determined here are as 
follows for the colorectal indication. 
Commercial outcome—Low: $554x.70x.75x.15  = $43.63 
Commercial outcome—High: $975x.30x.75x.15  = $32.91 
Cost for Phase III:  -$47x.15  = -$7.05 
Cost for Phase II:  -$5x1.00  = -$5.00 




Sample Valuation Report—Transmittal Letter 
March 31, 2002 
Acquiring Company 
Address 
City, State, Zip code 
In accordance with your authorization, we have made an investigation and valuation of 
the intangible assets of 
Target Company 
headquartered in Mountain View, California, and hereby submit our findings in this report. 
The purpose of this valuation is to provide an opinion as of January 21, 2002 (also 
referred to as the acquisition or valuation date) of the fair value of the intangible assets, 
in connection with the acquisition by Acquiring Company (Acquiror) of the stock of 
Target Company (Target) for approximately $50 million. It is understood that our 
findings will serve to assist management in their allocation of the purchase price to the 
intangible assets acquired by Acquiror for financial reporting purposes under U.S. 
generally accepted accounting principles (GAAP). This valuation report is intended 
solely for the information and use of the managements of Acquiror and Target, 
Acquiror’s independent auditors, and the respective companies’ legal counsel.  It is not 
to be used, circulated, quoted, or otherwise referred to for any other purpose, including, 
but not limited to, the registration, purchase, or sale of securities, nor is it to be filed with 
or referred to, in whole or in part, in a registration statement or any other document, 
except that reference may be made to it in documents filed with the Securities and 
Exchange Commission upon our express written consent. 
For financial reporting purposes, the fair value of an asset is defined as the amount at 
which the asset could be bought or sold in a current transaction between willing parties, 
that is, other than in a forced or liquidation sale. Quoted market prices in active markets 
are the best evidence of fair value and would be used as the basis for the 
measurement, if available. If a quoted market price is not available, the estimate of fair 
value should approximate the price at which the asset would be expected to be bought 
or sold in a current transaction between a willing buyer and seller and would be based 
on the best information available in the circumstances. The estimate of fair value should 
consider prices for similar assets and the result of valuation methods to the extent 
available in the circumstances. The method selected to determine fair value should be 
consistent with the definition of fair value, as defined by GAAP. The method should 
incorporate assumptions that market participants would use in their estimates of fair 
values, future revenues, future expenses, and discount rates (if applicable). 
Historical and prospective financial data furnished to us by management was subjected 
to procedures consistent with the AICPA Practice Aid titled Assets Acquired in a 
Business Combination to Be Used in Research and Development Activities, and the 
data was deemed to represent business operations and conditions. 
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Our report consists of the following: 
1. This letter, identifying the assets valued, stating the objective and extent of the 
valuation, and presenting the conclusions of fair value. 
2. A narrative report, setting forth the purpose and scope of the valuation, the history 
and nature of the business, economic perspectives, industry conditions, a 
description of the assets valued, a presentation and correlation of the valuation 
techniques employed, and the conclusion of fair value, including associated 
exhibits, assumptions (including related support) and limiting conditions, certificate 
of appraiser, and general service conditions.  
3. Exhibits, comprising— 
a. Exhibit A  Valuation Summary 
b. Exhibit B  Business Enterprise Value (BEV) 
c. Exhibit C  Existing Technology—Product PT 
d. Exhibit D-1–D-4 Technologies Under Development  
e. Exhibit E  Stage of Completion Analysis 
f. Exhibit F  Tax Benefit Amortization Calculation 
 
4. Statements of Assumptions and Limiting Conditions, Certificate of Appraiser, and 
General Service Conditions.  (Note to reader: these are not provided in this 
Practice Aid.) 
Working papers underlying the valuation are retained by the valuation specialist and are 
available upon request and acquiror consent. 
The intangible assets valued include the existing software technology, which includes 
base (or core) technology and developed technology; technologies under development; 
three noncompete agreements; an established trademark/trade name; and an installed 
customer base.1 All current assets, tangible assets, other assets, and goodwill 
associated with the product and professional services businesses were not subject to 
independent valuation in this report. However, many of those assets were incorporated 
into the valuation of the intangible assets through contributory asset charges. In 
addition, the effects of the professional services business (activities that are not in-
process research and development [IPR&D]) were eliminated from the prospective 
financial information used to value acquired IPR&D (see exhibit B to this report). 
For the purpose of this valuation, audited historical financial statements, unaudited 
financial information, other records and documents, and prospective financial 
information (PFI) pertaining to the business operations and assets valued were 
furnished. We make no representations about the achievability of this PFI. Actual results 
may differ, and these differences could be material. We have not performed agreed-
upon procedures, a compilation, or an examination of the PFI as contemplated by the 
AICPA standards covering such matters. However, we have performed certain 
procedures to test the reasonableness of this PFI for use in the valuation process. 
These procedures include, among others: (1) comparison of changes in unit volumes 
and average selling prices over the life cycle of the technology with historical changes 
                                            
1
 The FASB recently issued FASB Statement No. 141, which provides guidance on determining which intangible 
assets should be recognized apart from goodwill in the allocation of purchase price in a business combination.  
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experienced by the Target, Acquiror, and the industry (per analysts’ reports); (2) 
comparison of expected costs as a percent of revenue with historical results for the 
Target, Acquiror, and the industry comparables; (3) changes in unit prices over the life 
cycle of the technology with historical changes experienced by the Target, Acquiror, and 
the industry (per analysts’ reports); and (4) preparation of a business enterprise value 
that compares the PFI, in aggregate, to the purchase price paid. Explanations were 
obtained for differences identified in these comparisons and the reasonableness of the 
explanations was investigated. Based on these procedures, we have determined that 
the PFI are reasonable and appropriate for use in reaching a conclusion of fair value for 
the intangible assets. 
Based on the investigation and analysis outlined above and on the valuation 
approaches, methods, and techniques employed, it is our opinion that, as of January 
21, 2002, the fair value of the acquired intangible assets2 of Target, is reasonably 
represented in the aggregate amount of $18,493,600, distributed as follows: 
 
Existing technology  6,398,100  
Technologies under development  7,892,100 
Noncompete agreements  1,849,200  
Trademark/trade name  546,200 
Customer list  1,808,000  
Total  $18,493,600 
 
A valuation summary is provided as exhibit A to this report. 
Respectfully submitted, 
 
Valuation Specialist or Firm 
                                            
2 
 See footnote 1. 
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EXHIBIT 5-2.2 
Sample Valuation Report—Introduction 
1. The purpose of this valuation is to provide an opinion as of January 21, 2002 (also 
referred to as the acquisition or valuation date) of the fair value of the intangible assets, in 
connection with the acquisition by Acquiring Company (Acquiror) of the stock of Target 
Company (Target). It is understood that our findings will serve to assist management in 
their allocation of the purchase price to the intangible assets acquired by Acquiror for 
financial reporting purposes under U.S. generally accepted accounting principles (GAAP). 
This valuation report is intended solely for the information and use of the management of 
Acquiror and Target, Acquiror’s independent auditors, and the respective companies’ legal 
counsel.  It is not to be used, circulated, quoted, or otherwise referred to for any other 
purpose, including, but not limited to, the registration, purchase, or sale of securities, nor is 
it to be filed with or referred to, in whole or in part, in a registration statement or any other 
document, except that reference may be made to it in documents filed with the Securities 
and Exchange Commission upon our express written consent.  Furthermore, it is 
understood that financial accounting and reporting for the acquisition includes consideration 
of the following accounting pronouncements and guidance:3 
• Financial Accounting Standards Board (FASB) Statement of Financial Accounting 
Standards No. 141, Business Combinations 
• FASB Statement No. 142, Goodwill and Other Intangible Assets 
• FASB Statement No. 2, Accounting for Research and Development Costs 
• FASB Interpretation No. 4, Applicability of FASB Statement No. 2 to Business 
Combinations Accounted for by the Purchased Method 
• AICPA Practice Aid Assets Acquired in a Business Combination to be Used in 
Research and Development Activities 
2. For financial reporting purposes, the fair value of an asset is defined as the amount at 
which the asset could be bought or sold in a current transaction between willing parties, 
that is, other than in a forced or liquidation sale. Quoted market prices in active markets are 
the best evidence of fair value and would be used as the basis for the measurement, if 
available. If a quoted market price is not available, the estimate of fair value should 
approximate the price at which the asset would be expected to be bought or sold in a 
current transaction between a willing buyer and seller and would be based on the best 
information available in the circumstances. The estimate of fair value should consider 
prices for similar assets and the result of valuation methods to the extent available in the 
circumstances. The method selected to determine fair value should be consistent with the 
definition of fair value, as that term is defined by GAAP. The method should incorporate 
assumptions that market participants would use in their estimates of fair values, future 
revenues, future expenses, and discount rates (if applicable). 
                                            
3  See footnote 1.  In addition, FASB Interpretation No. 6, Applicability of FASB Statement No. 2 to Computer 
Software, and Statement of Position 98-1, Accounting for the Costs of Computer Software Developed or 
Obtained for Internal Use, should be considered, if applicable. 
 107 
3. The intangible assets valued include the existing software technology, which includes 
base (or core) technology and developed technology; technologies under development; 
three noncompete agreements; an established trademark/trade name; and an installed 
customer base.4 All current assets, tangible assets, other assets, and goodwill associated 
with the product and professional services businesses were not subject to independent 
valuation in this report. However, many of those assets were incorporated into the valuation 
of the intangible assets through contributory asset charges. In addition, the effects of the 
professional services business (activities that are not in-process research and development 
[IPR&D]) were eliminated from the prospective financial information used to value acquired 
IPR&D (see exhibit B to this report). 
4. Historical and prospective financial data furnished to us by management were 
subjected to procedures consistent with the AICPA Practice Aid titled Assets Acquired in a 
Business Combination to Be Used in Research and Development Activities, and the data 
were deemed to represent business operations and conditions. 
5. For the purpose of this valuation, audited historical financial statements, unaudited 
financial information, other records and documents, and prospective financial information 
(PFI) pertaining to the business operations and assets valued were furnished. We make no 
representations about the achievability of this PFI. Actual results may differ, and these 
differences could be material. We have not performed agreed-upon procedures, a 
compilation, or an examination of the PFI as contemplated by the AICPA standards 
covering such matters. However, we have performed certain procedures to test the 
reasonableness of this PFI for use in the valuation process. These procedures include, 
among others: (a) comparison of changes in unit volumes and average selling prices over 
the life cycle of the technology with historical changes experienced by the Target and the 
industry (per analysts’ reports); (b) comparison of expected costs as a percent of revenue 
with historical results for the Target and its industry comparables; (c) changes in unit prices 
over the life cycle of the technology with historical changes experienced by the Target and 
the industry (per analysts’ reports); and (d) preparation of a business enterprise value that 
compares the PFI, in aggregate, to the purchase price paid. Explanations were obtained for 
differences identified in these comparisons and the reasonableness of the explanations 
was investigated. Based on these procedures, we have determined that the PFI are 
reasonable and appropriate for use in reaching a conclusion of fair value for the intangible 
assets. 
                                            
4
 See footnote 1. 
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EXHIBIT 5-2.3 
Sample Valuation Report—Industry Conditions (Internet) 
6. The Internet market is a constantly evolving and highly volatile market, characterized 
by rapid technology developments and frequent new product introductions. The needs of 
the graphics professional are rapidly changing to encompass online publishing as well as 
print-based publishing. The consumer software market, which is focused on digital imaging 
and Web publishing, is characterized by intense competition, price sensitivity, brand 
awareness, and strength in retail distribution. The dynamic media market is an increasingly 
competitive market as professionals, enthusiasts, and home users migrate away from 
analog video tools toward digital camcorders and digital video production.  
7. The success of the Internet in streamlining business-to-consumer commerce is 
encouraging companies to seek similar efficiencies in their transactions with other 
businesses. Companies are increasingly using the Internet to enter new markets, improve 
supply chains, and meet the challenges of increased competition and global markets. 
Forrester Research estimates that U.S.-based Internet commerce between companies will 
grow from $109 billion in 1999 to $1.3 trillion in 2003. Forrester Research further estimates 
that by 2003 this market for business-to-business transactions will be more than ten times 
larger than the related business-to-consumer transactions market. 
8. Initial efforts by businesses to reduce transaction costs and increase commerce 
efficiency focused on automating supply chains, particularly for the purchase and sale of 
raw materials, unfinished items, and other direct goods. Most large companies have 
historically relied upon enterprise resource planning (ERP) and supply chain automation 
systems to increase the efficiency of their internal procurement processes for direct goods. 
These systems are based on complex client-server architectures that are designed to be 
used by a relatively small number of sophisticated users. In addition, since ERP solutions 
do not typically tie the corporation with its suppliers or customers, they do not address any 
transaction costs or inefficiencies that are external to the organization.  
9. A variety of point-to-point solutions have been developed to address procurement 
cycle inefficiencies for both buyers and suppliers. The most successful of these has been to 
integrate electronic data interchange (EDI) into existing ERP systems. EDI has gained wide 
acceptance in automating the sale and procurement of selected direct goods, principally in 
environments characterized by high-dollar-volume transactions with a few suppliers. 
However, because EDI relies on the execution of certain predefined transactions, it typically 
is not well suited for situations involving many buyers and suppliers, a wide variety of goods 
and services, or numerous low-dollar-volume transactions. Moreover, EDI does not support 
real-time interactions between trading partners, making it difficult for buyers to obtain up-to-
date supplier information about price, availability, and order status. Finally, the expense and 
complexity associated with licensing, implementing, and managing both ERP and EDI 
solutions makes them unsuitable for all but the largest organizations. 
10. Similar efforts have been made to improve the procurement process for indirect goods 
and services, which include information technology and telecommunications equipment, 
office equipment and supplies, travel and entertainment, professional services, and other 
repeat purchase items. The purchase and sale of these goods constitute a large portion of 
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business-to-business transactions. The process of procuring these goods often involves 
thousands of internal users, as numerous work groups, departments, and divisions within 
an enterprise are involved in the purchase of indirect goods and services. As a result, the 
indirect goods procurement process is also mired in several inefficiencies, including high 
purchasing costs (as paper-based, manual processes still dominate this process), wasted 
time on low-value activities within purchasing departments, and poor communication 
between buyers and suppliers.  
11. A number of desktop-based requisitioning solutions have been introduced to focus on 
automating the indirect goods and services procurement processes within the enterprise. 
These solutions serve to enforce purchasing policies and improve the efficiency of supplier 
management, buying authorization, approval routing, and order processing. However, 
these buyer-focused approaches offer limited ability to address the costs and inefficiencies 
associated with the supplier side of the transaction. They also typically lack the interactivity 
users need to check prices, availability, and order status, while they also generally fail to 
provide a mechanism to automatically update supplier information relating to these areas. 
Consequently, both internal users and suppliers must still rely upon costly, manual phone- 
and fax-based processes to interact and conduct commerce. 
12. Accompanying the growth in the use of the Web has been a trend toward customer 
self-service. Just as consumers have extensively used automated teller machines rather 
than using the services of a bank teller, the Web now allows a wide range of businesses 
the ability to offer electronic self-service to their customers. For example, consumers are 
now shopping for goods and services and seeking answers to customer service questions 
on their own from their computers at any hour of the day. The Gartner Group estimated that 
by 2001 companies would receive 25 percent of all customer contacts and inquiries over 
the Web, through e-mail messages and other Web-based forms. Companies are using this 
Web-based customer interaction to augment more traditional means of handling customer 
service and commerce, such as telephone-based customer service. Rather than replacing 
the technology systems designed to support telephone-based customer service, 
companies are actively seeking ways to integrate their various forms of customer 
interaction, such as Web communications, e-mail, and the telephone. Businesses are 
seeking solutions such as Target’s products to coordinate these various media and present 
a consistent interface to their customers for service and commerce. 
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EXHIBIT 5-2.4 
Sample Valuation Report—Historical Financial Analysis 
INTRODUCTION 
13. Target, a California-based software and professional services company, has brought 
historic photographic shots and technology together by creating digital catalogs and 
portfolios. These relational databases, filled with digitized photographs of historical 
significance, allow Target’s customers to browse through thousands of historical shot 
pieces on their own time. Target’s Web-enabled solutions provide the support that editorial 
teams need. Target’s customer list includes many of the nation’s leading newspapers and 
magazine publishing companies. 
14. Target grew from a start-up with five people in 1995 to a company employing fifty-four 
people and on track for over $30 million in revenue for fiscal year 2002. Target’s sales are 
derived only from the U.S. market. Target’s existing product offering was introduced in 1999 
and is nearing the end of its life cycle. 
15. The digital imaging industry is subject to rapid and significant technological change, 
and frequent introductions of new competitive products. To remain competitive, Target will 
be required to continue to invest substantially in research and development, enhance its 
existing products, introduce new competitive products, and maintain price/performance 
advantages in its selected markets.  
16. Target’s research and development programs are focused on advancing digital 
imaging software technologies that strengthen its core product and service offerings. Target 
devotes substantial resources to ensure that its evolving technology roadmap is aligned 
with the technology direction of industry-leading vendors. This is evidenced by Target’s 
current research and development of its next generation software technologies, all of which 
are discussed in detail in this report. 
SOFTWARE GROUP 
17. Target’s Web-ready software solutions reduce costs, increase sales, and maximize 
the customer’s technology investment. Product PT, a high-performance publishing tool, 
connects management, sales, customer service, and production teams simply and 
efficiently, enhancing relationships with customers and partners at every point of contact. 
Whether for a small publishing group or multinational enterprise, Target has the solutions 
for today’s business needs. 
18. Product PT combines digital images and company data in powerful, simple-to-use 
applications. The users can create targeted material in seconds. Preformatted layouts 
make it easy to produce custom layouts, visual portfolios, and merchandised assortments. 
Web capabilities link everyone in the user’s supply chain in one collaborative environment. 
 111 
PROFESSIONAL SERVICES 
19. Target’s professional services group provides consulting, training, and installation 
services to help customers maximize their use of software products. Services are provided 
in time and material arrangements. 
20. The historical financial statements of Target were analyzed to understand Target’s 
past performance and operating trends. Target management provided audited financial 
statements for the fiscal years ended December 31, 2000 (fiscal 2000) and December 31, 
2001 (fiscal 2001). The following is extracted from the historical financial statements: 
• Net sales: For the twelve months ended December 31, 2001, net sales of Target 
were approximately $25 million. This represents a 25 percent compound annual 
growth rate from fiscal 1999. 
• Operating expenses: During the years ending 1999 through 2001, cost of sales 
averaged 15 percent of net sales.  During that same period, sales and marketing 
expenses averaged 30 percent of net sales, general and administrative expenses 
averaged 22 percent of net sales, and R&D expenses averaged 12 percent of net sales. 
• Operating income: During the years ending 1999 through 2001, operating income 
averaged 21 percent of net sales. During that same time period, operating income 
increased from about $2 million to $5 million. 
• Return on equity: During the years ended 2000 and 2001, Target generated return 
on equity of 21 percent and 20 percent, respectively. 
• Shareholders’ equity: From December 31, 2000 to December 31, 2001, total 
shareholders’ equity increased from $25 million to $30 million. 
• Current ratio: Target’s average current ratio during 2000 and 2001 was 3.2x, indicating 
that the Target had $3.20 in current assets for every $1.00 in current liabilities. 
• Leverage ratio: For the year ended December 31, 2001, Target’s debt level was nominal. 
• Target’s five-year historical information: 
 
   
Years Ended December 31 
  1997  1998  1999  2000  2001 
Revenue  $0  $5,100   $9,920  $19,840   $24,800 
Operating expenses  5,000 7,000  7,936 15,475  19,592
EBITDA   (5,000)  (2,000)   1,984  4,365   5,208 
Depreciation   200  200   300  400   500
Pre-tax income   (5,200)  (2,200)   1,684  3,965   4,708 
Income taxes   0  0   0  0   1,351 
Net income   ($5,200)  ($2,200)   $1,684  $3,965   $3,357
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EXHIBIT 5-2.5 
Sample Valuation Report—Valuation Analysis and Valuation Approaches 
DESCRIPTION OF ASSETS VALUED 
Overview 
21. The valuation of intangible assets of acquired technology-based companies is 
particularly important since the most valuable assets of this type of company generally are 
not recorded on the balance sheet before acquisition. Intangibles that may exist at the time 
of the acquisition include: (a) base (or core), developed, and in-process technologies; (b) 
customer-related intangibles (such as a distribution network or a customer base); (c) 
trademark(s), trade name(s), and related intellectual property; and (d) covenants not-to-
compete.5  In the determination of the fair value for each intangible asset, each assessment 
should consider specific factors to the asset, including (but not limited to)— 
• The value of economic or monetary benefit to market participants. 
• The remaining economic life. 
• The relative risk profile. 
Summary of Intangible Assets Under Consideration 
22. With respect to Target, all intangible assets that may have existed at the date of 
valuation were initially considered in the valuation analysis. Potential intangible assets were 
identified through an assessment of the economics of the transaction, a review of all 
supporting documents and materials, and discussions with Target management. (Step 4 in 
chapter 5 of the AICPA Practice Aid identifies many of the materials reviewed). As a 
result of our review, five intangible asset categories (which meet the criteria for separate 
recognition apart from goodwill; see paragraph 39 of FASB Statement No. 141) were 
identified for our analysis: (a) existing technology, (b) technologies under development, 
(c) noncompete agreements, (d) trademark and tradename, and (e) customer list. Please 
see the following description of intangible assets for all of Target’s divisions and entities. 
Technology Accounting Considerations 
23. To determine whether a technology was complete or under development, FASB 
Statement No. 2 and FASB Interpretation No. 4 guidelines were reviewed. 
                                            
5
 This list is not all-inclusive; intangible assets listed above are for illustrative purposes only. The identification of 
intangible assets is specific to each transaction and depends on the facts and circumstances surrounding the 
acquisition.  Also, see footnote 1. 
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24. Published in October 1974, FASB Statement No. 2 provides accounting guidelines for 
research and development (R&D) with the objective of reducing the number of reporting 
practices previously employed. The statement is broken into four specifications concerning 
R&D: activities identified, elements of cost, accounting for, and disclosure of. 
25. FASB Statement No. 2 identifies R&D activities using the following definitions: 
• Research is defined as a planned search or critical investigation aimed at discovery 
of new knowledge with the hope that such knowledge will be useful in developing a 
new product or service (hereinafter, “product”) or a new process or technique 
(hereinafter, “process”) or in bringing about a significant improvement to an existing 
product or process. 
• Development is defined as the translation of research findings or other knowledge 
into a plan or design for a new product or process or for a significant improvement to 
an existing product or process, whether intended for sale or use. It includes the 
conceptual formulation, design, and testing of product alternatives, construction of 
prototype, and operation of pilot plants. It does not include routine or periodic 
alterations to existing products, production lines, manufacturing processes, and 
other ongoing operations, even though alterations may represent improvements, and 
it does not include market research or market testing activities. 
26. Elements of R&D cost include personnel cost for those employed in R&D activities; 
materials, equipment, and facilities that have no alternative future use; and intangible 
assets purchased from others that have no alternative future use and, therefore, no 
separate economic values. 
27. According to FASB Statement No. 2, accounting for R&D costs requires charging 
them to expense when incurred. Appropriate disclosure in financial statements is then 
required. 
28. FASB Interpretation No. 4, issued in February 1975, addresses the accounting 
treatment for assets to be used in R&D activities acquired in a business combination. More 
specifically, FASB Interpretation No. 4 makes a distinction between those assets resulting 
from R&D activities of the acquired enterprise and those to be used in R&D activities of the 
combined enterprise. It indicates that, according to APB Opinion No. 16 (which is 
superseded by FASB Statement No. 141), the costs assigned to assets either resulting 
from or to be used in R&D projects are determined from the amount paid by the acquiring 
enterprise and not from the original cost to the acquired enterprise. It also confirms that, 
according to FASB Statement No. 2, the costs assigned to assets to be used in R&D 
projects that have no alternative future use are charged to expense. 
29. In November of 1998, the AICPA convened a task force to identify best practices with 
regard to the accounting for, valuation of, and auditing of acquired in-process research and 
development (IPR&D). The AICPA published a Practice Aid titled Assets Acquired in a 
Business Combination to Be Used in Research and Development Activities. 
30. The information in this report has been subjected to procedures consistent with the 
AICPA Practice Aid. 
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31. The technologies under development were reviewed as of the valuation date to 
determine their stages of completeness and the specific stages achieved; discussions also 
were held with Target and Acquiror management concerning the scheduled release dates 
of the products employing the technologies. After considering all of the guidance and facts 
outlined in this report, a decision was made about whether the technologies were complete 
or under development. 
32. On the basis of discussions with Target and Acquiror management and a review of 
the appropriate accounting literature addressing the identification and valuation of 
intangible assets, as well as their classification as completed technology or technologies 
under development, the categories of Target technology as of the valuation date were 
identified as described in the following sections. 
Existing Technologies 
33. Product PT, a high-performance publishing tool, combines digital images and 
company data in powerful, simple-to-use applications, creating targeted material in 
seconds. Preformatted layouts make it easy to produce custom layouts, visual portfolios, 
and merchandised assortments. Web capabilities link everyone in the supply chain in one 
collaborative environment. Combination of the functionality of a database with a Web 
browser allows for instant worldwide access to the client’s Product PT solution. 
34. Product PT was developed in fiscal years 1998 and 1999, introduced in June 1999, 
and is expected to be sold through the remainder of 2002. The developed technology 
embodied within Product PT also will be present in Software A and D. The fair value of 
the developed technology, therefore, is represented by the excess earnings of Product 
PT and a portion of the projected operating income of Products A and D, expressed as 
a base (or core) technology charge to cash flows. 
Technologies Under Development 
35. Software A—When developed, Software A will incorporate two modules into the basic 
product. Design Module will add 100 new layouts and the ability to add thousands more. 
Slides Module will create freestanding CD-ROM or e-mail-based slide shows (runtimes) for 
customer distribution.  
36. Software B—The Software B Suite program will be customized to create LAN and 
Web-based all-encompassing shop creation tools for the publishing industry. Graphics 
personnel will use these tools to maintain the image on the shop floor to maximize selling to 
consumers and save hundreds of thousands of dollars in shop development costs. 
37. Software C—Software C Suite, a workgroup-centric planning and selling technology, 
will replace spreadsheets into a networkable, business-rule, scalable solution for 
merchandising, production, retail and wholesale planning, sales, and management. When 
developed, this tool is intended to increase sales by 10 percent, lower costs by 45 percent, 
and increase productivity by 145 percent. 
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38. Software D—Software D is a Web-based digital asset management and 
workflow management tool for content creation and photo studios. It will be designed for 
keeping track of hundreds of thousands of digital images and coordinating of the 
photography, editing, and information regarding their styling, editing, and use. Software D 
also will track shipments of goods to be digitized, where goods are loaded, who shoots 
them in what bay, and who edits them. When developed, this tool will report on planned 
versus actual productivity, manage the original and edited version, allow the customer to 
review images, and give Web-based styling and editing notes. In addition, the tool will allow 
for the creation of a copy to be included on e-commerce Web sites and interfaces 
with customers’ legacy systems. 
39. For each technology under development, we have analyzed the stage of 
completion to adjust the discount rate to include the risk associated with the completion 
effort. We obtained information about the accumulated costs incurred through the 
valuation date, the estimated cost to complete, and the total estimated development 
costs to compute the stage of completion based on costs incurred. We also have 
discussed with management the technical issues that were overcome before the 
valuation date, as well as those to be resolved. We concluded on a stage of completion, 
as shown in exhibit E. 
Noncompete Agreements 
40. The fair value of a noncompete agreement stems from the protection afforded to the 
acquirer from competition from key management. Such competition could significantly 
erode the value of the acquired assets. As of the valuation date, three-year noncompete 
agreements were entered into with three key personnel. [For purposes of the sample 
valuation report, the fair value of this intangible is stated without related details because that 
determination is beyond the scope of this Practice Aid.] 
Trademark/Trade Name 
41. Target’s name is well known in the marketplace and Acquiror intends to continue 
using that name in the marketplace. End-user recognition and acceptance of a 
trademark/trade name may be a valuable asset that can be separated from other 
intangible assets. A trademark is a letter, word, symbol, or design, or any combination 
thereof, used by a company to identify its products and to distinguish them from those 
of its competitors. The history of continued use of its products is essential to the 
maintenance of trademark rights. A trade name, as defined herein, includes not only 
the legal trademark but also the presentation and image that this intangible asset 
infers. [For purposes of the sample valuation report, the fair value of this intangible is 




42. Target’s customer accounts numbered approximately 100 at December 31, 2001. 
Customer accounts are very important assets of this business because of the 
propensity of the customers to generate revenue for Target beyond the initial sale is the 
underlying worth of the customer accounts. Acquiror will not have to duplicate historical 
marketing, training, and start-up expenses to develop a customer base to the same 
level. [For purposes of the sample valuation report, the fair value of this intangible is 
stated without related details because that determination is beyond the scope of this 
Practice Aid.] 
VALUATION INTRODUCTION 
43. The designated assets have been valued on the basis of their fair value, which has 
been defined in the introduction of this report. 
44. Certain of the historical financial analyses of Target and a capsule description of the 
business operations and the assets valued are presented in this report. Expected operating 
results of Target were analyzed and current and estimated cash flows were discussed with 
members of Target and Acquiror management and were determined to be reasonable for 
use in the valuation. 
45. Before arriving at the opinion of fair value of the intangible assets, the following, as 
well as other relevant factors, were considered: 
• The extent, character, and utility of the intangible assets 
• The income-generating or cost-savings attributes of the intangible assets 
• The nature and timing of the functional or economic obsolescence of each intangible asset 
• The relative risk and uncertainty associated with an investment in intangible assets  
46. The acquired technologies under development were reviewed for alternative future 
use, other than those described herein, in accordance with the AICPA Practice Aid. 
The research and development process at Target is a focused effort to deliver new 
products with certain well-defined characteristics. It was concluded that the technologies 
under development have no alternative future use other than the objective of the 
current project. 
47. The methods used in determining fair value of the intangible assets included 
consideration of the three traditional approaches to value: market, income, and cost. 
48. The market approach considers prices recently paid for similar assets with 
adjustments made to the indicated market prices to reflect the condition and utility 
of the analyzed asset relative to market comparatives. As intangible assets 
typically are exchanged only in the context of the purchase of a business, this 
approach was not employed. 
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49. In an income approach, fair value is dependent on the present value of future 
economic benefits to be derived from ownership of an asset. Central to this approach is an 
analysis of the earnings potential represented by the asset and of the underlying risks 
associated with obtaining those earnings. Value indications are developed by discounting 
future net cash flows available for distribution to their present value at market-based rates 
of return. Based on the analysis performed, we have concluded that the future cash flows 
used result in a reasonably reliable estimate of fair value. Accordingly, the income 
approach has been employed to value the existing technology, the technologies under 
development, the noncompete agreements, and the trademark/trade name. The income 
approach was not selected to value the customer list since the amount of income directly 
attributable to this asset cannot be separately measured. 
50. The cost approach, as applied in the valuation of intangible assets, establishes fair 
value based on the cost of reproducing or replacing the assets, less depreciation for 
functional or economic obsolescence. Valuation results derived using the cost approach 
can be viewed as an upper limit of value in cases where the asset is easily replaced or 
reproduced since no prudent investor would purchase an existing asset for more than it 




Sample Valuation Report—Income Approach 
VALUATION OF EXISTING TECHNOLOGY AND TECHNOLOGIES UNDER 
DEVELOPMENT 
51. The fair values for the existing technology and technologies under development were 
estimated by discounting cash flows to be derived from the sales of these products to 
present value. 
52. The discounted net cash flow method of the income approach explicitly recognizes 
that the current value of an asset is premised upon the expected receipt of future economic 
benefits such as cost savings, periodic income, or sales revenue. Indications of value are 
developed (under what many view as a traditional approach) by discounting future net cash 
flows to their present value at a rate that reflects both the current return requirements of the 
market and the risks inherent in the specific investment.  
53. Management provided us with forecasts of (a) net sales for products employing the 
existing technology and (b) net sales of products expected to employ the technologies 
under development. The forecasts were reviewed for reasonableness, and are included in 
our valuation models. Management also provided us with forecasts of the operating 
expenses related to cost of sales, selling and marketing, and general and administrative for 
the products employing the existing technologies and for the products expected to employ 
the technologies under development. The forecasted operating expenses were compared 
to historical levels of operating expenses and the cost structure of comparable companies, 
and the forecast was determined to be reasonable. 
54. Management also provided us with their estimate of the costs to complete the R&D 
for each technology under development.  The estimated costs to complete were added 
to R&D expenses incurred prior to the valuation date, and were compared to data on 
costs incurred to develop similar products. The estimated costs to complete were 
determined to be reasonable, and are reflected in the valuation models as additional 
operating expenses. 
EXISTING TECHNOLOGY 
55. Existing technology consists of the current release of Product PT, which is expected to 
be sold for the remainder of the year 2002 and then replaced with Software A. Revenues 
are expected to be $9 million for fiscal year 2002 based on an expected growth rate over 
2001 revenues, adjusted downward for the expected release of Software A in late 2002. 
Expense expectations were based on historical experience combined with market 
participant data.  
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56. Existing technology also will be leveraged in the development of Softwares A and D. 
The contributions of existing technology are expected to last through 2006, indicating a 
remaining useful life of approximately five years. This fact has been accounted for through 
the imputation of a royalty (or contributory asset) charge to the forecasted operating income 
of the technologies under development. 
57. To estimate an appropriate charge, the operating margin for these technologies was 
analyzed. In an article published in The Encyclopedia of Patent Practice and Invention 
Management, author Albert S. Davis, Jr., states the following: 
Analysis of a great number of cases, both bargained-out and imposed as 
damages by the courts, makes it clear that a royalty rate of 25 to 33 1/3 per 
cent of the anticipated profit is about the average, with many exceptions 
outside this range. 
58. Considering the profit margin expected and the amount of base (or core) 
technology being employed by the technologies under development, a royalty rate at 
the upper end of the observed range was deemed to be reasonable. Therefore, a 
royalty rate of 33 percent of operating profit was selected. This 33 percent was 
deducted from the individual cash flows of the technologies under development that 
leverage existing technology, tax-effected, and discounted to present value. This value 
has been added to the value of existing technology and represents the contribution of 
base (or core) technology inherent in the technologies under development. See exhibit 
C for specific valuation calculations for existing technology. 
TECHNOLOGIES UNDER DEVELOPMENT 
59. For all technologies under development, revenue expectations, derived from 
management’s “base case” forecast, were based upon experience with prior releases, 
combined with expected industry growth as indicated in industry source document, number 
of other competitors, and estimated share of the market. In addition, expenses are 
expected to track historical experience because the sales, marketing, and management of 
the product is expected to be similar to past experience. The expectations of revenue and 
expenses are consistent with market participant data. 
Software A 
60. Software A is the next release of Product PT, scheduled for availability in late 2002. 
This release is a new technology platform that relies, in part, on the contribution of the 
existing technology. Revenues are expected to ramp up from $4,000,000 in 2002, 
reaching a peak of $40,000,000 in 2004, declining to $20,000,000 in 2006 when future 
releases and/or competition are expected to supplant this release and the technology 
underlying it. Expense expectations were again based on historical experience 
combined with market participant data. This technology is 90 percent complete as of the 
valuation date, based on cost, time, and complexity factors. See exhibit D-1 for specific 
valuation calculations for Software A. 
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Software B 
61. Software B represents a new technology designed to support Web-based publishing 
activities. As such, it represents a new source of income that does not rely on existing or 
core technology. Revenues are expected to grow from a base of $1,500,000 in late 2002, 
when introduced, peaking at $3,000,000 in 2004, and dropping to $1,500,000 in 2005 when 
new products and technologies are expected to replace Software B. This technology is 70 
percent complete as of the valuation date, based on cost, time, and complexity factors. See 
exhibit D-2 for specific valuation calculations for Software B. 
Software C 
62. Software C represents a new technology for sales management and productivity 
enhancement. As such, it also represents a new source of income that does not rely on 
core or existing technology. Revenues are expected to grow from a base of $2,500,000 in 
2003, to a peak of $5,000,000 in 2005, dropping to $2,500,000 in 2007, when new products 
and technologies are expected to replace Software C. This technology is 50 percent 
complete as of the valuation data, based on cost, time, and complexity factors. It is not 
expected to be released until late 2003, in contrast to Software A and B, which are 
expected to be released in late 2002 (due to their more advanced stage of completion). 
See exhibit D-3 for specific valuation calculations for Software C. 
Software D 
63. Software D is a Web-enabled asset management workflow module that is being 
designed to be an add-on to Product PT. As such, Software D relies on the contribution of 
the existing technology. Revenues are expected to grow from $750,000 in 2003, to a peak 
of $3,000,000 in 2005, dropping to $1,500,000 in 2006. This technology, although having 
significant substance in terms of progress, is only 30 percent complete as of the valuation 
date based on cost, time, and complexity factors. This product is not expected to be 
released until late 2003. See exhibit D-4 for specific valuation calculations for Software D. 
TAX RATES AND CONTRIBUTORY ASSET CHARGES 
64. The expected operating profit forecasted for each intangible asset valued under the 
income approach was then tax-effected at the industry (or market participant) rate of 38 
percent. The net income ascribable to the technologies under development was then reduced 
by a fair return on the required tangible assets and intangibles, including property, plant, and 
equipment; assembled workforce; trademark/trade name; customer list; and the required 
working capital. The chart in paragraph 5.3.64 of the AICPA Practice Aid was used as a basis 
for determining the contributory asset rate. A required return of 10.0 percent was calculated for 
working capital, a return on tangible assets was computed at 12.9 percent; a return of 19.0 
percent was used as the required return on the workforce and other intangible assets. 
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DISCOUNT RATES 
65. The discount rate used for the valuation of the completed technology was 19.0 
percent. The discount rate determination considered that the existing technology is both 
complete and has been in the marketplace since 1999, and it also considered the 
calculated weighted average cost of capital (WACC) for companies deemed comparable to 
Target as of the valuation date. A rate of 16.5 percent was concluded in the WACC. [For 
purposes of the sample valuation report, the WACC is stated without related details 
because that determination is beyond the scope of this Practice Aid.] In approximating the 
purchase price in the BEV (refer to analysis in exhibit B) a 19.0 percent discount rate was 
indicated as being more reflective of the Target and its reliance on technologies under 
development to produce a majority of its future cash flows. Therefore, the 19.0 percent rate 
was used as the discount rate for current technologies. A premium was added to the 
WACC to reflect the risk associated with investing in technologies under development. 
66. The incomplete technology represents a mix of near-term and mid-term prospects for 
the business and imparts a level of uncertainty to its prospects. It is the nature of the 
business to be constantly developing new technology for future product releases. 
Therefore, a reasonable expectation of return on the incomplete technology would be 
higher than the WACC.  
67. To estimate what the relative risk/return should be for the incomplete technology, an 
analysis of the work effort already completed compared to what was needed to complete 
the project was undertaken. In general, the earlier in the development process, the higher 
the risk of successfully completing the project and realizing the expected revenue and 
profit. The closer a project is to completion, the lower the risk of completion and the 
associated future expectations. The following chart summarizes this relation and the 
resulting discount rate for each of the incomplete technology: 
TAX AMORTIZATION BENEFITS 
68. One additional adjustment to the indicated values derived above using the income 
approach is required to reflect the hypothetical tax benefits associated with amortizing the 
asset for income tax purposes. 
  Percent Premium to Existing Concluded 
Product  Complete Technology Discount Rate Discount Rate 
Product PT   100%  19% 
Software A    90%   3% 22% 
Software B    70% 12% 31% 
Software C    50% 21% 40% 
Software D    30% 31% 50% 
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69. When a business combination is structured as a stock purchase for income tax 
purposes, there generally is not a corresponding change in the tax basis of assets 
acquired. That is, the tax basis of the intangible assets generally carries over from Target. 
Historically, valuation practice would dictate that no tax benefit should be included in the 
valuation of the intangible assets acquired because the buyer would not be able to amortize 
the intangible assets acquired for income tax reporting purposes, and thus would not 
benefit from the tax savings associated with amortization of the assets. 
70. However, the value of tax amortization benefits associated with intangible assets, 
including IPR&D assets, should be recognized when the purpose of the valuation is to 
estimate fair value as that term is defined under U.S. generally accepted accounting 
practices, including for transactions where the buyer will not be allowed to gross up and 
amortize the value of purchased intangible assets for income tax purposes (that is, 
nontaxable business combinations rather than asset purchases). FASB Statement No. 109, 
Accounting for Income Taxes, prohibits the net-of-tax approach and requires assets 
acquired and liabilities assumed to be recorded at their “gross” fair value. In accordance 
with paragraph 5.3.102 of the AICPA Practice Aid, the fair value of the intangible assets 
includes the value of the tax benefit resulting from the amortization of those assets. The 
benefits of amortizing the values of the assets are shown in exhibit F and are added to the 
values previously determined. 
CONCLUSION 
71. Based on the investigation and analyses outlined above and on the valuation 
approaches, methods, and techniques employed, it is concluded that, as of January 21, 
2002, the fair value of the designated intangible assets6 of Target is reasonably 
represented in the amount of $18,493,600, distributed as follows: 
Existing technology  6,398,100  
Technologies under development  7,892,100  
Non-compete agreements  1,849,200  
Trademark/trade name  546,200 
Customer list  1,808,000  
Total  $18,493,600  
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Business Enterprise Value (see paragraph 5.3.111) 
Valuation Date: January 21, 2002 
For Fiscal Years Ending,  ($000's) 
             2002          2003           2004                  2005              2006   Stabilized Period 
Professional services  12,000 22,000 40,000 60,000 75,000  
Existing technology  9,000 0 0 0 0  
Technologies under development 9,500 35,500 54,000 39,500 22,500  
Future development  500 1,000 10,750 57,625 98,906  
 Total revenue  31,000 58,500 104,750 157,125 196,406 206,226 
         
Total expenses (services)  9,000 18,500 36,200 54,300 67,875 71,269 
Total expenses (existing)   6,390 0 0 0 0 0 
Total expenses (IPR&D)  9,151 24,788 40,500 29,625 16,875 0 
Total expenses (future)  259 4,682 15,480 54,345 88,087 110,210 
 Total expenses  24,800 47,970 92,180 138,270 172,837 181,479 
         
EBITDA  6,200 10,530 12,570 18,855 23,569 24,747 
         
Depreciation expense  736 1,388 2,486 3,728 4,660 4,893 
         
Net income  5,464 9,142 10,084 15,127 18,908 19,854 
         
Estimated income taxes @     38% 2,076 3,474 3,832 5,748 7,185 7,544 
         
Debt-free net income  3,388 5,668 6,252 9,379 11,723 12,309 
         
Add: depreciation expense 736 1,388 2,486 3,728 4,660 4,893 
Less: capital expenditures  1,700 1,700 1,700 1,700 1,700 4,893 
Less: working capital requirements     10% 1,900 2,750 4,625 5,238 3,928 982 
         
Net cash flow  524 2,606 2,413 6,169 10,755 11,327 
         
Partial period adjustment  0.94 1.00 1.00 1.00 1.00 1.00 
         
Adjusted net cash flow  491 2,606 2,413 6,169 10,755  
         
Discount period  0.46 1.42 2.42 3.42 4.42  
         
Discount rate WACC @     19% 0.9234 0.7816 0.6568 0.5519 0.4638  
         
Present value  453 2,037 1,585 3,405 4,988  
         
Present value of interim cash flows 12,468      
        Present 
    Terminal 
Cash Flow 




 Terminal value calculations      
   Capitalized stabilized annual net       
   cash flow @14%: WACC 19% less  5%  11,327   80,909 37,526 
         
   VALUATION SUMMARY     
         
   PV of PV of     
   Interim Terminal   Indicated  
     Cash Flows Value   Value  
  Based on:        
   Capitalized final year DFNCF       
   at WACC less g (h)  12,468 37,526   49,994 * 
        
      Indicated Value(rounded): 50,000  
         






Existing Technology—Product PT 
For Fiscal Years Ending 
                  2002                2003                2004                2005                2006 
        
Revenue   9,000 0 0 0 0 
        
Operating expenses   6,390 0 0 0 0 
        
Operating income   2,610 0 0 0 0 
        
Research & development 0 0 0 0 0 
        
EBIT   2,610 0 0 0 0 
        
Estimated income taxes @ 38% 992 0 0 0 0 
        
Net income   1,618 0 0 0 0 
        
Contributory charges:       
   Working capital @ 10% 90 0 0 0 0 
   Trade name   45 0 0 0 0 
   Customer list   147 0 0 0 0 
   Workforce   76 0 0 0 0 
   Fixed assets   18 0 0 0 0 
        
Net cash flow   1,242 0 0 0 0 
        
Partial period adjustment 0.94 1.00 1.00 1.00 1.00 
        
Adjusted net cash flow  1,164 0 0 0 0 
        
Discount period   0.46 1.42 2.42 3.42 4.42 
        
Discount rate WACC @ 19% 0.9234 0.7816 0.6568 0.5519 0.4638 
        
Present value   1,075 0 0 0 0 
        
Present value of interim cash flows 1,075    
        
Value indication: product sales 1,075    
                         core technology charge - see below 4,461    
    5,536    
                         benefits of tax amortization - see exhibit F 862    
Total    6,398    
        
        
    Contributory Charges - Core Technology 
                  2002                2003                2004                2005                2006 
        
Software A   766 3,062 3,630 2,228 1,403 
Software D   0 158 248 495 248 
Core technology royalty  766 3,221 3,878 2,723 1,650 
        
Estimated income taxes @ 38% 291 1,224 1,473 1,035 627 
        
Net income   475 1,997 2,404 1,688 1,023 
        
Partial period adjustment 0.94 1.00 1.00 1.00 1.00 
        
Adjusted net income  445 1,997 2,404 1,688 1,023 
        
Discount period   0.46 1.42 2.42 3.42 4.42 
        
Discount rate @  24.6% 0.9041 0.7323 0.5877 0.4717 0.3786 
        
Present value   402 1,462 1,413 796 387 
        





Technology Under Development—Software A 
For Fiscal Years Ending 
                2002              2003             2004             2005             2006 
        
Revenue   8,000 29,000 44,000 27,000 17,000 
        
Operating expenses   5,680 19,720 33,000 20,250 12,750 
        
Operating income  2,320 9,280 11,000 6,750 4,250 
        
Cost to complete (R&D) 500 0 0 0 0 
        
Contributory charge - core technology 766 3,062 3,630 2,228 1,403 
        
EBIT   1,054 6,218 7,370 4,523 2,848 
        
Estimated income taxes @ 38% 401 2,363 2,801 1,719 1,082 
        
Net income   654 3,855 4,569 2,804 1,765 
        
Contributory charges:       
   Working capital @ 10% 80 291 442 271 171 
   Trade name  40 138 115 47 24 
   Customer list  131 453 378 155 78 
   Workforce  68 235 196 80 40 
   Fixed assets  16 55 46 19 9 
        
Net cash flow  319 2,684 3,393 2,232 1,443 
        
Partial period adjustment 0.94 1.00 1.00 1.00 1.00 
        
Adjusted net cash flow  299 2,684 3,393 2,232 1,443 
        
Discount period  0.46 1.42 2.42 3.42 4.42 
        
Discount rate @    22% 0.9129 0.7545 0.6184 0.5069 0.4155 
        
Present value  273 2,025 2,098 1,131 600 
        
Present value of interim cash flows  6,127    
Benefits of tax amortization - see exhibit F 842    





Technology Under Development—Software B 
For Fiscal Years Ending 
             2002           2003          2004           2005         2006 
        
Revenue   1,500 2,500 3,000 1,500 0 
        
Operating expenses   1,065 1,700 2,250 1,125 0 
        
Operating income  435 800 750 375 0 
        
Cost to complete (R&D)  305 0 0 0 0 
        
Contributory charge - core technology 0 0 0 0 0 
        
EBIT   130 800 750 375 0 
        
Estimated income taxes @ 38% 49 304 285 143 0 
        
Net income   81 496 465 233 0 
        
Contributory charges:       
   Working capital @ 10% 15 25 30 15 0 
   Trade name  7 12 8 3 0 
   Customer list  25 39 26 9 0 
   Workforce   13 20 13 4 0 
   Fixed assets  3 5 3 1 0 
        
Net cash flow  18 395 385 201 0 
        
Partial period adjustment  0.94 1.00 1.00 1.00 1.00 
        
Adjusted net cash flow  17 395 385 201 0 
        
Discount period  0.46 1.42 2.42 3.42 4.42 
        
Discount rate @ 31%             0.8836 0.6821 0.5207 0.3975 0.3034 
        
Present value  15 269 200 80 0 
        
Present value of interim cash flows  564    
Benefits of tax amortization - see exhibit F 57    





Technology Under Development—Software C 
For Fiscal Years Ending 
            2002          2003          2004          2005          2006 
        
Revenue   0 2,500 4,000 5,000 2,500 
        
Operating expenses   0 1,700 3,000 3,750 1,875 
        
Operating income  0 800 1,000 1,250 625 
        
Cost to complete (R&D)  1,500 648 0 0 0 
        
Contributory charge - core technology 0 0 0 0 0 
        
EBIT   -1,500 152 1,000 1,250 625 
        
Estimated income taxes @ 38% -570 58 380 475 238 
        
Net income   -930 94 620 775 388 
        
Contributory charges:       
   Working capital @ 10% 0 25 40 50 25 
   Trade name  0 12 10 9 3 
   Customer list  0 39 34 29 11 
   Workforce   0 20 18 15 6 
   Fixed assets  0 5 4 3 1 
        
Net cash flow  -930 -7 513 669 340 
        
Partial period adjustment  0.94 1.00 1.00 1.00 1.00 
        
Adjusted net cash flow  -872 -7 513 669 340 
        
Discount period  0.46 1.42 2.42 3.42 4.42 
        
Discount rate @ 40% 0.8571 0.6208 0.4435 0.3168 0.2263 
        
Present value  -747 -4 227 212 77 
        
Present value of interim cash flows  -174*    
Benefits of tax amortization - see exhibit F 0    
 Fair value   0    





Technology Under Development—Software D 
For Fiscal Years Ending 
            2002          2003          2004          2005          2006 
        
Revenue   0 1,500 3,000 6,000 3,000 
        
Operating expenses   0 1,020 2,250 4,500 2,250 
        
Operating income  0 480 750 1,500 750 
        
Cost to complete (R&D)  101 0 0 0 0 
        
Contributory charge - core technology 0 158 248 495 248 
        
EBIT   -101 322 503 1,005 503 
        
Estimated income taxes @ 38% -38 122 191 382 191 
        
Net income   -63 199 312 623 312 
        
Contributory charges:       
   Working capital @ 10% 0 15 30 60 30 
   Trade name  0 7 8 10 4 
   Customer list  0 23 26 34 14 
   Workforce   0 12 13 18 7 
   Fixed assets  0 3 3 4 2 
        
Net cash flow  -63 139 231 496 255 
        
Partial period adjustment  0.94 1.00 1.00 1.00 1.00 
        
Adjusted net cash flow  -59 139 231 496 255 
        
Discount period  0.46 1.42 2.42 3.42 4.42 
        
Discount rate @ 50% 0.8304 0.5630 0.3754 0.2502 0.1668 
        
Present value  -49 78 87 124 43 
        
Present value of interim cash flows  283    
Benefits of tax amortization - see exhibit F 19    





Stage of Completion Analysis 
 
    
Product 
    Software  Software  Software  Software 
    A  B  C  D 
Cost-based            
Incurred to date  $4,500  $1,220  $2,148  $67 
To complete  500  305  2148  101
Percent complete   90%  80%  50%  40%
            
            
Time-based (months)           
Time from start to date  8  6  6  2
To complete  2  4  6  8
Percent complete   80%  60%  50%  20%
            
            
Complexity-based           
Management estimate          
of tasks completed             
weighted by complexity  95%  70%  60%  30%
            





Tax Benefit Amortization Calculation 
$000s 
Sample present value of tax benefits table              Product PT 
# of Months                Fraction         Years to            Annual              19.00%          PV of Tax 
Period Year                of Year        Midpoint        Amortization %       Tax Rate          PV Factor            Benefits 
                           
1 2002  0.000  0.000  0.00%  38.00%  1.0000  0.0000 
2 2003  1.000  0.500  6.67%  38.00%  0.9167  0.0232 
3 2004  1.000  1.500  6.67%  38.00%  0.7703  0.0195 
4 2005  1.000  2.500  6.67%  38.00%  0.6473  0.0164 
5 2006  1.000  3.500  6.67%  38.00%  0.5440  0.0138 
6 2007  1.000  4.500  6.67%  38.00%  0.4571  0.0116 
7 2008  1.000  5.500  6.67%  38.00%  0.3841  0.0097 
8 2009  1.000  6.500  6.67%  38.00%  0.3228  0.0082 
9 2010  1.000  7.500  6.67%  38.00%  0.2713  0.0069 
10 2011  1.000  8.500  6.67%  38.00%  0.2280  0.0058 
11 2012  1.000  9.500  6.67%  38.00%  0.1916  0.0049 
12 2013  1.000  10.500  6.67%  38.00%  0.1610  0.0041 
13 2014  1.000  11.500  6.67%  38.00%  0.1353  0.0034 
14 2015  1.000  12.500  6.67%  38.00%  0.1137  0.0029 
15 2016  1.000  13.500  6.67%  38.00%  0.0955  0.0024 
16 2017  1.000  14.500  6.67%  38.00%  0.0803  0.0020 
              
Totals   15.000    100.00%      0.1347 
                           
Calculation                         
Assets:                           
   Indicated Value**  Discount Rate  PV of Tax Benefits Tax Benefit*  Adjusted Value  Concluded Value 
              
Product PT   5,535,968  19.0%  0.1347  862,119  6,398,087  6,398,100 
Software A   6,127,169  22.0%  0.1208  841,559  6,968,729  6,968,700 
Software B   564,302  31.0%  0.0919  57,129  621,431  621,400 
Software C   0  40.0%  0.0745  0  0  0 
Software D   283,252  50.0%  0.0620  18,713  301,965  302,000 
              
* Sample calculation:  5,535,968/(1-0.1347)=6,398,087; 6,398,087-5,535,968=862,119 (rounded)     
** From exhibits C and D-1 through D-4   
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AUDITING ACQUIRED IPR&D ESTIMATES 
6.1 INTRODUCTION AND OVERVIEW 
6.1.01 Business combinations often result in material amounts of the purchase 
price attributed to goodwill or other long-lived intangible assets. In many situations, 
valuation specialists are engaged to perform a valuation of the assets acquired, 
including assets acquired to be used in research and development (R&D) activities 
(which includes specific in-process R&D [IPR&D] projects, referred to in this chapter 
as acquired IPR&D), and issue a report that sets forth, among other things, the 
results of the valuation study. As with any material accounting estimate, the auditor 
designs audit procedures to test the reasonableness of the amount allocated to the 
acquired IPR&D. 
6.1.02 Chapter 3 identifies best practices concerning the definition of assets 
acquired that are to be used in R&D activities and chapter 4 provides accounting and 
disclosure best practices. Chapters 2 and 5 set forth best practices for the valuation 
specialist to follow in performing a valuation to be used in connection with the allocation 
of the purchase price in conformity with generally accepted accounting principles 
(GAAP). The IPR&D Task Force believes that the auditor should review the best 
practices presented in those chapters. 
6.1.03 Given the complexity of the valuation process and the myriad of estimates 
and judgments that must be made, the development of the estimated fair value of the 
acquired IPR&D often is performed by persons having special skills and training, that 
is, valuation specialists. While an acquiring company may have persons with the 
requisite skills in its employ, in many instances, it engages the services of an outside 
valuation specialist. The auditor’s support for his or her conclusions about the 
reasonableness of the amount allocated to acquired IPR&D will be derived from the 
substantive audit procedures applied in evaluating the work of the valuation specialist. 
The guidance that follows is intended to assist the auditor in determining the nature, 
extent, and timing of the substantive audit procedures to be applied in the evaluation 
to reach a conclusion as to the reasonableness of the amount of the purchase price 
allocated to acquired IPR&D. 
6.1.04 This Practice Aid focuses on the software, electronic devices, and 
pharmaceuticals industries; however, modification of the guidance may be necessary in 
response to the specific circumstances of each acquisition. The nature and extent of the 
modifications may be influenced by the business, legal, and regulatory environments in 
which both the acquiring company and the acquired company operate. Accordingly, 
auditors should use their knowledge of those environments and their professional 
judgment in applying the guidance of this Practice Aid to each acquisition. 
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6.2 RESPONSIBILITY FOR ACQUIRED IPR&D ESTIMATES 
6.2.01 Overview 
6.2.02 Accounting estimates are pervasive throughout financial statements. 
Generally accepted auditing standards (GAAS) in the United States define an 
accounting estimate as an approximation of a financial statement element, item, or 
account. Some accounting estimates, such as allowances for uncollectible accounts, 
pension accruals, or provisions for warranty claims, may be considered “routine” in the 
sense that those estimates are often derived from analysis of historical experience with 
past events and transactions over an extended period of time. The measurement of 
other accounting estimates may be subject to significantly more uncertainty because the 
estimates derive from expectations of future events that may or may not correspond to 
past experience with similar events and transactions. An estimate of the fair value of 
IPR&D acquired in a business combination is an example of an accounting estimate 
that is highly dependent on expectations of future events and transactions for which 
information based on historical experience may not be relevant to the evaluation of the 
assumptions underlying the estimated fair value of acquired IPR&D. 
6.2.03 Statement on Auditing Standards (SAS) No. 57, Auditing Accounting Estimates 
(AICPA, Professional Standards, vol. 1, AU sec. 342), defines the respective 
responsibilities of management and the auditor with respect to accounting estimates and 
provides guidance to auditors in obtaining and evaluating sufficient competent evidential 
matter to support significant accounting estimates in an audit of financial statements. 
6.2.04 Management’s Responsibility for Accounting Estimates 
6.2.05 Management’s responsibility for accounting estimates included in the financial 
statements is described in SAS No. 57 (AU sec. 342.03) as follows: 
Management is responsible for making the accounting estimates included in 
the financial statements. Estimates are based on subjective as well as objective 
factors and, as a result, judgment is required to estimate an amount . . . . 
Management’s judgment is normally based on its knowledge and experience 
about past and current events and its assumptions about conditions it expects 
to exist and courses of action it expects to take. 
6.2.06 Management also is responsible for establishing processes for developing 
accounting estimates. Those processes, which may or may not be documented or formally 
applied, normally include the following steps noted in SAS No. 57 (AU sec. 342.05): 
• Identifying the relevant factors that may affect the accounting estimate. 
• Accumulating relevant, sufficient, and reliable data on which to base the estimate. 
• Developing assumptions that represent management’s judgment of the most likely 
circumstances and events with respect to the relevant factors. 
• Determining the amount of the estimate based on the assumptions and other 
relevant factors. 
• Determining that the accounting estimate is presented in conformity with applicable 
accounting principles and that disclosure is adequate. 
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6.2.07 The risk of material misstatement of accounting estimates normally varies 
with the complexity and subjectivity associated with the process, the availability and 
reliability of relevant data, the number and significance of assumptions that are made, 
the degree of uncertainty associated with the assumptions, and the qualifications and 
expertise of the personnel developing the accounting estimate. 
6.2.08 Developing an estimate of the fair value of acquired IPR&D in a business 
combination is a subjective and complex process. R&D projects in process should be 
identified and evaluated for their potential to result in marketable products. The stage of 
completion of each project should be estimated and expectations of costs to complete 
should be developed. Estimated future revenues and related costs associated with each 
project that is expected to result in a marketable product should be forecasted, and the 
assumptions and bases for them should be documented. Chapter 5 discusses the 
development of forecasts of cash flows.  
6.2.09 Auditor’s Responsibility in Evaluating the Reasonableness 
of Accounting Estimates 
6.2.10 SAS No. 57 (AU sec. 342.04) states that “the auditor is responsible for 
evaluating the reasonableness of accounting estimates made by management in the 
context of the financial statements taken as a whole.” The auditor’s objectives when 
evaluating accounting estimates, including the fair value of acquired IPR&D, are to 
obtain sufficient competent evidential matter to provide reasonable assurance that— 
• All accounting estimates that could be material to the financial statements have been 
developed. 
• Those accounting estimates are reasonable in the circumstances. 
• The accounting estimates are presented in conformity with applicable accounting 
principles and are properly disclosed. 
6.2.11 To accomplish those objectives with respect to the estimated fair value of 
acquired IPR&D, best practices indicate that the auditor should design and perform 
substantive auditing procedures to evaluate whether all of the following are true: 
• All tangible and intangible assets acquired and all liabilities assumed have been 
identified and allocated an appropriate portion of the purchase price. 
• The valuation methodology used to the estimate fair value of the acquired IPR&D is 
appropriate. 
• The assumptions underlying the income approach used to develop the fair value of 
acquired IPR&D are not unreasonable in the circumstances. 
6.2.12 An acquiring company may engage the services of a valuation specialist to 
estimate the fair value of certain assets acquired, including IPR&D, and the auditor may 
choose to use that specialist’s work as evidential matter in performing substantive tests 
of management’s estimate of the fair value of the acquired IPR&D. Alternatively, the 
auditor may engage a valuation specialist and consider the specialist’s work as an 
integral part of the auditor’s substantive testing. SAS No. 73, Using the Work of a 
Specialist (AICPA, Professional Standards, vol. 1, AU sec. 336), provides guidance to 
the auditor in both of those situations. Subsequent sections of this Practice Aid titled 
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“Engagement Planning Considerations” and “Performing Substantive Procedures” 
provide guidance concerning the auditor’s use of a valuation specialist in planning and 
performing the audit. 
6.3 ENGAGEMENT PLANNING CONSIDERATIONS 
6.3.01 Audit Risk Model 
6.3.02 SAS No. 47, Audit Risk and Materiality in Conducting an Audit (AICPA, 
Professional Standards, vol. 1, AU sec. 312.12), states that “the auditor should consider 
audit risk and materiality both in (a) planning the audit and designing auditing 
procedures, and (b) evaluating whether the financial statements taken as a whole are 
presented fairly, in all material respects, in conformity with generally accepted 
accounting principles.” Audit risk is the risk that the auditor may unknowingly fail to 
modify appropriately his or her opinion on financial statements that are materially 
misstated. The auditor’s consideration of materiality is a matter of professional judgment 
and is influenced by his or her perception of the needs of a reasonable person who may 
rely on the financial statements in making an investment or credit decision.1 
6.3.03 The auditor should plan the audit so that audit risk will be reduced to a low 
level, that is, in his or her professional judgment, appropriate for expressing an opinion 
on the financial statements. The nature, timing, and extent of the procedures to be 
applied in an audit are a matter of the auditor’s professional judgment, based on his or 
her evaluation of the risk of material misstatement of the financial statements taken as a 
whole and the specific facts and circumstances. However, the procedures adopted 
should be adequate to achieve the auditor’s specific objectives and reduce detection 
risk to a level acceptable to the auditor. The evidential matter obtained should be 
sufficient for the auditor to form conclusions concerning the validity of the individual 
assertions embodied in the components of financial statements, and should provide a 
reasonable basis for the expression of an opinion. 
6.3.04 An audit of financial statements is a cumulative process. The auditor may 
become aware of an acquisition involving acquired IPR&D while performing procedures 
relating to acceptance or continuance of a client or an engagement, during engagement 
planning, while obtaining an understanding of an entity’s internal controls, while 
performing reviews of interim financial statements, or while conducting fieldwork. 
Knowledge of such an acquisition may alter the auditor’s judgment about the levels of 
inherent and control risks and his or her preliminary judgment about materiality. In that 
situation, the auditor may wish to reevaluate the nature, timing, and extent of auditing 
procedures he or she plans to apply. 
6.3.05 Knowledge of the Business 
6.3.06 SAS No. 22, Planning and Supervision (AICPA, Professional Standards, vol. 
1, AU 311.06), states: 
                                            
1
 SEC Staff Accounting Bulletin No. 99, “Materiality,” presents a discussion of materiality considerations 
that are applicable to the financial statements of Securities and Exchange Commission registrants. 
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The auditor should obtain a level of knowledge of the entity’s business that will 
enable him [or her] to plan and perform [the] audit in accordance with 
generally accepted auditing standards. That level of knowledge should enable 
[the auditor] to obtain an understanding of the events, transactions, and 
practices that, in [the auditor’s] judgment, may have a significant effect on the 
financial statements. The level of knowledge customarily possessed by 
management relating to managing the entity’s business is substantially greater 
than that which is obtained by the auditor in performing the audit. Knowledge 
of the entity’s business helps the auditor in: 
a. Identifying areas for special consideration. 
b. Assessing conditions under which accounting data are produced, processed, 
reviewed, and accumulated within the organization. 
c. Evaluating the reasonableness of estimates, such as valuation of inventories, 
depreciation, allowances for doubtful accounts, and percentage of completion 
of long-term contracts.  
d. Evaluating the reasonableness of management representations. 
e. Making judgments about the appropriateness of the accounting principles 
applied and the adequacy of disclosures. 
6.3.07 The auditor should obtain a knowledge of the business that includes, for 
example, the types of products and services sold by the business, and its production, 
marketing, distribution, and compensation methods. Auditors also should consider matters 
and trends affecting the industry in which the acquiring company operates, such as 
economic conditions, changes in technology, government regulations, and competitive 
conditions, to the extent they may have an effect on the financial statements being audited. 
6.3.08 Knowledge of the acquiring company’s business is ordinarily obtained through 
experience with the company or its industry, and inquiry of company personnel. Working 
papers from prior years may contain useful information about the nature of the 
business, organizational structure, operating characteristics, and transactions that may 
require special consideration. Other sources include industry publications and 
periodicals, research reports or offering memoranda of other entities in the industry, 
participation in industry conferences, trade associations, and other persons in the 
auditor’s firm who may be knowledgeable about the industry. 
6.3.09 In planning the audit, auditors may find procedures such as those described in 
paragraphs 6.3.10 through 6.3.34 of this Practice Aid useful in obtaining knowledge about 
an acquisition, including the acquiring company’s procedures for allocating the purchase 
price among the tangible and intangible assets acquired and liabilities assumed. 
6.3.10 Obtaining an Understanding of the Acquisition 
6.3.11 Inquiry of management is an effective procedure for obtaining knowledge of 
events and transactions that require consideration in planning the audit. If a business 
combination has occurred or is contemplated before period end, the auditor should 
consider making inquiries of the chief executive officer, the chief financial officer, 
representatives of the client’s marketing, business development, R&D or technology 
departments, and of other client personnel familiar with the acquisition. Such inquiries 
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should enable the auditor to gain an understanding of the nature of the acquisition and 
any special terms that may be associated therewith. Information obtained from 
discussions with management and acquiring company personnel may help the auditor 
identify matters that need to be corroborated with evidence obtained from other 
procedures, including confirmation from independent sources outside the company. 
6.3.12 Reading and understanding the terms of acquisition agreements, due diligence 
reports, acquired company prospectuses or offering memoranda, analysts’ reports, 
appraisals, board minutes and other related board materials, and preacquisition 
disclosures made by the acquired company will help the auditor obtain an understanding 
of the nature of the assets acquired (including IPR&D) and liabilities assumed, and the 
relative importance of the various components acquired. 
6.3.13 Timing Considerations 
6.3.14 If the acquisition has not been consummated at the commencement of audit 
planning and the auditor plans to use the work of a valuation specialist as evidential 
matter in performing substantive tests, the auditor should consider completing many of 
the procedures to be performed in connection with the use of the work of a valuation 
specialist during the audit planning process. For example, the auditor should consider 
performing the following procedures before the valuation study is completed to identify 
any issues or concerns the auditor may have with the competence or objectivity of the 
valuation specialist or with the valuation methodology or assumptions:  
• Evaluate the qualifications of the valuation specialist. 
• Evaluate any relationships that may exist between the valuation specialist and the client. 
• Obtain an understanding of— 
 The types and sources of information to be provided by the company to the 
valuation specialist. 
 The methods and significant assumptions to be used by the valuation specialist. 
 The scope and nature of the conclusions expected to be included in the valuation 
specialist’s report. 
 Whether the valuation specialist intends to follow the best practices discussed in 
the Practice Aid, and, if not, where the valuation specialist plans to deviate from 
the best practices. 
6.3.15 If the transaction was consummated before audit planning, the auditor should 
consider performing the audit procedures related to the allocation of the purchase price, 
including the evaluation of the valuation specialists’ work, early in the audit so that 
issues that arise may be resolved in a timely manner. 
6.3.16 Personnel Considerations 
6.3.17 Complex acquisitions, including those involving IPR&D, may require the 
assignment of more experienced auditors and more extensive supervision. GAAS 
requires that audit team members be assigned to tasks and supervised commensurate 
with their level of knowledge, skill, and ability so that they can evaluate the audit 
evidence they are examining. Also, the auditor responsible for the overall performance 
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of the audit should possess a level of knowledge of the acquiring company’s business 
and its operating characteristics sufficient to understand the events, transactions, and 
practices that may have a significant effect on the financial statements being audited. 
However, management will possess a level of knowledge about the acquiring company’s 
business substantially greater than that obtained by the auditor in performing an audit. 
6.3.18 Best practices suggest that senior engagement team personnel should direct 
the planning of the substantive procedures applied in evaluating the reasonableness of 
the significant valuation assumptions. The extent of involvement by the engagement 
partner and manager generally depends on— 
• The experience of the personnel who will be performing the substantive procedures. 
• The complexity of the acquired and acquiring companies businesses. 
• The significance of the acquisition and the amount of the IPR&D charge in relation to 
the financial statements taken as a whole. 
• The auditor’s assessment of the risk factors that relate to potential misstatements 
arising from fraudulent financial reporting (see paragraph 6.3.35). 
6.3.19 The auditor should consider whether expertise is available within his or her 
firm to evaluate the valuation methodology. If the auditor concludes the requisite 
expertise is not available within his or her firm, best practices suggest that the auditor 
should engage the services of a valuation specialist to assist in that evaluation process. 
6.3.20 Use of a Valuation Specialist 
6.3.21 The sophistication of the acquiring company’s management and the skills of 
its personnel have a direct bearing on the substantive procedures to be performed by 
the auditor and the amount of reliance the auditor may place on client-performed 
procedures. In the unusual situation in which the acquiring company is experienced in 
accounting for acquisitions and competent in applying valuation techniques (including 
those appropriate to acquired IPR&D) and has developed its own valuation 
methodology, the auditor may conclude that the acquiring company need not engage an 
independent valuation specialist. Companies that do not have in-house IPR&D valuation 
expertise often engage an independent valuation specialist.  
6.3.22 Specialists typically are engaged in the following ways:  
• Management engages or employs a valuation specialist and the auditor uses that 
specialist’s work as evidential matter in performing substantive tests to evaluate the 
allocation of purchase price. 
• The auditor engages a valuation specialist to assist the auditor in evaluating the valuation 
procedures and findings performed by, or at the request of, the acquiring company. 
6.3.23 Regardless of the manner in which the valuation specialist is engaged, the 
auditor should follow the guidance provided in SAS No. 73 (AU secs. 336.08-.09) to— 
• Evaluate the professional qualifications of the valuation specialist. 
• Obtain an understanding of the work performed or to be performed, including the 
methods and assumptions to be used, the scope of the conclusions to be reached, 
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and the report to be issued; and the appropriateness of the valuation specialist’s 
work for the auditor’s purposes. 
• Evaluate the relationship of the valuation specialist to the acquiring company. 
6.3.24 Qualifications of the Specialist 
6.3.25 SAS No. 73 (AU sec. 336.08) states that the auditor should consider the 
following when evaluating the professional qualifications of the specialist in determining 
that the valuation specialist possesses the necessary skill or knowledge: 
• The professional certification, license, or other recognition of the competence of the 
specialist in his or her field. 
• The reputation and standing of the specialist in the views of peers and others 
familiar with the specialist’s capability or performance. 
• The specialist’s experience in the type of work under consideration. 
6.3.26 Following are factors the auditor should consider in assessing the 
qualifications of the valuation specialist: 
• Whether the specialist possesses an accreditation in valuation issued by a 
recognized body, such as the American Society of Appraisers, the Institute of 
Business Appraisers, or the AICPA. 
• Whether the specialist is experienced in the valuation of tangible and intangible 
assets (including IPR&D) acquired in a business combination. 
• Whether the specialist has valuation experience in the acquired company’s industry 
or is otherwise knowledgeable of that industry. 
• Whether the specialist is familiar with the best practices discussed in this Practice Aid. 
6.3.27 If the auditor is uncertain whether the valuation specialist has the requisite 
qualifications, the auditor should consult with the appropriate acquiring company 
management to determine whether another specialist should be engaged who does 
possess the requisite skills and experience to perform the valuation. The auditor also 
may engage a qualified valuation specialist to review the work of the acquiring 
company’s valuation specialist or otherwise assist the auditor in evaluating the 
qualifications of the acquiring company’s valuation specialist.  
6.3.28 Relationship of the Specialist to the Acquiring Company 
6.3.29 The auditor should evaluate the relationship of the valuation specialist to the 
acquiring company and acquired company, paying particular attention to any situations 
in which the companies have the ability—through employment, ownership contractual 
rights, family relationships, or otherwise—to directly or indirectly control or significantly 
influence the valuation specialist’s work. 
6.3.30 There is no single, uniform set of conflict of interest standards applicable to 
valuation specialists; each credentialing body establishes the ethical standards 
applicable to its own members. For example, Uniform Standards of Professional 
Appraisal Practice (USPAP) requires that the valuation specialist disclose, in the 
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valuation report, the existence of any circumstances that might be deemed to 
present a conflict of interest. Nondisclosure of any such matter is a breach of USPAP 
standards. If the valuation specialist’s report does not disclose any relationships with 
the acquiring company, the auditor ordinarily would not question such matters. If the 
auditor is uncertain about the possibility of a relationship between the acquiring 
company and the valuation specialist, the auditor should consider contacting the 
specialist and inquiring about any relationship between the acquiring company and 
the valuation specialist. 
6.3.31 If a relationship between the acquiring company and the valuation specialist is 
disclosed or otherwise identified, the auditor should contact the valuation specialist and 
obtain a full understanding of the nature of the matter in order to assess its potential 
impact, if any, on the valuation study. For example, the valuation specialist may disclose 
that the valuation firm receives a $5,000 per month retainer from the acquiring company 
to ensure the valuation firm’s availability to provide services on short notice. If the 
valuation firm is a large, well-known firm, it is unlikely that such a retainer would unduly 
influence the work of the valuation firm. Such a retainer, if paid to a small or single 
member valuation firm, could lead to the auditor’s further consideration of the 
relationship. If the auditor is uncertain about whether the existence of a relationship is 
significant, the auditor may wish to consult with another valuation specialist to evaluate 
the possible impact of the matter on the valuation study. Alternatively, the auditor could 
apply the guidance in paragraph 6.3.32. 
6.3.32 If the auditor is unable to conclude that the relationship would not unduly 
influence the valuation study, the auditor should— 
• Perform the substantive procedures described in paragraph 6.4 with a heightened 
degree of professional skepticism. 
• Pay special attention to those elements of the valuation (for example, the 
assumptions) that are highly dependent on the valuation specialist’s judgment. The 
evidence considered in support of the assumptions should be scrutinized for 
completeness and lack of bias. 
If the auditor is unable to conclude that the valuation specialist’s assumptions, methods 
or findings are not unreasonable, the auditor should engage another valuation specialist 
for that purpose. 
6.3.33 Understanding the Work of the Specialist 
6.3.34 The auditor should obtain an understanding of the nature of the work to be 
performed by the valuation specialist, including— 
• The objective and scope of the specialist’s work. 
• The specialist’s relationship to the acquiring company. 
• The methods or assumptions used or to be used. 
• The methods and significant assumptions as compared with those used in any 
previous valuations that included acquired IPR&D. 
• The extent to which the best practices discussed in this Practice Aid are not followed. 
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• The valuation specialist’s understanding that the valuation findings will be used by 
the auditor to evaluate the reasonableness of the related assertions in the financial 
statements. 
• The valuation specialist’s agreement that the valuation report will include sufficient 
detail to enable the auditor to perform that evaluation.  
6.3.35 OVERALL RISK ASSESSMENT 
6.3.36 SAS No. 47 (AU sec. 312.26) states:  
The auditor needs to consider audit risk at the individual account-balance or 
class-of-transactions level because such consideration directly assists in 
determining the scope of the auditing procedures for the balance or class and 
related assertions.  
Elements of audit risk assessment include inherent, control, and detection risk. 
6.3.37 Inherent risk is the susceptibility of an assertion to a material 
misstatement, assuming that there are no related controls. The risk of such 
misstatement is greater for some assertions and related balances or classes than for 
others. For example, complex calculations are more likely to be misstated than 
simple calculations. Accounts consisting of amounts derived from accounting 
estimates pose greater risks than do accounts consisting of relatively routine, factual 
data. External factors also influence inherent risk. For example, technological 
developments might make a particular product obsolete, thereby causing amounts to 
be more susceptible to overstatement. The amount of acquired IPR&D included in 
the financial statements is based on accounting estimates involving complex 
calculations and depends on future developments. 
6.3.38 The auditor also should consider the inherent risks typically associated with 
the acquired IPR&D estimate. Overstating acquired IPR&D understates goodwill, other 
intangible assets, and current period earnings. Understating acquired IPR&D overstates 
goodwill and earnings in the period of acquisition. Misstatements of the acquired IPR&D 
estimate of fair value may be intentional or unintentional. Intent is often difficult to 
determine, particularly in matters involving extremely subjective accounting estimates, 
such as the fair value of acquired IPR&D. Unreasonable accounting estimates may be 
unintentional or the result of an intentional attempt to misstate the financial statements. 
Although the auditor has no responsibility to determine intent, the auditor does have a 
responsibility to plan and perform the audit to obtain reasonable assurance about 
whether the financial statements are free of material misstatement, whether caused by 
error or fraud. 
6.3.39 SAS No. 55, Consideration of Internal Control in a Financial Statement Audit 
(AICPA, Professional Standards, vol. 1, AU sec. 319), as amended by SAS Nos. 78 and 
94, requires that the auditor obtain a sufficient understanding of internal control to plan 
the audit. The auditor then should assess control risk, which is the process of evaluating 
the extent to which internal control may be relied upon in designing substantive tests to 
be performed. Some entities make many acquisitions during the course of a year and 
have developed substantial internal controls over accounting for the acquisitions and 
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the related purchase price allocations. These internal controls may ensure that 
management’s objectives, including compliance with GAAP, are achieved in 
determining purchase price allocations. The auditor could evaluate those controls and 
assess control risk at less than maximum. However, in most situations, the auditor will 
not place significant reliance on controls and will perform substantive audit procedures 
to determine whether the acquired IPR&D estimate is reasonable. 
6.3.40 The auditor should understand the environment in which the acquiring 
company operates to be able to assess the risk of a material misstatement. For 
example, pressure to meet future earnings expectations of analysts or other external 
parties may provide incentives for management to intentionally misstate the acquired 
IPR&D estimate. To address such risks, the auditor may want to be aware of analysts’ 
earnings expectations and how they might influence the acquired IPR&D estimate. An 
understanding of the factors that could affect this estimate will benefit the auditor as he 
or she designs appropriate substantive audit procedures. 
6.3.41 SAS No. 82, Consideration of Fraud in a Financial Statement Audit (AICPA, 
Professional Standards, vol. 1, AU 316.16) groups risk factors that relate to 
misstatements arising from fraudulent financial reporting into the following three 
categories: 
• Management’s characteristics and influence over the control environment 
• Industry conditions 
• Operating characteristics and financial stability 
SAS No. 82 (AU sec. 316.17) also provides examples under each category that might 
be applicable to the acquired IPR&D estimate. The individual risk factors that should be 
considered may vary from entity to entity. However, the auditor should evaluate the 
examples and consider their effect on the nature and extent of the substantive 
procedures to be applied in the audit. 
6.3.42 Risk factors relating to management’s characteristics and influence over the 
control environment may include— 
• A motivation for management to engage in fraudulent financial reporting. Specific 
indicators might include— 
 A significant portion of management’s compensation represented by bonuses, 
stock options, or other incentives. 
 An excessive interest by management in maintaining or increasing the entity’s 
stock price or earnings trend. 
 Pressures to achieve what may be aggressive or unrealistic forecasts. 
• A failure by management to display and communicate an appropriate attitude 
regarding internal control and the financial reporting process. Specific indicators 
might include— 
 Domination of management by a single person or small group without effective 
oversight by the board of directors or audit committee. 
 Management setting unduly aggressive financial targets and expectations for 
operating personnel. 
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 Management displaying a significant disregard for regulatory authorities. 
 Management continuing to employ an ineffective accounting, information 
technology, or internal auditing staff. 
• Nonfinancial management’s excessive participation in, or preoccupation with, the 
selection of accounting principles or the determination of the acquired IPR&D 
estimate. 
• Strained relationship between management and the current or predecessor auditor. 
Specific indicators might include— 
 Frequent disputes with the current or predecessor auditor on accounting, 
auditing, or reporting matters. 
 Unreasonable demands on the auditor including unreasonable time constraints 
regarding the completion of the audit or the issuance of the auditor’s reports. 
 Formal or informal restrictions on the auditor that inappropriately limit his or her access 
to people or information relevant to the evaluation of the acquired IPR&D estimate. 
 Domineering management behavior in dealing with the auditor, especially 
involving attempts to influence the scope of the auditor’s work concerning the 
determination of the acquired IPR&D estimate. 
6.3.43 Risk factors relating to industry conditions may include— 
• A high degree of competition (for example, the effect of not being “first to market” 
with the product).  
• The presence of rapidly changing technology.  
• High vulnerability to rapid product obsolescence (for example, the effect of next 
generation products on the estimated economic life of the products under 
development). 
6.3.44 Risk factors relating to operating characteristics and financial stability may include— 
• Inability to generate cash flows from operations while reporting earnings and 
earnings growth. 
• Financial statement elements, such as acquired IPR&D charges, based on 
significant estimates that involve subjective judgments or uncertainties. 
• Other significant, unusual, or complex transactions (especially those close to year 
end) that pose difficult “substance over form” questions. 
• Aggressive sales or profitability incentive programs. 
6.4 PERFORMING SUBSTANTIVE PROCEDURES 
6.4.01 Overview 
6.4.02 Acquired IPR&D may represent a significant portion of the purchase price in 
an acquisition, especially in technology-based industries. Therefore, the auditor should 
design substantive procedures that are appropriate in the circumstances and can be 
reasonably expected to detect a material misstatement of the estimated fair value of the 
acquired IPR&D in relation to the financial statements taken as a whole. 
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6.4.03 The significant financial statement assertions applicable to acquired IPR&D 
are valuation and allocation (acquired IPR&D is included in the financial statements at 
an amount that is reasonable in the circumstances), and presentation and disclosure 
(acquired IPR&D is properly classified, described, and disclosed). Accordingly, the 
auditor should design substantive audit procedures to obtain and evaluate evidential 
matter that will corroborate and support these assertions. 
6.4.04 Preliminary Procedures 
6.4.05 The auditor should obtain an understanding of the business purposes for the 
acquisition sufficient to enable the auditor to evaluate whether the accounting is 
consistent with the business purpose. For example, if the business purpose of the 
acquisition is primarily to obtain access to the acquired company’s existing products and 
intellectual property, work force, and customer lists, one would not expect that a 
significant portion of the purchase price would be allocated to acquired IPR&D. The 
auditor ordinarily obtains this knowledge primarily from discussions with appropriate 
acquiring company personnel (including those of the acquired company) and analysis of 
due diligence or other acquisition studies performed by or for the acquiring company. 
Best practices indicate that in addition to discussions with the chief executive officer and 
chief financial officer, the auditor should consider discussing the business purpose of 
the acquisition with (a) marketing personnel familiar with the acquired company’s 
products and markets, and (b) R&D, production, and business development personnel 
who are familiar with the products and product development plans related to the 
acquired technology. 
6.4.06 The auditor’s inquiries of the above parties should provide information about— 
• Base (or core) technology. 
• Historical and existing product lifecycles and changes in volumes and average 
selling prices over those lifecycles. 
• Future products and dependency of future products on base (or core) technology. 
• Management’s technology development plans. 
• Capabilities of personnel to conduct R&D. 
• Markets served by the company and those it would like to serve. 
• Competitive conditions. 
• Regulatory requirements. 
• Sensitivity to economic conditions. 
6.4.07 This listing is not meant to be all-inclusive. It is designed to illustrate a 
process that the auditor undergoes and the knowledge that he or she needs of the 
acquired company’s business to design effective substantive auditing procedures. The 
nature of the acquired IPR&D estimate is such that virtually every situation will be 
unique to the particular entity and industry to which it applies. 
6.4.08 Generally, independent third party verification of management’s expectations 
leading to the determination of the fair value of acquired IPR&D is not practicable. Best 
practices suggest that, under these conditions, auditors should exercise a heightened 
degree of professional skepticism and be alert to any information that may contradict 
management’s stated expectations. Also, best practices indicate that the auditor should 
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obtain and review the following types of information that may either corroborate or 
contradict management’s stated expectations: 
• Internal budgets 
• Technology development plans 
• Materials presented to the board of directors in support of the acquisition 
• Other corporate documents, including Web site content and press releases 
Additionally, events occurring after the acquisition date may provide the auditor with 
evidence corroborating management’s expectations at the time of the acquisition. 
Auditors should be skeptical when management’s expectations change shortly after the 
acquisition date. Changes in management’s expectations after the acquisition date should 
occur only as a direct result of events occurring subsequent to the acquisition date. 
6.4.09 The information developed in performing the preliminary procedures set forth 
above should be used to tailor further substantive procedures and evaluate the 
reasonableness of the results. 
6.4.10 Valuation Report 
6.4.11 The appropriateness of the methods and the reasonableness of the 
assumptions used and their application are the responsibility of the valuation specialist. 
The valuation specialist prepares a valuation report that documents the results of the 
specialist’s work, describes the methods and assumptions used in estimating the fair 
value of the items, and expresses conclusions as to the results of the work performed. 
The auditor should consider arranging to receive a copy of the draft or preliminary 
valuation report and study its contents to become informed of the significant 
assumptions and valuation techniques applied in the valuation of acquired IPR&D. 
6.4.12 The auditor should consider whether the preliminary valuation is 
unreasonable considering the knowledge of the acquiring company’s business and the 
business purpose of the acquisition. That consideration includes an assessment of 
whether the key assumptions appear reasonable based on the auditor’s knowledge of 
the business and the IPR&D projects. If the auditor has not previously discussed the 
valuation methodology and assumptions with the valuation specialist, he or she should 
do so to clarify any questions or concerns the auditor may have. 
6.4.13 The following provide guidance to the auditor in performing procedures to 
evaluate the reasonableness of the valuation results. 
6.4.14 The Valuation Methodology 
6.4.15 The valuation specialist uses specialized skills and industry experience to 
value acquired IPR&D. While the auditor cannot be expected to possess these skills, 
the auditor should perform procedures to determine that the methodology used by the 
specialist reconciles to the best practices discussed in this Practice Aid and includes 
consideration of the following matters. 
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6.4.16 Identification of All Intangibles 
6.4.17 An appropriate valuation should identify all intangible assets acquired, including 
IPR&D (see paragraph 5.3.26). However, care should be taken to exclude from the 
IPR&D valuation amounts attributable to IPR&D projects that— 
• Are not the results of R&D costs incurred by the acquired company (see paragraph 3.1.03). 
• Do not have a fair value that is supported by the report (satisfactory to the auditor) of 
the valuation specialist (see paragraph 3.2.02). 
• Are not controlled by the acquiring company or used for its economic benefits (see 
paragraph 3.2.03). 
• Have yet to exhibit substance (see paragraph 3.2.04). 
• Are complete (see paragraph 3.2.04). 
• Have an alternative future use (see paragraph 3.2.06). 
• Represent base (or core) technology or other contributory assets (see paragraph 5.3.54). 
• Represent entity-specific synergies (see paragraph 5.3.17). 
The auditor should consider, based on his or her knowledge of the acquiring company, 
the industry and the particular acquisition, whether other intangibles may exist that are 
not included in the valuation. Paragraph 5.3.60 references other types of intangible 
assets that may be present in a business combination. 
6.4.18 The auditor can accomplish this objective by reviewing the allocation of the 
purchase price to the individual assets acquired. As discussed previously, generally the 
auditor does not have the skills to value the assets acquired, but the auditor can 
evaluate the completeness of the allocation based on his or her understanding of the 
business. If this knowledge indicates intangibles or other assets that may exist for which 
no allocation of fair value has been made, the auditor should discuss those matters with 
appropriate acquiring company personnel, including the valuation specialist, to ascertain 
that proper consideration of those other assets was made in the allocation of purchase 
price for the acquisition. 
6.4.19 Projects in Progress 
6.4.20 The valuation specialist generally will determine the value of developed 
product and base (or core) technology as well as technology under development. The 
auditor should consider whether only projects in process meeting the characteristics 
and attributes discussed in chapter III are included in the acquired IPR&D valuation. 
While this is an area of considerable judgment, the following will assist the auditor when 
evaluating in-process projects: 
• Detailed description of each project 
• Consideration of technological feasibility of the project 
• Detailed project development chart (concept to completion) 
• Overview of the status of the project as of the acquisition date 
• Detailed project cost chart (concept to completion) 
• The nature and complexity of the remaining development effort and schedule of the 
amount and timing of expenditures required to complete the project (that is, product-
specific characteristics) 
• Expected completion date/time to market 
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• Consideration of alternative uses of the project or any components thereof 
• Economic justification for the project, including anticipated market, market share, 
and cash flow assumptions 
• Competitors’ activities/efforts 
• Industry data. 
6.4.21 This listing is not intended to be all-inclusive. Rather, it is intended to provide 
the auditor with guidance of matters to consider in evaluating whether all projects in 
process included in the valuation have continuing viability. This information should be 
obtained from appropriate acquiring company personnel and evaluated for 
reasonableness based on the auditor’s knowledge of the business. 
6.4.22 Significant Assumptions 
6.4.23 SAS 73 (AU sec. 336.12) states: 
The appropriateness and reasonableness of methods and assumptions used 
and their application are the responsibility of the specialist. The auditor should 
(a) obtain an understanding of the methods and assumptions used by the 
specialist, (b) make appropriate tests of data provided to the specialist, taking 
into account the auditor’s assessment of control risk, and (c) evaluate whether 
the specialist’s findings support the related assertions in the financial 
statements. Ordinarily, the auditor would use the work of the specialist unless 
the auditor’s procedures lead him or her to believe the findings are 
unreasonable in the circumstances. … 
6.4.24 The auditor should evaluate whether the significant assumptions used by the 
valuation specialist are unreasonable based on the knowledge of the business and 
other information available. 
6.4.25 Cash flow forecasts of IPR&D projects provided by management are among 
the most subjective of all estimates. The auditor should be satisfied that the estimates 
result in a valuation of acquired IPR&D that is not unreasonable. The extent of work that 
an auditor performs on such estimates is a matter of professional judgment regarding— 
• Materiality of the acquired IPR&D. 
• Complexity of the transaction. 
• Conclusions about the thoroughness of the valuation and the qualifications of the 
valuation specialist. 
• The asserted stage of completion of the project. 
• The asserted state of the technology. 
• The asserted assumptions used to arrive at an estimate of fair value (for example, 
discount rates and forecasted revenues and expenses). 
6.4.26 The cash flow forecasts provided to or prepared by the valuation specialist 
should present (under the commonly used traditional approach) the best estimate of the 
future cash flows expected to be derived from each IPR&D project that is expected to 
be completed, using market participant assumptions (see paragraph 5.3.17) rather than 
entity-specific assumptions. The auditor should perform procedures to evaluate whether 
the significant assumptions are unreasonable. The auditor should determine the extent 
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of the procedures he or she will perform after evaluating the extent of the valuation 
specialist’s work concerning the data supporting the significant assumptions. The 
auditor should consider the sources of information (both internal and external to the 
company) used by the valuation specialist in developing (or evaluating) the significant 
cash flow assumptions, such as expected costs to complete each IPR&D project in 
process, expected product sales volumes, prices and production costs, and expected 
product life cycles. 
6.4.27 Matters to be considered when evaluating whether the significant cash flow 
assumptions are unreasonable include the following: 
• Can information be obtained and informed judgments made about past and future 
events or circumstances in support of the underlying assumptions? 
• Are any of the significant assumptions so subjective that no reasonable basis could 
exist to prepare a forecast of cash flows that results in a reasonably reliable 
measurement of fair value? 
• Which entities comprise market participants? 
• Would other persons knowledgeable in the acquiring company’s business and 
industry select materially similar assumptions? 
• Is the length of the forecast period appropriate given the historical product life 
cycles, potential for technological obsolescence, and expected market responses of 
customers and competitors? 
• Is the market for the products expected to be produced from the technology mature 
or growing? Is it volatile or stable? 
• Is the acquiring company well established in the market for the expected products or 
a newcomer? 
6.4.28 Moreover, the auditor specifically should consider the significant cash flow 
assumptions that are particularly sensitive to risk of misstatement. Among the more 
significant assumptions are the following: 
• Potential for introduction of new technologies that may lead to reduced selling prices 
or obsolete the acquired technology 
• Likelihood of completion of product 
• Estimates of stage of completion and time to completion 
• Cost to complete 
• Product life cycle and technology development strategies 
• Expected sales volumes, product pricing, and expected revenues, and charges for 
base (or core) technology and other contributory assets  
• Production and other costs, exclusive of the effects of buyer synergies 
• Discount rates used to present value estimated cash flows 
• Competitors’ expected market responses 
6.4.29 While the appropriateness and reasonableness of the assumptions used and 
their application are the responsibility of management and the valuation specialist, best 
practices suggest that the auditor perform procedures to determine whether the 
assumptions used and factors considered in developing the acquired IPR&D valuation are 
unreasonable. The nature and extent of the specific procedures to be performed by the 
auditor will be influenced by the extent of the procedures undertaken, and the conclusions 
reached, by the valuation specialist. The following procedures should be considered: 
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• Evaluate the support for the assumptions and conclusions of the valuation specialist, 
giving special attention to specific assumptions that are— 
 Material to the valuation 
 Especially sensitive to variations 
 Deviations from historical patterns 
 Especially uncertain 
• For significant assumptions, if practicable, obtain the internal and external sources of 
information that were used in formulating the assumptions. The assumptions used 
should be market participant assumptions rather than those that are entity-specific 
(see paragraph 5.3.17). The following information may be useful to the auditor in 
evaluating the assumptions: 
 Knowledge of the business 
 Due diligence studies 
 Research reports of analysts 
 Product plans and budgets developed by the acquiring company 
 Market research studies 
 Historical experience with new product development activities of the acquiring 
company 
 Offering memoranda 
 Board of director materials prepared in support of the acquisition 
 Development progress subsequent to the acquisition 
 Forecasts provided to lenders 
• On a test basis, consider whether that information supports the significant assumptions. 
• If the information is taken from internal analyses, consider the need for testing the 
supporting information. 
• Review the acquiring company’s business plan (including product development 
plans, marketing plans and programs), budgets, and objectives, and consider their 
relationship to the significant assumptions. 
• Consider the existence of external sources of information about the acquiring 
company and its product development activities, the industry and competitors’ 
activities, analysts reports, and trade publications. If appropriate, consider confirming 
information supporting significant assumptions with the external sources. 
• Inquire about and analyze any historical data used in developing the significant 
assumption to assess: 
 Whether the data are comparable and consistent for all periods, and 
 Whether the data are sufficiently relevant for the purpose 
• If the support for significant assumptions comes from experts, such as lawyers, 
engineers, economists, and investment bankers: 
 Consider their professional standing and objectivity 
 Review the data and business plans the acquiring company submitted to the 
expert for consistency with the forecast assumptions and supporting data. 
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6.4.30 Internal Consistency 
6.4.31 Upon completion of the procedures enumerated above, the auditor should 
assess the conclusions reached and the evaluation of the overall financial statement 
presentation. This generally would include considering the internal consistency of the 
results and assumptions with the acquiring company’s business plans, forecasts, press 
releases, board presentations, and discussions with key personnel. When the results 
are not consistent with other information disseminated by the acquiring company, the 
auditor should request a reconciliation of such inconsistencies or appropriate revision of 
the valuation assumptions. If the acquiring company is unable to reconcile any 
inconsistencies or declines to modify the valuation assumptions, the auditor should 
consider the effect of this situation on his or her report on the financial statements (see 
paragraph 6.4.32). 
6.4.32 Evaluating Results of Procedures Performed 
6.4.33 In considering whether to rely on the findings of a valuation specialist about 
the fair value of the acquired IPR&D, the auditor should evaluate whether the valuation 
specialist’s procedures and findings support management’s assertion about the fair 
value of acquired IPR&D in the financial statements. Ordinarily, the auditor would 
accept the work of the valuation specialist unless other evidential matter developed in 
the course of the audit leads the auditor to believe that the valuation specialist’s findings 
are unreasonable. In that event, or in the event there is a material difference between 
the valuation specialist’s findings and management’s assertion in the financial 
statements about the fair value of the acquired IPR&D item, the auditor should apply 
additional procedures designed to provide whatever additional information or 
corroborating evidential matter is needed to resolve the matters in question.  
6.4.34 If, after applying additional appropriate audit procedures, the auditor is unable 
to resolve the matters, the auditor should obtain the opinion of another valuation 
specialist, unless it appears to the auditor that the matters cannot be resolved. The 
existence of a matter that cannot be resolved ordinarily will cause the auditor to 
conclude that the audit report should be qualified, because the inability to obtain 
sufficient competent evidential matter as to an assertion of material significance in the 
financial statements constitutes a scope limitation, and the guidance in paragraph 
6.5.07 should be considered. 
6.4.35 Preliminary Purchase Price Allocations 
6.4.36 Situations may arise wherein an acquiring company consummates a business 
combination at or near the end of a reporting period, and the valuation specialist has been 
unable to complete a detailed valuation of the acquired IPR&D. Paragraph 4.1.02 
provides an accounting question and answer for those situations and indicates that a 
tentative allocation of the purchase price should be made using the values that have been 
determined and preliminary estimates of the fair values that have not yet been finalized. 
The acquiring company may be able to make a good faith best estimate of the IPR&D 
allocation because it performs due diligence before or immediately after agreeing to the 
terms of the acquisition. Guidance also is provided when the acquiring company cannot 
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determine a best estimate for a preliminary allocation to acquired IPR&D, but it has a 
range of estimates, as may be the case in a hostile takeover situation. 
6.4.37 In such situations, the auditor should ascertain that a valuation specialist has 
been engaged and expects to complete the valuation study within a reasonable period 
of time subsequent to the acquisition. The auditor also should ascertain that a 
preliminary estimate of the IPR&D charge has been recorded and perform appropriate 
procedures to evaluate the reasonableness of that preliminary estimate. In evaluating 
the reasonableness of the preliminary estimate, the auditor should perform essentially 
the same procedures as set forth in paragraphs 6.4.04 through 6.4.30. In addition, the 
auditor should discuss with the valuation specialist the preliminary estimate and data 
supporting the estimate to identify any concerns that the auditor or the valuation 
specialist may have with regard to the reasonableness of the estimate recorded. 
6.4.38 If the auditor is unable to satisfy himself or herself about the reasonableness 
of the recorded allocation of the purchase price to the acquired IPR&D, the auditor (and 
the valuation specialist, if necessary) should meet with management and resolve the 
difference of opinion. It may be possible to accelerate the completion of the valuation 
study, delay the issuance of the financial statements, or both, until a better estimate can 
be developed. If the matter is not resolved to the satisfaction of the auditor, the 
guidance in paragraph 6.5.13 should be considered. 
6.4.39 Management Representations 
6.4.40 The auditor should obtain representations from management regarding its 
responsibility for the presentation of acquired IPR&D in the financial statements at the 
appropriate amount when the amounts are material in relation to the financial 
statements taken as a whole. An example of such representations follows: 
In connection with the amounts recorded for the transaction to acquire 
Company X, we agree with the findings of the valuation specialist in 
calculating the fair value of acquired in-process research and development 
(IPR&D) and have adequately considered the qualifications of the specialist 
in determining whether to use the results of the specialist’s valuation as the 
basis for the amount of the IPR&D charge. We believe the IPR&D assets 
identified as those to be used in R&D activities meet the definition of such 
assets (including that they have substance, are incomplete, and have no 
alternative future use) and their fair value is estimable with reasonable 
reliability. We expect to complete the development of all such assets, based 
on information that is available to us at the date of the final purchase price 
allocation. We believe the amount of the charge is appropriate and is 
consistent with generally accepted accounting principles, including the 
guidance in FASB Interpretation No. 4, and the related disclosures are 
appropriate. The historical financial data provided to the valuation specialist 
was prepared on a basis consistent with the company’s audited financial 
statements. Forecasts and other estimates provided to the valuation 
specialist are consistent with those developed for other parties, internal 
use, or both. The forecasts of future cash flows used in the valuation 
represent our best estimate of future conditions consistent with the 
assumptions specified in the specialist’s valuation using market participant 
 155 
assumptions rather than those that are entity-specific. [If using the 
traditional approach] The discount rate applied to estimated future net cash 
flows appropriately reflects the nature and complexity of the remaining 
development effort and the amount and timing of estimated expenditures 
necessary to complete the development of the IPR&D projects. We did not 
give or cause any instructions to be given to the valuation specialist with 
respect to the values or amounts derived in an attempt to bias his or her 
work, and we are not otherwise aware of any matters that have had an 
adverse effect on the independence or objectivity of the specialist. 
6.4.41 The auditor should consider whether other representations concerning the 
accounting for the acquisition should be obtained from management. 
6.5 REPORTING CONSIDERATIONS 
6.5.01 The purpose of this section is to identify best practices in addressing reporting 
matters relating to acquired IPR&D that could arise in the course of performing 
substantive audit procedures. Issues could result from concerns over the auditor’s 
ability to rely on the work of the specialist or to obtain competent evidential matter in 
support of the financial statement assertion as to the IPR&D valuation, the estimation or 
presentation of the acquired IPR&D amounts in conformity with GAAP, and the auditor’s 
association with IPR&D disclosures outside of the financial statements, such as in 
management’s discussion and analysis (MD&A). 
6.5.02 Reliance on the Work of the Specialist 
6.5.03 If, upon the successful completion of the substantive procedures set forth in 
paragraph 6.4, the auditor determines that the specialist’s findings support 
management’s assertions about the valuation of the acquired IPR&D, the auditor 
usually would conclude that sufficient competent evidential matter has been obtained. 
Generally, the auditor should not refer to the work or findings of the specialist in the 
auditor’s report on the financial statements. Reference to the specialist might be 
misunderstood to be a qualification of the auditor’s opinion or a division of responsibility, 
neither of which is intended. 
6.5.04 Circumstances may arise, as a result of the report or the findings of the 
specialist, wherein the auditor decides to add explanatory language to the auditor’s 
standard report in the form of an emphasis paragraph, or when a departure from an 
unqualified opinion on the financial statements is required. Reference to and 
identification of the specialist may be made in the auditor’s report if in the auditor’s 
judgment the reference will facilitate an understanding of the reason for the explanatory 
paragraph or the departure from an unqualified opinion.  
6.5.05 SAS No. 58, as amended, provides guidance with respect to the addition of 
an explanatory paragraph in the auditor’s report to emphasize a matter regarding the 
financial statements. For example, an acquiring company may incur a significant IPR&D 
charge that could affect the comparability of the current period results of operations with 
those of the preceding period. In that situation, the auditor may wish to direct attention 
to the disclosures of the business combination and the IPR&D charge by means of an 
 156 
emphasis paragraph in the auditor’s report. Emphasis paragraphs are never required; 
they may be added solely at the auditor’s discretion. A cursory review of current practice 
indicates that emphasis paragraphs are rarely, if ever, used in connection with a 
business combination. 
6.5.06 If, as a result of performing audit procedures on the acquired IPR&D, the 
auditor concludes that a departure from an unqualified opinion is required, the form of 
the auditor’s report will be governed by the nature of the circumstances giving rise to the 
need for the report modification. The requirements of the Securities and Exchange 
Commission (SEC) staff concerning qualified opinions on financial statements filed with 
the SEC are set forth in Staff Accounting Bulletin 13 (Topic 1E) and would be applicable 
to financial statements filed with the SEC. 
6.5.07 Scope Limitations 
6.5.08 The auditor is able to express an unqualified opinion on the financial 
statements only if the audit has been performed in accordance with GAAS, and if the 
auditor has been able to apply all the audit procedures considered necessary in the 
circumstances. Restrictions on the scope of the audit, whether imposed by the acquiring 
company or by circumstances, such as the timing of the audit work, the inability to 
obtain competent evidential matter, or an inadequacy of the accounting records, may 
require the auditor to modify the report on the financial statements. 
6.5.09 The auditor’s decision to express a qualified opinion or to disclaim an opinion 
because of a scope limitation depends on the auditor’s assessment of the importance of 
the omitted audit procedures in relation to the auditor’s ability to form an opinion on the 
financial statements taken as a whole. That assessment will be affected by the nature 
and magnitude of the potential effect of a misstatement of acquired IPR&D and its 
significance to the financial statements being audited. 
6.5.10 When the auditor is unable to resolve disagreements regarding the 
reasonableness of the work of the valuation specialist (see paragraph 6.4.32), the 
auditor ordinarily will conclude that the audit report should be qualified because the 
inability to obtain sufficient competent evidential matter as to an assertion of material 
significance in the financial statements constitutes a scope limitation. SAS No. 58 (AU 
sec. 508.22–.32) provide additional guidance to the auditor with respect to scope 
limitations (as distinguished from uncertainties) and their effect on the auditor’s report. 
6.5.11 The procedures described above should be applied in situations in which the 
limitation on the scope of the audit is imposed by circumstances beyond the control of 
the acquiring company or the auditor, such as a lack of historical or other information to 
enable the auditor to evaluate the reasonableness of the significant assumptions used 
by the valuation specialist to estimate the fair value of the acquired IPR&D. In the rare 
situation in which a restriction that significantly limits the scope of the audit is imposed 
by the acquiring company, the auditor ordinarily should disclaim an opinion on the 
financial statements. 
6.5.12 Situations may arise where an acquiring company that lacks the sophistication 
to perform its own valuation (see paragraph 6.3.21), refuses to engage a valuation 
specialist and makes their own estimate of the fair value of the acquired IPR&D. In those 
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circumstances, the auditor should consider insisting that the acquiring company engage 
a qualified independent valuation specialist. The acquiring company may suggest that 
the auditor perform the valuation and propose adjustments to the recorded estimate. 
For public registrants, the SEC staff believes that an auditor’s independence would be 
impaired by performing such services for an audit client since he or she would be in the 
position of auditing their own work. The client’s refusal to engage a qualified 
independent valuation specialist may result in a lack of competent evidential matter in 
support of the amount assigned to acquired IPR&D. In that situation, the lack of such 
evidential matter would constitute a scope limitation, as discussed in paragraph 6.5.11.  
6.5.13 GAAP Departures 
6.5.14 After performing the requisite audit procedures, including evaluating the 
findings of the valuation specialist, the auditor may conclude that management’s 
assertions in the financial statements about the identification of or estimate of the fair 
value of the acquired IPR&D are not presented or measured in conformity with GAAP. 
This situation could arise from unresolved differences of opinion over whether all 
intangibles (for example, base [or core] technology) have been properly identified and 
valued, the appropriateness of the valuation methodology, or the reasonableness of the 
significant valuation assumptions (for example, the discount rate applied to compute the 
present value of estimated future net cash flows). When financial statements are 
materially affected by a departure from GAAP and the auditor has performed an audit in 
accordance with GAAS, the auditor should issue a qualified or adverse opinion on the 
financial statements. In deciding whether the effects of a GAAP departure are 
sufficiently material to require either a qualified or adverse opinion, the auditor should 
consider not only the dollar magnitude of the departure but should also consider the 
qualitative implications of the matter.2 
6.5.15 Auditor’s Responsibility for Information in Documents Containing 
Audited Financial Statements 
6.5.16 The auditor’s responsibility for information published in certain documents 
containing audited financial statements is described in SAS No. 8, Other Information in 
Documents Containing Audited Financial Statements (AICPA, Professional Standards, 
vol. 1, AU sec. 550.04) as follows: 
Other information in a document may be relevant to an audit performed by an 
independent auditor or to the continuing propriety of his report. The auditor’s 
responsibility with respect to information in a document does not extend 
beyond the financial information identified in his report, and the auditor has no 
obligation to perform any procedures to corroborate other information 
contained in a document. However, he should read the other information and 
consider whether such information, or the manner of its presentation, is 
materially inconsistent with information, or the manner of its presentation, 
appearing in the financial statements. [Footnote omitted.] 
                                            
2
 SEC Staff Accounting Bulletin No. 99, “Materiality,” presents a discussion of materiality considerations 
that are applicable to the financial statements of Securities and Exchange Commission registrants. 
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6.5.17 Accordingly, the auditor should read the acquired IPR&D disclosures in the 
MD&A presented in annual reports to shareholders and other documents to consider 
whether the disclosures are consistent with the auditor’s knowledge of the client and the 
audited financial statements. 
6.5.18 While the auditor does not have an obligation to corroborate acquired IPR&D 
information presented outside the financial statements, if such information is materially 
inconsistent with the audited financial statements, the auditor should discuss these 
matters with appropriate acquiring company personnel. If the inconsistencies are not 
corrected to the auditor’s satisfaction, the auditor should follow the guidance set forth in 
SAS No. 8 (AU secs. 550.05-.06). 
6.6 OTHER CONSIDERATIONS—INTERIM PERIOD REPORTING 
6.6.01 An auditor may become aware of an acquisition involving IPR&D while 
performing a review of interim period financial information in accordance with SAS No. 
71, Interim Financial Information (AICPA, Professional Standards, vol. 1, AU sec. 722) 
as amended by SAS No. 90. That guidance notes that the objective of a review of 
interim financial information is to provide a basis for reporting whether the auditor is 
aware of any material modifications that should be made for the information to conform 
with GAAP. Procedures applied in performing a review of interim financial information 
generally are limited to inquiries and analytical procedures concerning significant 
accounting matters relating to the interim financial information. Those procedures do not 
contemplate (a) tests of accounting records through inspection, observation, or 
confirmation; (b) obtaining corroborating evidential matter in response to inquiries; or (c) 
the application of certain other procedures ordinarily performed during an audit. 
6.6.02 When a business combination has been reported in interim period financial 
statements that are the subject of a SAS No. 71 review, the auditor ordinarily would 
make inquiries of management and perform analytical procedures designed to ascertain 
whether the business combination as a whole appears to have been accounted for in 
conformity with GAAP. When making inquiries and performing analytical procedures 
with respect to a material IPR&D charge, the auditor should consider performing the 
following procedures: 
• Inquire of the CEO and CFO about the business purpose for the acquisition, the principal 
products, processes, and types of assets acquired, and whether a valuation specialist 
was engaged to value the acquired IPR&D and has rendered a valuation report. 
• Determine whether the amount allocated to acquired IPR&D is preliminary and 
subject to completion of a valuation study. If so, ascertain that its preliminary nature 
is properly disclosed in the financial statements. 
• If a valuation report has been rendered, the report should be read and the assumptions 
and findings considered for consistency with the amounts reported in the financial 
statements and for reasonableness, based on the auditor’s knowledge of the acquiring 
company’s business and the industry, and for conformity with the best practices set forth 
in this Practice Aid. The auditor also should consider whether a discussion of the 
valuation assumptions and methodology with the valuation specialist would be helpful in 
enhancing the auditor’s understanding of the estimation of the IPR&D charge. 
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6.6.03 The auditor should consider obtaining, in the representation letter, a specific 
representation concerning the valuation of and accounting for the acquired IPR&D similar to 
that presented in paragraph 6.4.32, tailored as appropriate for the specific circumstances. 
6.6.04 If, based on performing the procedures set forth above, the auditor has 
reason to believe the acquiring company’s estimation or presentation of the acquired 
IPR&D may not be in conformity with GAAP, the auditor should discuss his or her 
concerns with the acquiring company’s senior management and perform additional 
procedures, such as those noted in paragraph 6.4, as may be necessary to determine 
whether a material misapplication of GAAP or appropriate valuation practices may have 
occurred. If the additional procedures confirms a material error in the determination or 
recording of the IPR&D charge, and the interim period financial information has not 
been issued or filed with the SEC on Form 10-Q in the case of a public company, the 
interim period financial information should be corrected before issuance or filing of Form 
10-Q. If Form 10-Q already has been filed, management should be advised to discuss 
with its legal counsel the need to disclose publicly, such as in a Form 8-K Current 
Report, that the previously issued interim period financial information requires 
restatement and to prepare appropriate public filings to correct that interim information. 
6.6.05 If, in the auditor’s judgment, management does not respond appropriately to 
the auditor’s concerns within a reasonable period of time, the auditor should inform the 
audit committee (or board of directors in the absence of an audit committee) of the 
matter as soon as practicable. If, in the auditor’s judgment, the audit committee (or 
board of directors) does not respond appropriately to that communication, the auditor 
should evaluate whether (a) to resign the review engagement, (b) to resign or decline 
to stand for reelection as the acquiring company’s auditors, and (c) the actions of the 
acquiring company and its audit committee trigger the auditor’s reporting obligations 
(with respect to public entities) under Section 10A of the Securities Exchange Act of 
1934. The auditor may wish to consult with his or her legal counsel when making 
these evaluations. 
6.6.06 If a business combination has not been consummated at the date of the 
review of the interim financial information, the auditor should obtain from the acquiring 
company’s senior management an understanding of the nature and purpose of the 
transaction and review the acquiring company’s plan for completing the acquisition. The 
auditor may wish to consider the matters discussed in paragraph 6.3, including the need 
to engage the services of a competent independent valuation specialist. The auditor 
also should consider discussing with management the extent of the disclosures that 
should be made concerning the acquisition, such as disclosure in the MD&A by a 
company subject to the reporting requirements of the SEC.  
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EXHIBIT 6-1 
Sample Audit Program — In-Process Research and Development 
GENERAL 
A portion of the purchase price in a business combination may be allocated to in-
process research and development (IPR&D), but IPR&D is particularly common in 
acquisitions of software, electronic devices, and pharmaceutical companies. This 
sample audit program outlines audit procedures that should be considered when an 
acquiring company has consummated a business combination that may involve IPR&D. 
This sample audit program is best read and used in conjunction with best practices 
identified in chapter 6. 
The procedures focus on the software, electronic devices, and pharmaceutical 
industries; however, further tailoring of the recommended procedures may be necessary 
in response to the specific circumstances of each acquisition. The nature and extent of 
the needed tailoring may be influenced by the business, legal, and regulatory 
environments in which both the acquiring company and the acquired company operate. 
Accordingly, auditors should use their knowledge of those environments and their 
professional judgment in tailoring the recommended procedures to each acquisition. 
The services of a valuation specialist usually are required in estimating the amount of 
the purchase price allocated to IPR&D. Some entities employ valuation specialists in 
their organizations; others will find it necessary to engage the services of an external 
valuation specialist. Regardless of who performs the valuation, the auditor should 
determine that the specialist has the requisite skills and expertise to develop a valuation 
of the acquired IPR&D in conformity with generally accepted accounting principles 
(GAAP). In gathering audit evidence about the appropriateness of the IPR&D valuation, 
the auditor also may require the assistance of a valuation specialist. That specialist may 
be an employee of the auditor’s firm or may be an external valuation specialist engaged 
by the auditor to assist in evaluating the reasonableness of the IPR&D valuation. 
PROCEDURES 
1. Obtain an understanding of the acquisition. 
a. Inquire of appropriate acquiring company personnel about the nature and business 
purpose of the acquisition and whether special terms or conditions may exist. 
 
[Persons of whom inquiry might be made include the chief executive officer, the 
chief financial officer, and appropriate personnel from marketing, business 
development, research and development, and technology departments. The 
auditor should become familiar with the types of products and services sold by 
the acquired company, and its production, marketing, distribution, and 
compensation methods. The auditor also should become aware of significant 
matters and trends affecting the industry, including economic conditions, 
changes in technology, government regulations, and competition.] 
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b. Obtain and read the acquisition agreements, due diligence reports prepared by 
acquiring company personnel or other parties engaged by the acquiring 
company, analyst’s reports, acquired company prospectuses or offering 
memoranda, and other industry analyses pertinent to the acquisition. 
c. Obtain and read presentations to the board of directors and any press releases 
concerning the acquisition. 
2. Ascertain the identity and affiliation of the valuation specialist. Arrange to meet with the 
valuation specialist and discuss the following: 
a. The objectives and scope of the valuation study. 
b. Whether the valuation specialist has any relationships with the acquiring 
company that might impair the valuation specialist’s objectivity. 
c. The valuation specialist’s understanding of the requirements of GAAP as they 
relate to the valuation, including the definition of fair value. 
d. The types and sources of information to be provided by the acquiring company to 
the valuation specialist. 
e. The methods and significant assumptions used in the valuation, including the 
selection of discount rates. 
f. The consistency of methods and assumptions with previous valuations. 
g. The scope and nature of the conclusions included in the valuation report. 
3. Ascertain the following: 
a. The professional competence of the valuation specialist as evidenced by 
accreditation or certification, licensure or recognition by a recognized 
professional organization. 
b. The professional reputation of the valuation specialist as viewed by his or her 
peers and others familiar with his or her capabilities or performance. 
c. The experience of the valuation specialist in the industry or in the valuation of 
tangible and intangible assets, including acquired IPR&D. 
4. Inquire of acquiring company personnel regarding any relationship between the 
valuation specialist and the acquiring company. 
[The auditor should evaluate any relationship between the valuation specialist and the 
client to ascertain whether the client has the ability—through employment, ownership, 
contractual rights, family relationship or otherwise—to directly or indirectly control or 
significantly influence the valuation specialist’s work The valuation report should 
identify such relationships.]  
5. With respect to the valuation report— 
a. Determine whether the valuation methodology used reconciles to the AICPA 
Practice Aid, Assets Acquired in a Business Combination to be Used in Research 
and Development Activities. 
b. Review the reconciliation of the valuation to the purchase price paid. 
[This information is normally found in the “Valuation Analysis” section of the 
valuation report.]  
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c. Consider whether other intangibles exist to which a portion of the purchase has 
not been allocated. 
[The report should identify and value all intangibles acquired (when several 
specialists are used to value intangibles, there may be more than one report, but 
the intangibles should be valued).] 
6. If the income approach to valuation is used, review the cash flow forecasts and consider 
whether the significant assumptions applied to the projects in process are 
unreasonable. 
[Among the more significant assumptions are the following: 
• Potential for introduction of new technologies that may obsolete the acquired 
technology 
• Likelihood of project completion 
• Estimates of stage of completion and time to completion 
• Cost to complete 
• Product life cycle and technology development strategies 
• Expected sales volumes, product pricing, and expected revenues (exclusive of 
amounts attributable to contributory assets and core technology) 
• Production and other costs (exclusive of the effects of buyer synergies) 
• Discount rates 
• Competitors’ expected prices] 
7. Test the data furnished to the valuation specialist as follows: 
a. Assess the relative importance of IPR&D to the acquisition by considering the 
materials reviewed during the planning procedures as well as other materials, such 
as presentations to the board, white papers, and due diligence working papers. 
b. Test the mathematical accuracy of the forecasts furnished to the specialist. 
c. Determine whether cash flow estimates were developed using “market 
participant” assumptions. With respect to “market participant” assumptions, 
paragraph 1.1.16 of the AICPA Practice Aid states: 
For purposes of assigning cost to the assets acquired in 
accordance with FASB Statement No. 141, the amount of the 
purchase price allocated to an acquired intangible asset would not 
include any entity-specific synergistic value. Fair value does not 
include strategic or synergistic value resulting from expectations 
about future events that are specific to a particular buyer because 
the value associated with those components are unique to the 
buyer and seller and would not constitute market-based 
assumptions. As such, entity-specific value associated with 
strategic or synergistic components would be included in goodwill. 
Fair value would incorporate expectations about future events that 
affect market participants. If the acquiring company concludes that 
the discounted cash flow method best approximates the fair value 
of an acquired intangible asset, the discounted cash flows would 
incorporate assumptions that market participants would use in their 
estimates of future revenues and future expenses.  
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[A footnote to paragraph 1.1.16 refers readers to current developments in 
accounting related to market participant assumptions.] 
d. Consider the amounts of R&D costs expended to date and estimated remaining 
completion costs for reasonableness. 
e. Review descriptions of the milestones achieved and compare the status with the 
actual costs incurred and projected remaining costs. 
f. Consider whether IPR&D is related to products that will be marketed externally. 
g. Inquire of appropriate acquiring company personnel whether IPR&D has 
achieved technological feasibility (or the equivalent) and has no alternative 
future use. 
8. Evaluate the overall results of the valuation. Consider— 
a. Whether the size of the IPR&D charge is consistent with the overall nature of the 
business and management’s purchase rationale. 
b. The size of the existing base (or core) technology value relative to the IPR&D 
value is reasonable. 
c. The reasonableness of the IPR&D value with respect to the extent of completion 
efforts remaining. 
d. Whether the IPR&D value will be realizable and whether both the buyer and 
seller are compensated considering the risks. 
e. Major milestones achieved in the IPR&D project as of the purchase date and 
their consistency with the valuation. 
f. The entire purchase price allocation reflects the acquiring company’s 
technology, industry position, age, reputation, and strategic plan. 
9. Obtain a representation letter from the acquiring company that includes the following: 
a. Management agrees with the findings of the valuation specialist. 
b. The IPR&D assets have substance, are incomplete, and have no alternative 
future use. 
c. The historical financial data provided to the valuation specialist was prepared on 
a basis consistent with the audited financial statements. 
d. Forecasts and other estimates provided to the valuation specialist are consistent 
with those developed for other parties or for internal use. The forecasts of future 
cash flows used in the valuation represent management’s best estimate of 
future conditions consistent with the assumptions specified in the specialist’s 
valuation using market participant assumptions rather than those that are entity 
specific (see the footnote to paragraph 1.1.16 of the AICPA Practice Aid). 
e. Under the traditional approach, the discount rate applied to estimated future net 
cash flows appropriately reflects the nature and complexity of the remaining 
development effort and the amount and timing of estimated expenditures 
necessary to complete the development of the IPR&D projects. 
10. Determine that information requiring separate disclosure in the financial statements is 
properly identified in the working papers and presented in the financial statements, 
including the disclosures identified in paragraph 4.2 of the AICPA Practice Aid. 
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CONCLUSION 
Based on the procedures performed, we are satisfied that our working papers 
appropriately document that acquired IPR&D does not contain any material 
misstatements, in relation to the financial statements taken as a whole. Exceptions are 






GLOSSARY OF TERMS 
Base technology. (Also referred to in practice as core technology.)  Those technical 
processes, intellectual property, and the institutional understanding that exist within an 
organization with respect to products or processes that have been completed and that 
will aid in the development of future products, services, or processes that will be 
designed in a manner to incorporate similar technologies. 
Developed product technology. Technology as it exists in a current product(s) 
offering.  Today’s developed product technology may be tomorrow’s base (or core) 
technology. In a valuation model that “splits” revenues or profits, developed product 
technology and base (or core) technology may be combined into one category.  From a 
generally accepted accounting principles perspective, base (or core) and developed 
technology should be separately identified if they have different amortizable useful lives. 
Expected cash flow approach. When determining present value, the sum of 
probability-weighted cash flows in a range of possible estimated amounts; the estimated 
mean or average. 
In-process research and development (IPR&D). Research and development project 
that has not yet been completed.  Acquired IPR&D is a subset of an intangible asset to 
be used in R&D activities. 
Multi-period excess earnings method. A specific application of the discounted cash 
flow method, which is more broadly a form of the income approach.  The most common 
method used to estimate the fair value of an intangible asset. 
Synergies. In the context of developing prospective financial information, the difference 
between the assumptions used to estimate cash flows that are unique to an entity and 
the assumptions that would be used by market participants. 
Traditional approach. When determining present value, the use of a single set of 





GLOSSARY OF ABBREVIATIONS 
AICPA. American Institute of Certified Public Accountants 
FASB. Financial Accounting Standards Board 
FDA. Food and Drug Administration 
GAAP. Generally accepted accounting principles 
GAAS. Generally accepted auditing standards 
IPR&D. In-process research and development 
MD&A. Management discussion and analysis 
PFI. Prospective financial information 
R&D. Research and development 





Following are titles of authoritative financial reporting literature referenced in this 
Practice Aid. 
STATEMENTS OF FINANCIAL ACCOUNTING STANDARDS 
• FASB Statement No. 2, Accounting for Research and Development Costs 
• FASB Statement No. 7, Accounting and Reporting by Development Stage Enterprises 
• FASB Statement No. 38, Accounting for Preacquisition Contingencies of Purchased 
Enterprises 
• FASB Statement No. 68, Research and Development Arrangements 
• FASB Statement No. 86, Accounting for the Costs of Computer Software to Be Sold, 
Leased, or Otherwise Marketed 
• FASB Statement No. 96, Accounting for Income Taxes, which was superseded by 
FASB Statement No. 109. 
• FASB Statement No. 109, Accounting for Income Taxes 
• FASB Statement No. 121, Accounting for the Impairment of Long-Lived Assets and 
for Long-Lived Assets to Be Disposed Of 
• FASB Statement No. 131, Disclosures about Segments of an Enterprise and 
Related Information 
• FASB Statement No. 133, Accounting for Derivative Instruments and Hedging Activities 
• FASB Statement No. 141, Business Combinations 
• FASB Statement No. 142, Goodwill and Other Intangible Assets 
ACCOUNTING PRINCIPLES BOARD OPINIONS 
• APB Opinion 16, Business Combinations 
• APB Opinion 17, Intangible Assets 
• APB Opinion 18, The Equity Method of Accounting for Investments in Common Stock 
FASB STATEMENTS OF CONCEPTS 
• FASB Concepts Statement No. 2, Qualitative Characteristics of Accounting Information 
• FASB Concepts Statement No. 5, Recognition and Measurement in Financial 
Statements of Business Enterprises 
• FASB Concepts Statement No. 6, Elements of Financial Statements 
• FASB Concepts Statement No. 7, Using Cash Flow Information and Present Value 
in Accounting Measurements 
FASB INTERPRETATIONS 
• FASB Interpretation No. 4, Applicability of FASB Statement No. 2 to Business 
Combinations Accounted for by the Purchase Method 
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• FASB Interpretation No. 6, Applicability of FASB Statement No. 2 to Computer Software 
• FASB Interpretation No. 35, Criteria for Applying the Equity Method of Accounting for 
Investments in Common Stock 
AICPA STATEMENT OF POSITIONS 
• SOP 81-1, Accounting for Performance of Construction-Type and Certain 
Production-Type Contracts 
• SOP 94-6, Disclosure of Certain Significant Risks and Uncertainties 
• SOP 98-1, Accounting for the Costs of Computer Software Developed or Obtained 
for Internal Use 
EMERGING ISSUES TASK FORCE ISSUES 
• EITF Issue No. 87-11, Allocation of Purchase Price to Assets to Be Sold 
• EITF Issue No. 95-21, Accounting for Assets to Be Disposed Of Acquired in a 
Purchase Business Combination 
• EITF Issue No. 98-3, Determining Whether a Nonmonetary Transaction Involves 
Receipt of Productive Assets or of a Business 
• EITF Issue No. 00-5, Determining Whether a Nonmonetary Transaction Is an 
Exchange of Similar Productive Assets 
AICPA STATEMENTS ON AUDITING STANDARDS 
• SAS No. 1, Codification of Auditing Standards and Procedures (AICPA, Professional 
Standards, vol. 1, AU sec. 560), “Subsequent Events” 
• SAS No. 8, Other Information in Documents Containing Audited Financial 
Statements (AICPA, Professional Standards, vol. 1, AU sec. 550) 
• SAS No. 22, Planning and Supervision (AICPA, Professional Standards, vol. 1, AU sec. 311) 
• SAS No. 47, Audit Risk and Materiality in Conducting an Audit (AICPA, Professional 
Standards, vol. 1, AU sec. 312) 
• SAS No. 55, Consideration of Internal Control in a Financial Statement Audit 
(AICPA, Professional Standards, vol. 1, AU sec. 319), as amended by SAS No. 78 
• SAS No. 57, Auditing Accounting Estimates (AICPA, Professional Standards, vol.1, 
AU sec. 342) 
• SAS No. 58, Reports on Audited Financial Statements (AICPA, Professional 
Standards, vol. 1, AU sec. 508), as amended by SAS No. 79 
• SAS No. 71, Interim Financial Information (AICPA, Professional Standards, vol. 1, 
AU sec. 722) 
• SAS No. 73, Using the Work of a Specialist (AICPA, Professional Standards, vol. 1, 
AU sec. 336) 
• SAS No. 82, Consideration of Fraud in a Financial Statement Audit (AICPA, 
Professional Standards, vol. 1, AU secs. 110, 230, 312, and 316) 
• SAS No. 90, Communication With Audit Committees (AICPA, Professional 
Standards, vol. 1, AU secs. 380 and 722) 
• SAS No. 94, The Effect of Information Technology on the Auditor’s Consideration of 
Internal Control in a Financial Statement Audit (AICPA, Professional Standards, vol. 







evaluation of, 6.2.10–6.2.12 
introduction to, 6.1.01–6.1.04 
management's responsibility for, 6.2.05–6.2.08 
Accounting of acquired assets, 4.1.01–4.1.23 
Acquisition(s) 
accounting estimates issues of, 6.2.02–6.2.12 
engagement planning considerations for, 6.3.02–6.3.44 
reporting considerations for, 6.5.01–6.5.06 
substantive procedures for, 6.4.02–6.4.41 
Administrative expenses, verification of, 5.3.14 
Allocation costs 
to acquired assets, 3.2.05 
disclosure of, 4.2.05 
timing for recording of, 4.1.02–4.1.03 
Alternative future use 
of acquired assets, 3.2.06–3.2.11, 3.3.70–3.3.73, 3.3.75–3.3.76, 3.3.79–3.3.80, 3.3.89–3.3.90 
determining, 5.3.33 
Amortization, tax, 5.3.98, 5.3.102, 5.3.105–5.3.108 
Asset(s). See also Intangible assets 
fixed, 5.3.60–5.3.61, 5.3.64 
long-lived, 5.3.71 
management's role in identifying, 5.3.27–5.3.31 
sale, 5.3.99 
tangible, 5.3.14 
treatment of, 12.1.04–12.1.05 
Assets, acquired. See also Alternative future use; Valuation methods/issues 
accounting of, 4.1.01–4.1.23 
amortization of, 5.3.98, 5.3.102, 5.3.105–5.3.108 
in business combinations, 1.1.01–1.1.05, 3.1.01–3.1.04 
capitalization of costs of, 3.3.70–3.3.73 
characteristics and attributes of, 3.2.02–3.2.12, 3.3.13–3.3.16 
confirming existence of, 5.3.33–5.3.34 
disclosure of, 4.2.01–4.2.08 
economic benefits of, 3.3.17–3.3.21 
fair value concept of, 1.1.07–1.1.12 
identification of, 5.3.27–5.3.31 
measurement criteria for, 3.3.22–3.3.26 
net-of-tax approach and, 5.3.100 
PFI attributable to, 5.3.39–5.3.40 
on single asset basis, 1.1.14 
synergistic value excluded from, 1.1.15–1.1.19 
tax benefits and, 5.3.98–5.3.108 
Assumptions 
fair value concept and, 1.1.04 
significant, 6.4.23–6.4.29 
used in PFI preparation, 5.3.18 
Audit(ing) 
of financial statements, 6.3.04, 6.5.08–6.5.09 
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risk assessment, 6.3.37–6.3.44 
Auditor 
accounting estimates evaluation by, 6.2.10–6.2.12 
allocations issues for, 6.4.37–6.4.38 
auditing procedures planning by, 6.3.02–6.3.04 
audit risk assessment by, 6.3.39–6.3.40 
entity's business knowledge as requirement for, 6.3.06–6.3.09 
in-process projects evaluation by, 6.4.20–6.4.21 
interim period reporting by, 6.6.01–6.6.06 
personnel considerations issues for, 6.3.17–6.3.19 
responsibility for financial statements' contents, 6.5.16–6.5.18 
significant assumptions evaluation by, 6.4.23–6.4.29 
understanding of acquisition by, 6.3.10–6.3.12, 6.4.05 
valuation report evaluation by, 6.4.14–6.4.21 
valuation specialist and, 6.3.21–6.3.27, 6.3.29–6.3.34, 6.5.03–6.5.06, 6.5.10–6.5.11 
B 
Base technology 
basis of charge for, 5.3.64 
contributory asset charge related to, 5.3.43 
defined, 5.3.47 
revenue split model and, 5.3.49–5.3.50 
Bridge/IPO investments, 5.3.91 
Business combination. See also Acquisition(s); Valuation methods/issues 
acquiring assets in, 1.1.01–1.1.05, 3.1.01–3.1.04 
assets' allocation issues of, 4.1.17–4.1.23 
assets' disclosure in, 4.2.01, 4.2.03 
future use of assets in, 3.3.75–3.3.90 
PFI alternatives preparation for, 5.3.07–5.3.08 
R&D projects with incompleteness in, 3.3.61–3.3.68 
software development costs and, 3.3.06–3.3.07 
C 
Capital asset charge, 5.3.59, 5.3.64 
Capital charges 
allocation of, 5.3.61 
defined, 5.3.56 
Capitalization of costs of acquired assets, 3.3.70–3.3.73 
Cash flows 
after-tax, 5.3.05, 5.3.36–5.3.38, 5.3.103–5.3.104 
allocation of, 5.3.41 
calculating present value of, 5.3.69–5.3.96 
contributory asset charge and, 5.3.55–5.3.57 
discount rate and, 5.3.77 
estimation of, 5.3.72 




indications of, 2.1.10–2.1.14 
probability-adjusted, 5.3.79 
reporting of, 4.1.14–4.1.16 




assets' allocation issues of, 4.1.17–4.1.23 
control characteristic issues of, 3.3.15–3.3.16 
PFI preparation issues of, 5.3.19 
R&D sub-projects and, 3.3.58 
Common stocks, accounting for investments in, 4.1.09–4.1.13 
Contributory asset charge 
cash flows issues and, 5.3.37, 5.3.55–5.3.57 
determining, 5.3.62 
principle of, 5.3.65 
related to base technology, 5.3.43 
vs. revenue-splitting method, 5.3.44 
Contributory assets 
charging returns for, 5.3.61 
fair value of, 5.3.63 
types of, 5.3.59–5.3.60 
Control environment, risk factors related to, 6.3.42–6.3.44 
Core technology. See Base technology 
Cost approach, 2.1.04–2.1.05 
D 
Development stage enterprise, 3.3.27–3.3.29 
Disclosure 
of assets, 4.2.01, 4.2.03 
of expenses, 4.2.05 
of R&D projects, 4.2.04 
of valuation methods, 4.2.02 
Discounted cash flow method 
after-tax cash flows and, 5.3.103–5.3.104 
for R&D projects, 1.1.18 
Discount rate 
calculating present value of cash flows using, 5.3.69 
selection of, 5.3.77, 5.3.81–5.3.96 
E 
Early development stage investments, 5.3.89 
Economic benefits 
of acquired assets, 3.3.17–3.3.21, 5.3.33 




Engagement planning considerations 
audit risk model, 6.3.01–6.3.04 
knowledge of business, 6.3.06–6.3.09 
overall risk assessment, 6.3.36–6.3.44 
personnel considerations, 6.3.17–6.3.19 
timing considerations, 6.3.14–6.3.15 
understanding of acquisitions, 6.3.10–6.3.12 
use of valuation specialist, 6.3.21–6.3.34 
Equity method, 4.1.09–4.1.13 




attributable to IPR&D subcomponent, 5.3.53 
marketing, 5.3.14 
F 
Fair market value (FMV), 1.1.07 
Fair value estimation. See also Accounting estimates; Valuation methods/issues 
of acquired assets, 1.1.08–1.1.14 
assumptions and, 1.1.04 
cost approach for, 2.1.04–2.1.05 
defined, 1.1.03 
for financial reporting, 1.1.03–1.1.07 
market approach for, 2.1.07 
measurement criteria for assets and, 3.3.24–3.3.29 
multi-period excess earnings method for, 5.3.01–5.3.05 
net-of-tax approach and, 5.3.100 
summary, 1.1.21 
synergistic value and, 1.1.16 
traditional approach for, 5.3.71 
Financial statements 
assets' allocation issues and, 4.1.01–4.1.08 
audit of, 6.3.04 
auditor's responsibility for contents of, 6.5.16–6.5.18 
disclosure of assets and expenses in, 4.2.05–4.2.06 
GAAP departures in, 6.5.14 
interim period reviewing of, 6.6.01–6.6.06 
risk factors for frauds in, 6.3.41 
Fixed assets, 5.3.60–5.3.61, 5.3.64 
H 
I 
Income approach, fair value estimation with, 2.1.09–2.1.20, 5.3.73 
Income tax benefits 
with amortization, 5.3.98, 5.3.102, 5.3.105–5.3.108 
computing, 5.3.98 
fair value of assets and, 5.3.102 
Income tax synergies, elimination of, 5.3.23 
Incompleteness issues 
handling, 5.3.33 
related to R&D projects, 3.3.55–3.3.68 
Incremental revenue, 2.1.10 
In-exchange value, 1.1.07 
Inherent risk 
defined, 6.3.37 
related to acquired IPR&D estimates, 6.3.38 
In-process projects, evaluation of, 6.4.20–6.4.21 
Intangible assets 
basis of charge for, 5.3.64 
capitalization of costs of, 3.3.70–3.3.73 
examples of, 5.3.60 
identification of, 6.4.17–6.4.18 
measurement criteria for, 3.3.24 
required levels of, 5.3.14 
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synergistic value and, 1.1.17–1.1.19 
tax benefits and, 5.3.98 
valuation of, 2.1.07, 2.1.09–2.1.20, 5.3.01–5.3.05, 5.3.107–5.3.108 
value on single asset basis, 1.1.09–1.1.14 
Intellectual property, 3.3.14 
Interim period reporting, 6.6.01–6.6.06 
Internal-use software, 3.3.04–3.3.07 
In-use value, 1.1.07 
Investment value, 1.1.07 
IPR&D projects. See Research and development projects 
L 
Liquidation value, 1.1.07 
M 
Management 
accounting estimates responsibility for, 6.2.05–6.2.08 
PFI preparation responsibility for, 5.3.10–5.3.12 
representations from, 6.4.40–6.4.41 
role in acquisition's control environment, 6.3.42–6.3.44 
role in identifying assets, 5.3.27–5.3.31 
Management's discussion and analysis (MD&A) 
IPR&D charges and, 4.2.08 
purpose of, 4.2.07 
Manufacturing cost savings, 2.1.10 
Market approach, fair value estimation with, 2.1.07 
Marketing expenses, 5.3.14 
Market value, fair value concept and, 1.1.07 
Measurability issues 
fair value estimation issues and, 3.3.31–3.3.38 
related to acquired assets, 3.3.22–3.3.26, 5.3.33 
Multi-period discounted cash flow method, 2.1.11 
Multi-period excess earnings method 
cash flow indications with, 2.1.10 
fair value concept and, 1.1.21 
overview of, 5.3.01–5.3.03 
steps to application of, 5.3.04 
N 
Net working capital, verification of, 5.3.14 
P 
Patents, basis of charge for, 5.3.64 
Present value measurements 
elements of, 5.3.76 
fair value as objective in using, 5.3.74 
Private Securities Litigation Reform Act of 1995, 4.2.04 
Process changes costs as R&D activity, 3.3.08–3.3.09 
Proprietary intellectual property. See Intellectual property 
Prospective financial information (PFI) 
allocation of, 5.3.39–5.3.40 
eliminating synergies from, 5.3.18–5.3.25 
non-IPR&D activities and, 5.3.36–5.3.53 
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purchase price and, 5.3.07–5.3.12 
revenues' forecast in, 5.3.41–5.3.43 
valuation report contents and, 5.2.07 
verifying elements of, 5.3.14–5.3.16 
R 
R&D expenses 
attributable to IPR&D subcomponent, 5.3.53 
verification of, 5.3.14 
Real option method, 2.1.17–2.1.20 
Relief-from-royalty method, 2.1.12–2.1.15 
Reporting considerations 
auditor's responsibility for financial statements, 6.5.16–6.5.18 
GAAP departures, 6.5.14 
interim period reporting, 6.6.01–6.6.06 
introduction to, 6.5.01 
reliance on specialist's work, 6.5.03–6.5.06 
scope limitations, 6.5.08–6.5.12 
Research and development projects. See also Acquisition(s); Allocation costs; Valuation methods/issues 
after-tax cash flows related to, 5.3.36–5.3.38 
assets' attributes for, 3.2.03–3.2.12 
assets' characteristics for, 3.2.02, 3.3.13–3.3.16 
assets' economic benefits in, 3.3.17–3.3.21 
confirming assets' existence in, 5.3.33–5.3.34 
considerations for disclosure about, 4.2.04 
fair value estimation issues and, 1.1.07–1.1.13, 3.3.27–3.3.29, 3.3.31–3.3.38 
identifying assets in, 5.3.27–5.3.31 
incompleteness attributes related to, 3.3.55–3.3.68 
management's discussion and analysis and, 4.2.08 
measurement issues related to, 3.3.22–3.3.26 
phases of, 3.3.40–3.3.43 
process changes as, 3.3.08–3.3.09 
risk premiums for, 5.3.84 
scope of, 3.3.02 
software development costs and, 3.3.06–3.3.07 
with substance, 3.3.45–3.3.53, 5.3.33 
synergistic value issues and, 1.1.15–1.1.19 
valuation of, 2.1.04–2.1.05, 2.1.07, 2.1.09–2.1.20, 5.3.93–5.3.96 
venture capital for, 5.3.87 
Revenue 
ancillary, 5.3.36 
attributable to IPR&D subcomponent, 5.3.52 
forecast, 5.3.41–5.3.42 
incremental, 2.1.10 
related to technology migration, 5.3.45–5.3.46 
synergies, 5.3.23 
verifying, 5.3.14 
Risk-free rate of return, 5.3.75, 5.3.77, 5.3.82 
Risk premiums, 5.3.84 
S 
Sales costs and expenses, verification of, 5.3.14 
Securities and Exchange Act of 1933, 5.2.03 
Securities and Exchange Act of 1934, 6.6.05 
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Securities and Exchange Commission (SEC), 4.1.08, 6.5.06 
Single-period-capitalization method, 2.1.11 
Start-up investments, 5.3.89–5.3.90 
Stock sale, tax benefits and, 5.3.99 
Substance, R&D projects with, 3.3.45–3.3.53, 5.3.33 
Substantive procedures 
evaluating results of procedures performed, 6.4.33–6.4.34 
internal consistency, 6.4.31 
management representations, 6.4.40–6.4.41 
overview of, 6.4.01–6.4.03 
preliminary procedures, 6.4.05–6.4.09 
purchase price allocations, 6.4.36–6.4.38 
significant assumptions, 6.4.23–6.4.29 
valuation report, 6.4.11–6.4.21 
Synergistic value/revenues 
acquired assets and, 1.1.15–1.1.19 
elimination of, 5.3.18, 5.3.22 
T 
Tangible assets, 5.3.14 
Tax benefits. See Income tax benefits 
Tax expenses 
attributable to IPR&D subcomponent, 5.3.53 
verification of, 5.3.14 
Technical support expenses 
attributable to IPR&D subcomponent, 5.3.53 
verification of, 5.3.14 
Technology migration 
concept of, 5.3.48 
forecasted revenues issues and, 5.3.45–5.3.46 
Technology subcomponents 
evaluating contribution of, 5.3.41 
role in forecasting future revenues, 5.3.42 
Traditional approach, fair value estimation with, 5.3.71, 5.3.73 
U 
Uniform Standards of Professional Appraisal Practice (USPAP), 5.2.10, 6.3.30 
V 
Valuation methods/issues 
cost approach, 2.1.04–2.1.05 
disclosure of, 4.2.02 
evaluation of, 6.4.15 
fair value concept and, 1.1.03–1.1.07 
income approach, 2.1.09–2.1.20 
introduction to, 2.1.01–2.1.02, 5.1.01–5.1.02 
market approach, 2.1.07 
measurability issues and, 3.3.31–3.3.38 
objective of, 5.1.03 
Valuation procedures 
engagement acceptance, 5.2.03 
engagement letters, 5.2.05 
introduction to, 5.2.01 




evaluation of, 6.4.13–6.4.21 
financial statements and, 6.6.02 
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